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Abstract 
 
Patients with nephrotic range proteinuria have a higher risk of cardiovascular 
disease through qualitative and quantative changes in lipids and lipoproteins.  
The aim of this study was to examine the effect of omega-3 fatty acids derived 
from fish oil in this population. 
Treatment with omega-3 fatty acids in these patients was well tolerated and 
had a number of beneficial effects. They reduced small dense LDL 
concentration, remnant lipoproteins, VLDL and triglyceride levels. 
Postprandial lipaemia was improved with an improvement in chylomicron 
clearance. However, we found that treatment increased LDL-C and although 
there was a redistribution to protective HDL2 rather than HDL3, HDL-C was 
not significantly increased. Furthermore, there was no improvement in 
endothelial function or inflammatory markers. 
Thus, we do not recommend treatment with omega-3 fatty acids alone for 
dyslipidaemia in this population of patients. The combination of omega-3 fatty 
acids with a statin merits further work. 
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Summary 
Nephrotic range proteinuria is associated with increased risk from CHD. This 
is thought to be in part through qualitative and quantative change in lipids and 
lipoproteins. Among the lipid and lipoprotein abnormalities possessed by 
these patients, increased concentration of triglyceride rich lipoproteins, 
lipoprotein remnants and excess small dense LDL contribute significantly to 
this risk. Furthermore, postprandial lipaemia plays an important role in the 
development of atherosclerosis as triglyceride rich lipoproteins are mainly 
produced in the postprandial state. This suggests that abnormalities of 
postprandial lipoprotein metabolism may contribute to the increase in 
triglyceride rich lipoproteins observed in this population. Low levels of HDL are 
an important risk factor for CVD independent of other factors and increasing 
these levels have been shown to reduce this risk. Experimental and clinical 
data has shown that endothelial dysfunction and inflammation is important 
early in the development of atherosclerosis. Both epidemiological data and 
randomised controlled trials have shown that increased intake of omega-3 
fatty acids is associated with reduced CV disease. Omega-3 fatty acids act 
through a number of mechanisms. Their main effect on lipoprotein metabolism 
results in a reduction in triglyceride levels. They also have anti-thrombotic, 
anti-inflammatory and anti-arrhythmic properties contributing to their beneficial 
effect on CV disease.  
The main hypothesis of this research was that omega-3 fatty acids have the 
ability to correct the dyslipidaemia of proteinuric renal disease. First, we aimed 
to examine whether omega-3 fatty acids provided adequate triglyceride 17 
 
lowering effects and consequent benefits on LDL phenotype and HDL 
concentration. Next, we aimed to examine whether omega-3 fatty acids 
improved postprandial lipaemia in this population and finally we aimed to 
assess their effect on endothelial function.  
We recruited 19 patients with primary glomerular disease and nephrotic range 
proteinuria and compared them with normal controls. Patients and controls 
were treated with 4g daily of omega-3 fatty acids for a period of 8 weeks. 
Treatment was generally well tolerated with only one patient withdrawing due 
to adverse gastrointestinal side effects. An additional patient withdrew prior to 
commencing the study, therefore we analysed 17 patients. 
At baseline, patients with nephrotic range proteinuria had increased 
concentration of total cholesterol, plasma triglyceride, VLDL, remnant 
lipoproteins and small dense LDL (LDL III). Omega-3 fatty acids reduced 
triglyceride rich lipoproteins, remnant lipoproteins and LDL III in the patients 
with nephrotic range proteinuria but also increased LDL-C. However, the 
increase in LDL-C was also associated with a redistribution to larger, lighter 
and potentially less atherogenic LDL.  
Postprandial lipaemic response was assessed following a fat load both pre 
and post treatment with omega-3 fatty acids. Postprandial chylomicron 
concentration was greater in the patients with nephrotic range proteinuria 
compared with the controls at baseline but postprandial VLDL1 concentration 
did not differ between the two groups. Treatment with omega-3 fatty acids 
reduced postprandial chylomicron in the patient group but not the controls. 
Postprandial VLDL1 was not affected by treatment in patients or controls, 18 
 
however peak postprandial VLDL1 concentration was significantly lowered in 
all subjects. 
On examining the structure and composition of these chylomicrons, we found 
that patients with nephrotic range proteinuria had significantly higher levels of 
apolipoprotein CII, CIII and E per particle with greater quantities of triglyceride, 
total cholesterol, free cholesterol and phospholipid indicating that these 
particles are bigger. We did not demonstrate any difference in the structure or 
composition of VLDL1 particles between patients and controls. However, 
despite the reduction in postprandial chylomicron concentration observed post 
treatment; omega-3 fatty acids did not influence the structure or composition 
of either chylomicrons or VLDL1 in patients or controls. This suggests that any 
improvement in postprandial dyslipidaemia results from reduced chylomicron 
synthesis rather than any change in their structure.  
HDL subfractions were measured in both patients and controls at baseline 
and following treatment with omega-3 fatty acids. There was no difference in 
the concentration of these subfractions in patients compared with controls. 
Treatment had a beneficial effect on the HDL subfractions with an increase in 
protective HDL2 and a reduction in HDL3 concentration in spite of any change 
in HDL-C. 
Finally, we measured microvascular endothelial function using the technique 
of laser doppler imaging and also by analysing markers of endothelial function 
and inflammation in the patients compared with the controls. We were unable 
to demonstrate a difference in endothelial function but plasma PLA2 were 
increased in the patients at baseline. Omega-3 fatty acids did not affect 
endothelial function or markers of inflammation in patients or controls. 19 
 
In conclusion, in this research we have shown that omega-3 fatty acids have a 
number of beneficial effects on lipids and lipoproteins in patients with 
nephrotic range proteinuria. However, any potential benefit that may result 
has to be balanced against the increase in LDL-C and so monotherapy with 
omega-3 fatty acids in this population may not be advisable. We suggest that 
the combination of omega-3 fatty acids and HMG Co A reductase inhibitor 
merits further investigation to ascertain whether this is the optimum 
therapeutic option to achieve the dual goal of reducing triglyceride rich 
atherogenic lipoproteins as well as LDL-C in this high-risk patient population. 
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1.1 Cardiovascular Risk and Proteinuria 
The presence of excess urinary protein is associated with increases in both 
cardiovascular  disease  (CVD)  and  coronary  heart  disease  (CHD)(1).  An 
increasing number of studies have suggested that microalbuminuria is a risk 
factor  for  CVD.  This  risk  has  been  shown  to  increase  as  the  level  of 
proteinuria increases. In the „HOPE‟ (Heart Outcomes Evaluation Trial),which 
examined  3577  diabetics  aged  55  or  over  with  either  one  previous 
cardiovascular  event  or  risk  factor,  microalbuminuria  was  associated  with 
increased risk of the combined end-point of myocardial infarction, stroke or 
cardiovascular (CV) death in patients with and without diabetes(2). This risk 
increased  as  the  level  of  proteinuria  increased.  In  studies  examining  the 
general  population,  this  risk  is  evident  even  at  low  levels  of  albuminuria, 
independent  of  other  CV  risk  factors(3;4).  In  a  population  based  study 
examining  over  40,000  subjects,  increased  urinary  albumin  excretion  was 
associated with increased CV mortality independent of other risk factors(3). 
Klausen et al found a 2 fold increase in the relative risk of CHD and a 1.9 fold 
increase  in  relative  risk  of  death  in  subjects  with  low  levels  of 
microalbuminuria  independent  of  age,  sex,  creatinine  clearance  (CrCl), 
diabetes mellitus, hypertension and plasma lipids(4).  This risk is higher in 
patients with persistently positive dipstick proteinuria as found in the MRFIT 
study(5).  This  showed  that patients  with 1+  of  persistently  positive  dipstick 
proteinuria  was  associated  with  a  2  fold  relative  risk  of  death  from  CHD, 
increasing  to  2.5  fold  with  2+  proteinuria(5).  Furthermore,  Miettinen  et  al 
demonstrated that clinical proteinuria (>300mg/l) was associated with a 5 fold 22 
 
increase  in  the  incidence  of  stroke  in  non-diabetics(6).  This  risk  increases 
further in patients with nephrotic range proteinuria. Ordonez et al showed that 
patients  with  nephrotic  range  proteinuria  (>3g/24hrs)  possessed  a  3  fold 
increase  in  the  risk  of  CHD  death  and  5.5  fold  increase  of  myocardial 
infarction independent of hypertension and smoking (7). There are, however, 
no  prospective  intervention  trials  examining  risk  reduction  in  patients  with 
nephrotic range proteinuria. 
The precise mechanism behind the association of proteinuria with CV risk is 
unknown. Glomerular capillary leaking of albumin may be a manifestation of a 
widespread vascular process caused by atherosclerosis (8;9). A link between 
microalbuminuria and endothelial dysfunction has been observed (10). Non-
diabetic  hypertensive  patients  with  microalbuminuria  have  been  shown  to 
have higher levels of von Willebrand factor (vWF) antigen than those without 
microalbuminuria(11).  vWF  is  a  glycoprotein  which  is  secreted  in  larger 
amounts  when  there  is  damage  to  the  vascular  endothelium,  therefore 
microalbuminuria may reflect damage to the systemic vascular endothelium.  
It  is  not  clear  whether  proteinuria  leads  to  increased  CV  risk  or  whether 
proteinuria is a marker of increased risk. However, nephrotic range proteinuria 
is associated with a number of qualitative and quantative changes in lipids 
and lipoproteins (described later), which contribute to the increased CV risk. 
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1.2 Normal Lipoprotein Metabolism 
1.2.1 Lipids 
Lipids play an important role in metabolism as they are both a source of 
energy, are essential for the structure of cell membranes and precursors to 
essential vitamins and hormones. Cholesterol and phospholipid are required 
for the formation of the cell membrane. Cholesterol also acts as a precursor 
for vitamin D, bile acids and steroid hormones. Triglycerides provide a high 
energy source. These lipids are hydrophobic neutral particles and cannot be 
transported in the circulation in their free form. As a result, they are bound to 
proteins and other lipids to form amphipathic lipoprotein particles. 
 
1.2.2 Lipoproteins 
Lipoproteins are globular particles with differing lipid and protein content. They 
can be classified by a number of different methods; size, density, flotation 
constant and electrophoretic mobility. The most widely used method of 
classification is when lipoproteins are classified by density ultracentrifugation 
(12).This divides lipoproteins into 5 main classes: chylomicrons, very-low 
density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), low-density 
lipoprotein (LDL) and high density lipoprotein (HDL). The properties of these 
are outlined in table 1.1. 
Lipoproteins may also be classified according to their protein component 
(apolipoprotein).  Each lipoprotein contains one or more apolipoproteins. 
Individual apolipoproteins control lipoprotein metabolism in a variety of ways 
such as by binding to specific cell membrane receptors or by acting as co-24 
 
factors for enzymes involved in lipoprotein metabolism. They are also 
essential for the structural integrity of lipoprotein particles. These properties 
are outlined in table 1.2. 
Chylomicrons are the largest lipoprotein and are also the lightest. They are 
synthesised in the intestine from dietary fat. The main apolipoprotein is apo B-
48 but acquires apo CII and E. Chylomicrons have a high triglyceride content. 
VLDL are the next step down in terms of density and size. They contain 5 –
12% protein, 50-55% triglyceride, 18 –20% phospholipid, 12 –15% cholesteryl 
ester and 8 –10% free cholesterol. They differ from chylomicrons in that they 
are synthesised in hepatocytes and their main function is the transport of 
endogenously synthesised triglyceride. Furthermore, in contrast to 
chylomicrons, the main apolipoprotein is B-100. They also contain apo CII, 
apo CIII and apo E.  VLDL can be separated into 2 subfractions by 
cumulative- gradient ultracentrifugation according to their flotation coefficients. 
VLDL1 (Sf 60-400) is larger, lighter and rich in triglyceride while VLDL2 (Sf 20-
60) is smaller, denser and more enriched in cholesteryl ester. VLDL1 and 
VLDL2 production is regulated independently. VLDL1 is associated with raised 
triglycerides (13).  It is metabolised slowly and is integral to the formation of 
small dense LDL, whereas VLDL2  is metabolised more rapidly to IDL and 
LDL. 
IDL is smaller than VLDL and more dense. It is composed of 10-12% protein, 
24- 30% triglyceride, 25-27% phospholipid, 32 –35% cholesteryl ester and 8-
10% free cholesterol. IDL is primarily derived from triglyceride hydrolysis of 
VLDL. IDL is taken up by the liver or undergoes further triglyceride hydrolysis 25 
 
to become LDL. IDL contains both apo-B100 and apo E. Increased plasma 
IDL concentration has been associated with atherogenesis(14). 
 
LDL is smaller than IDL and more dense. LDL contains 20-22% protein, 10-
15% triglyceride, 20-28% phospholipid, 37-48% cholesteryl ester and 8-10% 
free cholesterol. LDL is the main transporter of cholesterol and cholesteryl 
esters. The main apolipoprotein of LDL is B-100 accounting for approximately 
25% of the particle mass. Excess LDL is associated with atherogenesis. LDL, 
itself, can be further subdivided by a number of different methods including 
size, density and electrophoretic mobility. This will be discussed further later. 
HDL is the smallest of the lipoproteins and the most dense. HDL contains 
approximately 55% protein, 3-15% triglyceride, 15-30% cholesteryl ester, 24-
46% phospholipid, 15-30% cholesteryl ester and 2-10% free cholesterol. The 
main function of HDL is in reverse cholesterol transport as it takes cholesterol 
from peripheral tissues to the liver. The main apolipoprotein constituents of 
HDL are AI, and II and also contain apolipoproteins CII, CIII and Apo E. HDL 
may be separated into 2 subclasses, HDL2 and HDL3.  HDL2 is larger and 
richer in lipids and HDL3 is smaller and denser. There is an important inverse 
relationship between HDL and coronary artery disease risk, which will also be 
discussed later. 
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Table 1.1: Properties of Plasma Lipoproteins 
 
________________________________________________________________________________________________________ 
 
Lipoprotein      Density      Particle Size     Flotation Coefficient   Molecular Weight   
 
          (kg/l)                (nm)                  (Sf)             
________________________________________________________________________________________________________ 
 
Chylomicron     <0.94        75-1200        >400        50-1000 x 10
6 
 
VLDL        0.94-1.006        30-80        20-400      10-80 x 10
6 
 
IDL        1.006 –1.019       25-35        12-20       5-10 x 10
6 
 
LDL        1.019-1.063        18-25        0-12        2-3 x 10
6 
 
HDL        1.063-1.21         5-12          0-9*        65-386 x 10
3 
 
________________________________________________________________________________________________________ 
 
*at solvent density 1.20kg/l 
 
Adapted with permission (15)   
 
 
 27 
 
Table 1.2: Plasma Apolipoproteins  
_______________________________________________________________________________________________________ 
 
Apolipoprotein    Particle        Main Function          Molecular Weight 
________________________________________________________________________________________________________ 
 
A-I        HDL          Accepts cholesterol         28,000 
Ligand for HDL binding 
LCAT activator 
 
AII        HDL          Ligand for HDL          17,500 
                  LCAT cofactor 
 
A-IV        HDL          Ligand for HDL          46,000 
                  LCAT cofactor   
 
B-48        Chylomicrons      Forms structure          264,000 
 
B-100       VLDL, IDL, LDL      Forms structure          512,000     
                  Ligand for LDL receptor 
CII        Chylomicrons, VLDL    Activates LPL          9000 
 
CIII        Chylomicrons, VLDL    LPL inhibitor           9000     
   
E        Chylomicrons, VLDL, IDL,    Ligand for IDL receptor, LDL-RP      34,000 
        Lipoprotein Remnants     & VLDL Receptor 
________________________________________________________________________________________________________ 
 
LCAT=Lecithin cholesterol acyltransferase, LPL= Lipoprotein lipase, LDL-RP= LDL receptor- related protein 28 
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Figure 1.1 Exogenous Lipoprotein Metabolism 
 
Dietary cholesterol and fatty acids are absorbed in the intestine where triglyceride is synthesised from free fatty acids with glycerol and 
cholesterol is esterified to form cholesteryl esters. These are assembled into chylomicrons. Apo CII and E are acquired as the chylomicrons 
enter the circulation. LPL hydrolyses the core triglyceride making the chylomicrons progressively smaller and releasing free fatty acids 
which are used as an energy source, converted to triglyceride or stored in adipose tissue. The end products are chylomicron remnants, 
which are cleared from the circulation by hepatic chylomicron remnant receptor. 
(FFA = Free fatty acids, TG = Triglyceride, LPL= Lipoprotein Lipase) 29 
 
1.2.3 Exogenous Lipid Metabolism 
Lipoprotein metabolism can be considered as either exogenous or 
endogenous pathways. The exogenous pathway involves transport of dietary 
fat from the intestine (mainly in the form of triglyceride) as chylomicrons to the 
liver (fig 1.1). This pathway begins with the intestinal absorption of dietary 
cholesterol and fatty acids. Triglyceride is synthesised from the combination of 
free fatty acids with glycerol and absorbed cholesterol is esterified to form 
cholesteryl esters within the small intestine. These are assembled to form 
chylomicrons. The main apolipoprotein is B-48 but CII and E are acquired as 
the chylomicrons enter the circulation. Apo-B48 permits lipid binding to the 
chylomicrons but does not bind to the LDL receptor thereby preventing 
premature clearance of chylomicrons from the circulation. Apo C II is a 
cofactor for lipoprotein lipase (LPL), which hydrolyses the core triglyceride 
thus making the chylomicrons progressively smaller and at the same time 
releases free fatty acids. These free fatty acids are used as an energy source, 
converted to triglyceride or stored in adipose tissue. The end product of 
chylomicron metabolism is chylomicron remnants, which are cleared from the 
circulation by hepatic chylomicron remnant receptor, for which apo E is a 
ligand. Surface components are transferred from the chylomicron remnants to 
HDL. 
 
1.2.4 Endogenous Lipid Metabolism 
The endogenous pathway involves transport of lipids, which are synthesised 
in hepatocytes to peripheral tissues. This pathway begins with the synthesis of 
VLDL particles in the liver, which are released as nascent VLDL particles 30 
 
containing apo A-I, and B-100. Apolipoproteins CII, CIII and apoE are picked 
up from circulating HDL. As VLDL passes through the circulation, its structure 
is altered. Triglyceride is removed through the action of LPL (activated by apo 
C-II) generating either VLDL remnants or IDL. Surface components including 
the C and E apolipoproteins (originally donated from HDL) are transferred to 
HDL. In addition to this hydrolysis, a large amount of exchange takes place 
between VLDL and HDL. Cholesteryl ester is transferred from HDL to VLDL in 
an exchange reaction that concomitantly transfers triglyceride from VLDL to 
HDL. This is mediated through cholesteryl ester transfer protein (CETP). 
Therefore, VLDL particles lose triglyceride via lipolysis and become 
cholesteryl ester enriched via the action of CETP thereby forming IDL. Further 
hydrolysis of IDL is mediated via hepatic lipase allowing further depletion of 
triglyceride and loss of apoE, which in turn leads to the formation of a smaller 
particle LDL. 
 
1.2.5 HDL Metabolism 
The protective effect of HDL is largely through reverse cholesterol transport, 
which removes excess cholesterol from cells and atherosclerotic plaques.  
Small nascent HDL particles are synthesised in the liver and intestinal cells. 
These particles acquire free cholesterol from peripheral tissue via the 
adenosine triphosphate- binding cassette protein A1 receptor (ABCA1). Free 
cholesterol is esterified by lecithin cholesterol acyltransferase (LCAT) forming 
cholesteryl ester, which moves to the particle core and results in larger, 
mature HDL particles. These particles transport cholesterol to the liver by 
interaction with the scavenger receptor class B1 receptor (SRB1) which frees 31 
 
them to recirculate and participate in another cycle of reverse transport. The 
major apolipoprotein on HDL is A-1. Apo A-1 is involved at many points 
throughout this pathway namely interaction with the ABCA1 receptor, 
activation of LCAT and recognition of the SRB1 receptor. This pathway allows 
the removal of cholesterol from peripheral sites such as arterial vessel walls. 
Both the HDL mediated reverse cholesterol transport pathway in combination 
with the endogenous lipoprotein pathway involving the apo B containing 
lipoproteins (VLDL, IDL and HDL) allow exchange of cholesterol and 
triglyceride mediated by CETP. Thus, cholesterol within HDL is exchanged 
with triglyceride within Apo B containing particles enabling transport to the 
liver and removal from the circulation by the LDL receptor(16). 
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Figure 1.2 Endogenous Lipoprotein Metabolism 
 
VLDL is synthesised in the liver and released as nascent VLDL particles containing apo A-I, and B-100. Apolipoproteins CII, 
CIII and apoE are picked up from circulating HDL. As VLDL passes through the circulation, triglyceride is removed through 
the action of LPL (activated by apo C-II) generating either VLDL remnants or IDL. Further hydrolysis of IDL is mediated via 
hepatic lipase allowing further depletion of triglyceride and loss of apoE, which in turn leads to the formation of a smaller 
particle LDL. 
(TG= Triglyceride) 
Nascent VLDL 
Apo B100 
Mature VLDL 
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1.3 Dyslipidaemia and Atherosclerosis 
1.3.1 Cholesterol and LDL-C 
The association between hypercholesterolaemia and CVD was initially based 
on epidemiological data. Studies have demonstrated a continuous graded 
correlation between cholesterol and risk of CHD (17;18). The impact of 
cholesterol lowering in both primary prevention and secondary prevention of 
CVD is now well established. 
The West of Scotland Coronary Prevention Study (WOSCOPS) is one of the 
most important studies examining the use of statins in primary prevention. 
Treatment with pravastatin significantly reduced cholesterol and LDL-C levels 
as well as CV end-points(19). A subsequent meta-analysis of primary 
prevention trials using statins also shows reductions in cholesterol and CVD 
mortality(20).  
There have been many trials examining the effect of cholesterol lowering in 
secondary prevention. A number of studies have looked at the effect of 
cholesterol lowering on the regression of atherosclerosis. These studies 
evaluated regression either through coronary angiography (21-23) or 
ultrasonic techniques (24;25). Furthermore, there have been several large 
studies assessing clinical outcome with lipid lowering. The Scandinavian 
Simvastatin Survival Study (4S) found a 25% reduction in cholesterol and 
35% reduction in LDL-C with a significant reduction in mortality in over 4000 
patients treated with simvastatin(26). More recently, in the „Treating to New 
Targets‟ (TNT) study, LDL-C levels were significantly lower (2.0 mmol/l with 
80mg of atorvastatin vs 2.6 mmol/l with 10mg). Fewer patients reached the 34 
 
primary end-point which was a major CV event in the high dose arm (27). The 
benefit of lipid lowering in patients in the absence of substantially elevated 
lipid levels has been observed. The Cholesterol and Recurrent Events 
(CARE) study included patients with a mean total cholesterol of 5.4mmol/l, 
and LDL-C of 3.6mmol/l. Treatment with pravastatin significantly reduced the 
combined end-point of coronary death and non fatal myocardial infarction 
(28). 
 
1.3.2 HDL 
Low levels of plasma HDL-C are a significant independent predictor of 
increased risk of CHD. This has been demonstrated in several observational 
studies. The Framingham Heart study showed that, in the normal population, 
the risk for myocardial infarction increases by about 25% for every 0.13mmol/l 
reduction in HDL-C (29). This is also evident in patients already diagnosed 
with CHD. An analysis of the LIPID and CARE studies encompassing over 
13,000 patients, revealed that low HDL-C was a significantly stronger 
predictor of CHD in patients with LDL-C less than 125mg/dl (3.2mmol/l) 
compared with those with LDL-C greater than or equal to 125mg/dl (30). 
This cardioprotective effect is due to, in part, its role in reverse cholesterol 
transport. Furthermore, HDL is thought have a number of other protective 
effects. These include anti-inflammatory, anti-oxidant and pro-fibrinolytic 
effects (31). 
There are several studies examining the effect of raising HDL.  The Veterans 
Affairs High Density Lipoprotein Cholesterol Intervention Trial (VA-HIT) 
compared treatment with gemfibrozil to placebo in over 2000 patients with 35 
 
CHD. There was 6% increase in mean HDL concentration and significant 
reductions in nonfatal MI and CHD death in the gemfibrozil arm. This 
reduction in nonfatal MI and CHD deaths correlated with HDL and was 
independent of changes in LDL-C or triglyceride concentrations (32). The HDL 
Atherosclerosis Treatment Study examined a combination of simvastatin and 
niacin therapy. This combination reduced LDL-C by 42%, increased HDL-C by 
26%, induced regression of angiographic atherosclerosis and reduced the 
likelihood of sustaining a CV event. The magnitude of reduction in CV events 
and increase in HDL in this study was much greater than in studies which 
used statins alone, suggesting that the additional effect of raising HDL 
provides further benefits (33).  
 
1.3.3 Remnant Lipoproteins 
Remnant lipoproteins are formed from chylomicrons or VLDL particles, which 
have been partially metabolised by LPL. These particles are heterogeneous in 
size and  composition  and  determined  by  plasma  triglyceride  concentration. 
Elevated  remnant  lipoproteins  are  associated  with  atherosclerosis.  Patients 
with established coronary artery disease have been found to have increased 
levels  of  remnant  lipoproteins(34;35).  Karpe  et  al  found  that  carotid  artery 
intima-media thickness was positively related to baseline plasma remnant-like 
protein  cholesterol  (RLP-C)  independently  of  plasma  triglyceride  and  LDL 
levels (36). Two further Japanese studies have shown that elevated RLP-C 
levels  were  predictive  of  future  coronary  events  in  patients  with  CHD 
independent of other risk factors (37;38). 
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1.3.4 Oxidized LDL 
It is has been suggested that there is a link between lipids and inflammation in 
the development of atheroma. LDL, which is present in the lipid fraction of 
atheroma within the intima, undergoes oxidative modification. These modified 
lipids have a number of pro-atherogenic properties. They induce expression of 
adhesion molecules, chemokines, proinflammatory cytokines and other 
inflammatory mediators. They are also immunogenic and so capable of 
inciting T cell responses, which in turn can incite local responses within the 
plaque. 
The association of oxidized LDL with CHD has been observed in a number of 
studies.  Elevated  plasma  levels  of  oxidized  LDL  has  been  observed  in 
patients  with  stable  CHD compared  with healthy  controls  (39).  Ehara  et  al 
demonstrated that oxidized LDL levels correlated with the severity of acute 
coronary syndromes (40). In addition, Toshima et al found concentrations of 
oxidized LDL in patients with angiographically proven CHD to be 1.9 times 
higher than controls (41). 
 
1.4 Postprandial Lipaemia 
Postprandial lipaemia was first suggested to be linked with atherosclerosis in 
1979 by Zilversmit (42). Triglyceride rich lipoproteins (TRLs) are mainly 
produced postprandially (43;44). The triglyceride rich particles (chylomicrons 
and VLDL) are metabolised by LPL into glycerol and free fatty acids as 
described earlier. LPL activity is the rate-limiting step in the postprandial 
phase; therefore competition for this enzyme leads to accumulation of VLDL, 
as chylomicrons are the preferred substrate for LPL. This competition is more 37 
 
likely to occur in the presence of fasting hypertriglyceridaemia such as in type 
II diabetes.  Strong positive correlations between fasting triglyceride and 
postprandial triglyceride concentrations have been observed (45). However, 
subjects with normal fasting levels of triglyceride have also been found to 
have impaired lipoprotein clearance (46).  
Clinical studies have shown that peak and late postprandial triglyceride 
concentrations as well as retinyl palmitate (a marker of intestinally derived 
TRLs) are associated with CHD (47-52).  Simpson et al observed a prolonged 
and exaggerated period of hypertriglyceridaemia following a fat load and 
increased levels of retinyl palmitate in patients with severe CHD (51). Patients 
with CAD have also displayed a delay in the normalisation of triglyceride 
concentration and delayed clearance of retinyl esters (48). Furthermore, in a 
study by Patsch et al, both the maximal triglyceride increase and the 
magnitude of the postprandial triglyceride response following a fat load were 
higher in patients with CHD (50). Increased levels of chylomicron remnants 
have been shown to be related to the rate of progression of coronary lesion in 
post myocardial infarction males (53). Carotid intima-media thickness (IMT) is 
used as a surrogate marker for atherosclerosis. In one study of healthy males, 
following a fat load, the subsequent triglyceride response was related to IMT 
independent of other clinical risk factors (54). In summary, it is clear that there 
is a well-established relationship between postprandial lipaemia and 
atherosclerosis. Currently, the assessment of postprandial lipaemia is through 
the administration of a standard fat load followed by regular venesection for 
eight hours. However, this means of assessment cannot be applied to large 
numbers of patients in a clinical setting and so a more practical method for the 38 
 
assessment of postprandial lipaemia would need to be developed before this 
can be applied as a useful clinical tool. 
 
 
1.5 The Atherogenic Lipoprotein Phenotype 
The Atherogenic lipoprotein phenotype (ALP) is a term used to describe a 
collection of proatherogenic lipoprotein abnormalities. It was defined by Austin 
as hypertriglyceridaemia, low HDL-C levels and a predominance of small 
dense LDL (55).  
LDL was first subdivided using gradient gel electrophoresis (56) into a discrete 
number of subfraction with differing size and density. Subjects with a 
preponderance of large LDL were labelled as having „Pattern A‟ and those 
with small LDL „Pattern B‟(57) and ALP. „Pattern B‟ has been shown to be 
associated with a three-fold increased risk of myocardial infarction (58). An 
alternative method of analysis that allows quantification of each LDL 
subfraction is through density gradient ultracentrifugation. This divides LDL 
into three main subfractions (LDL I d=1.025-1.034g/ml, LDL II d=1.034-1.044 
and LDL III d=1.045-1.060)(59).  LDL I is large and predominates in 
premenopausal women with LDL II being the most common subfraction in 
males. LDL III is the smallest and most dense subfraction and has been linked 
with CHD in number of studies(58;60-64) (Fig 1.3).It is thought that the 
generation of small dense LDL is as a result of defective clearance or 
overproduction of VLDL (65). Chylomicron metabolism is also affected with 
increased production of chylomicron and chylomicron remnants and HDL falls 
with a shift towards smaller, denser HDL3. ALP has been observed to be 39 
 
common in a number of conditions: diabetes (66), metabolic syndrome (67), 
familial combined hyperlipidaemia (68) and patients with nephrotic range 
proteinuria (69). 
Small dense LDL particles have been associated with CHD in a number of 
studies including cross-sectional, prospective, epidemiological and 
intervention studies (70). Moreover, the National Cholesterol Education 
Program Adult Panel III has accepted small dense LDL as a cardiovascular 
risk factor (71). Whilst, most of the studies have shown that small LDL size is 
a predictor of CHD on univariate analysis only, several studies found LDL size 
to be an independent predictor on multivariate analysis. The Standard Five-
City project found that patients with myocardial infarctions had smaller LDL in 
a nested case control study independent of other factors(60). Griffin et al 
observed that LDL III concentration of > 100 mg/dl conferred a 4.5 fold 
increase in risk of CHD and 6.9 fold increase risk of myocardial infarction (61). 
The Quebec Cardiovascular Study examined 2072 men over a period of 13 
years. They observed a strong association between small dense LDL and risk 
of ischaemic heart disease, (72) again independent of other factors. The 
Pravastatin Limitation of Atherosclerosis in Coronary Arteries Trial (PLAC-1) 
used the technique of Nuclear Magnetic Resonance (NMR) to examine LDL 
particle size in patients with cardiovascular disease. They revealed that small 
LDL particles and not large LDL particles predicted angiographically 
measured disease progression independent of other lipid levels (73). Liu et al 
investigated the association between LDL particle size and carotid artery 
intima thickness (IMT) as a measure of atherosclerosis in asymptomatic family 
members with familial combined hyperlipidaemia (FCHL). They found that on 40 
 
multivariate analysis, smaller particle size was associated with increased 
IMT(74). A further study looking at patients with type II diabetes showed that 
LDL size was the strongest marker of CHD in a multivariate analysis(75). 
Thus, the association between small dense LDL and CHD is well established. 
 
Many theories have been suggested as to why small dense LDL is so 
atherogenic. It has been suggested that small dense LDL is more easily taken 
up by arterial tissue than larger LDL thereby leading to greater accumulation 
in atherosclerotic plaques (76). Another study suggested that the increased 
atherogenicity of small dense LDL was due to decreased hepatic clearance by 
the LDL receptor and enhanced binding to LDL receptor independent sites in 
extra-hepatic tissues such as the arterial wall (77). There is an increase in 
oxidative susceptibility and reduced antioxidant properties in small dense LDL 
further contributing to atherogenicity (78). 
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Figure 1.3 Typical LDL Subfractions in Different Populations 
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1.6 Normal Endothelial Function 
Endothelial dysfunction is thought to play an important role in the initiation and 
progression of atherosclerosis.  It is defined as alterations in the normal 
properties of the endothelium, which leads to impairment of organ function. 
Normal endothelium reduces vascular tone, regulates vascular permeability, 
limits platelet adhesion and aggregation, prevents activation of the 
coagulation cascade and restricts leucocyte adhesion.  Endothelial activation 
is the loss of endothelial anti-inflammatory properties through the increased 
expression of adhesive molecules such as e-selectin, ICAM and VCAM. Nitric 
oxide (NO) is one of the most important mediators released by the 
endothelium. It is a potent vasodilator that inhibits inflammation, growth of 
vascular smooth muscle and aggregation of platelets.  
 
Many different means of assessing endothelial dysfunction have been 
employed most of which usually measures an endothelial cell response to a 
stimulus. Endothelium dependant vasodilatation can be assessed in the 
coronary and peripheral circulation. Coronary angiography has been used to 
assess changes in vascular diameter in response to an infusion of an 
endothelium dependant vasodilator such as acetylcholine (Ach). In a healthy 
vessel, ACh causes a NO mediated vasodilatatory response, which is not 
observed in patients with endothelial dysfunction. Also, intracoronary Doppler 
can be used to measure coronary blood flow in response to stimuli (79). The 
degree of endothelial dysfunction in the peripheral circulation is proportionate 
to the degree of endothelial dysfunction occurring in the coronary arteries 
(80). Assessment of endothelial vasomotion in these peripheral arteries has 43 
 
been shown to correlate with coronary dysfunction (81). Peripheral circulation 
endothelial function can be assessed in the forearm by intra-arterial infusion of 
endothelium dependent vasodilators such as acetylcholine (82). Flow 
mediated dilatation of the brachial artery using high resolution ultrasound is a 
less invasive approach(83). Further non-invasive methods of assessing 
endothelial function are currently emerging such as laser doppler imaging. 
This technique is described later. 
 
 
1.7 Cardiovascular Disease, Endothelial Function and Inflammation 
1.7.1 Endothelial Function 
It is now accepted that abnormalities of endothelial function and inflammation 
play a major role in the development of atherosclerosis. This is supported by 
both experimental and clinical data. Furthermore, there is significant evidence 
for the use of inflammatory markers both as predictors of coronary heart 
disease and prognostic factors for CHD(84-88). 
Normal endothelium does not usually support binding of leucocytes but in the 
presence of early atheromatous changes, patches of arterial endothelial cells 
express selective adhesion molecules on their surface, which bind to various 
classes of leucocytes. Vascular Cell Adhesion Molecule- 1 (VCAM-1) 
expression has found to be increased on endothelial cells overlying atheroma 
(89). This increase in adhesion molecules is found at sites prone to 
developing atheroma, such as branch points in the arterial tree, where there is 
disturbed flow and reduced shear stress, which reduces local production of 
NO. NO has anti-inflammatory properties and can reduce V-CAM 44 
 
expression(90). This disturbed flow can also increase expression of 
intercellular adhesion molecule-1 (ICAM-1) (91). These leucocytes then 
penetrate the intima where they perpetuate a local inflammatory response 
with macrophages ingesting lipid and becoming foam cells. The activated 
leucocytes and arterial cells can release fibrogenic mediators that promote 
replication of smooth muscle cells leading to the development of an 
atherosclerotic plaque. Inflammatory processes also contribute to precipitating 
acute thrombotic complications of atheroma. The activated macrophages 
abundant in the atheroma can produce proteolytic enzymes capable of 
degrading the collagen within the fibrous plaque of the cap allowing it to 
rupture (Figure 1.4). 
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Fig 1.4 Participation of Inflammation in Atherosclerosis 
Reproduced with permission (92). 
A.  Leucocyte recruitment to the atherosclerotic plaque. 
B.  T-lymphocytes join macrophages in the intima during lesion evolution 
C.  Thinning of the fibrous cap caused by alteration of the extracellular 
matrix induced by collagenases produced by foam cells leading to 
plaque rupture 
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1.7.2 Markers of Inflammation 
Elevated levels of several inflammatory markers have shown to be predictive 
of  vascular  events  in  several  different  populations.  Prospective 
epidemiological  studies  have  shown  associations  with  increased  levels  of 
cytokines  Interleukin-6  (IL-6)  and  Tumour  Necrosis  Factor-α  (TNF-α)  and 
increased  vascular  risk(85-87;93).  This  has  also  been  observed  with 
increased levels of acute phase reactants such as C-reactive protein (CRP), 
fibrinogen and serum amyloid A(84;85;94;95). 
The most relevant clinically of these markers is CRP. It is an acute phase 
protein, which is a member of the pentraxin family of innate immune response 
proteins (96). Measurement of highly sensitive CRP (hs-CRP) as a biomarker 
of  inflammation  and  therefore  atherosclerosis  confers  several  advantages 
over the measurement of other novel biomarkers. CRP has a long half life and 
is stable without being affected by circadian variation (97). Furthermore, it is 
easily measured with a standardized high-sensitivity assay available.  
Several studies have indicated that increased levels of highly sensitive (hs) 
CRP are strong predictors of cardiovascular disease in healthy subjects(88) 
(Fig  1.5).  These  studies  included  men,  women,  middle-aged  and  elderly 
subjects. A large British study by Danesh et al showed that higher levels of 
baseline  CRP  predicted  coronary  heart  disease  after  adjustment  for  other 
vascular risk factors (84). Thus, CRP is an important biomarker useful for the 
prediction of vascular risk in most populations of patients independent of other 
factors. 
A  number  of  drugs  used  in  the  treatment  of  CHD have  been  observed  to 
reduce  CRP.  In  the  Physicians‟  Health  Study,  aspirin  has  been  shown  to 47 
 
reduce cardiovascular risk to a greater extent in subject with higher levels of 
CRP  (95).  A  number  of  studies  have  shown  that  statins  reduce  CRP  in 
patients  with  hyperlipidaemia.  In  the  Air  Force/  Texas  Coronary 
Atherosclerosis  Prevention  Study  (AFCAPS/  TexCAPS),  lovastatin  reduced 
CRP by almost 15%. In addition, not only was there a significant reduction in 
coronary events apparent in patients with increased total cholesterol to HDL 
ratio but a reduction was also present in patients with an increased CRP but 
no increase in cholesterol:HDL ratio(98).  
 
 
 
 
Fig 1.5 Prospective studies of hsCRP as a predictor for future vascular 
events 
(Reproduced with permission (88)) 
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1.8 Omega –3 Fatty acids 
The cardioprotective effects of omega-3 fatty acids were first noted following 
the observation that the Greenland Inuit had a low mortality from CHD despite 
a high incidence of smoking and obesity. In 1975, Dyerberg and Bang 
suggested that this was due to the high content of omega-3 fatty acids in the 
Inuit diet which comprised mainly of fish, seal and whale (99). 
Omega-3 fatty acids are polyunsaturated fatty acids. These omega-3 fatty 
acids are alpha linolenic acid (LNA), eicosapentenoic acid (EPA) and 
docosahexenoic acid (DHA) (Fig 1.6). LNA is a plant-based source of omega-
3 fatty acid while EPA and DHA are obtained from marine sources. They are 
essential fatty acids and so must be consumed in the diet. Omega- 3 fatty 
acids have a variety of potential cardioprotective properties including effects 
on lipoproteins, inflammation, thrombosis and endothelial function. 
 
1.8.1 Omega-3 Fatty Acids and CHD: Observational Studies 
The observation that the Greenland eskimos had lower mortality due to their 
high fish consumption has lead to several observational studies. A study 
examining middle aged men in the town of Zupthen in the Netherlands found 
that men who rarely or never ate fish had a higher rate of CHD than those 
who ate fish more than once a week(100). Similarly, the Chicago Western 
Electric Study also showed an inverse relationship between fish consumption 
and death from CHD (101) as did the Multiple Risk Factor Intervention Trial 
(MRFIT)(102). Zhang et al found that fish consumption was associated with 
reduced risk from all cause mortality, IHD and stroke across 36 countries 
(103). In women, the Nurses‟ Health Study found that CHD deaths were 50% 49 
 
lower in those women who consumed fish five times a week (104;105). A 
subgroup of these women with diabetes showed a stronger relationship with a 
60% reduction in CHD death in those who ate fish five times a week(106).  
However, not all observational studies have yielded similar results, with some 
studies showing a lack of association. The Health Professional Follow-up 
study showed no association between dietary fish consumption and the risk of 
coronary disease (107). Also, the US Physicians Health study found no 
association between the risk of MI, non-sudden cardiac death or total CV 
mortality but fish consumption was associated with a reduction in total 
mortality (108). There was an inverse association between fish consumption 
and 25 year mortality in the Seven Countries Study but this was no longer 
significant once the effects of saturated fats, flavinoids and smoking were 
taken into account (109).  
Various theories behind the conflicting data have been postulated. End-point 
definitions, experimental design, study populations and type of fish consumed 
have all thought to influence the varying results.  However, a recent meta-
analysis of 13 published cohort studies found a consistent inverse association 
between fish consumption and CHD mortality rates(110).  
 
1.8.2 Randomised Controlled Trials of Omega-3 Fatty Acids 
Several trials have suggested favourable effects of omega-3 fatty acids in 
reducing the risk of CHD. The diet and reinfarction trial (DART) included 2033 
Welsh men(111). It found that patients who received dietary advice on fish 
had a relative reduction in mortality of 29% during the 2 year follow-up mainly 
because of reductions in deaths from CHD. The Physician‟s Health Study 50 
 
(112) found a reduced risk of sudden cardiac death in subjects with increased 
blood  levels of omega- 3 fatty acids. The largest randomised controlled trial 
examining the efficacy of omega-3 fatty acids in secondary prevention of CHD 
was the Italian GISSI-Prevenzione trial, which examined 11, 324 patients with 
a recent myocardial infarction. Patients were randomised to either 300mg of 
vitamin E or 850mg of omega-3 fatty acids, both or neither. After 3.5 years, 
the omega 3 fatty acid group had a reduction in relative risk of 15% in the 
composite end-point of total mortality, non-fatal myocardial infarction and 
stroke with a 20% reduction in all cause mortality and 45% reduction in 
sudden death(113). The Study on Prevention of Coronary Atherosclerosis by 
Intervention with Marine Omega-3 fatty acids (SCIMO) Study demonstrated 
the positive effects of omega-3 fatty acid supplementation on coronary artery 
disease which was assessed angiographically (114). In spite of these large 
studies showing a beneficial effect from fish oil, a recent meta-analysis 
examining 48 randomised controlled trials found that omega-3 fatty acids had 
no effect on total mortality or combined CV events(115).  
 
1.8.3 Effect of Omega-3 Fatty Acids on Lipoproteins 
In a review of human studies, Harris et al reported that 4g daily of omega-3 
fatty acids reduced triglyceride levels by 25 to 30% with a decrease in HDL of 
1 to 3%. However, LDL cholesterol was found to increase by 5 to 10%. The 
triglyceride lowering effect was dose dependant (116). 
Human and animal studies have shown that omega-3 fatty acids inhibit 
hepatic triglyceride synthesis and secretion of VLDL from the liver (117-119). 
The primary mechanism of triglyceride lowering is thought to be via reduced 51 
 
production rather than enhanced clearance of triglyceride rich lipoproteins as 
activity of either postheparin LPL or hepatic lipase has been shown not to be 
stimulated by omega-3 fatty acids (120-122).  
The LDL raising effect of omega-3 fatty acids is well recognised and has been 
observed in both healthy (123) and hyperlipidaemic subjects (124). This effect 
is rare at doses of 1g per day(125). At higher doses (3-5g), the LDL raising 
effect may be offset by a redistribution of LDL to larger sizes(126), thus 
potentially reducing its atherogenicity. The mechanisms behind the LDL 
raising effect of omega-3 fatty acids are unclear. It has been suggested that 
the fish oil down regulates the LDL receptor (127;128).  Changes in LDL 
particle size occur as omega-3 fatty acids suppresses CETP activity thus 
reducing the transfer of cholesteryl ester from HDL to VLDL and LDL thereby 
favouring large cholesterol rich LDL(129). 
Most studies show a beneficial effect of omega-3 fatty acids on HDL. The 
reduction in activity of CETP also affects HDL particles favouring large 
cholesterol rich HDL (HDL2) again through reducing transfer of cholesteryl 
esters from HDL to VLDL(129). 
Omega-3 fatty acids have also been shown to reduce triglyceride levels  
postprandially (130). This effect has been observed in healthy men (131) and 
patients with hypertriglyceridaemia (120). Moreover, they lower postprandial 
chylomicrons and chylomicron remnants (122;131).  
 
1.8.4 Effect of Omega-3 Fatty Acids on Thrombosis 
Omega-3 fatty acids are thought to reduce the risk of thrombosis by affecting 
platelet function and haemostasis. The observation that the Greenland 52 
 
Eskimos had reduced platelet aggregation and prolonged bleeding times 
suggested an important mechanism relating to the reduction of CHD(132). 
They act by displacing arachidonic acid from platelet phospholipid stores, 
decreasing the available substrate for thromboxane A2 synthesis and so 
reducing the ability of thromboxane A2 to induce platelet aggregation, thereby 
resulting in prolongation of bleeding time(133). The results from studies 
examining the effect of omega-3 fatty acids on haemostatic and fibrinolytic 
factors are conflicting(134-137). Thus, omega-3 fatty acids have beneficial 
effect on platelet aggregation but their effect on thrombosis is yet to be 
established. 
 
1.8.5 Effect of Omega-3 fatty Acids on Arrhythmias 
The effect of omega-3 fatty acids on reducing CHD mortality may, in part, be 
attributable to their anti-dysrhythmic effects. Several studies have suggested 
that omega-3 fatty acids are useful in the prevention of atrial and ventricular 
dysrhythmias. These observations have arisen as a result of animal and cell 
culture studies and more recently clinical randomised controlled trials. Studies 
examining rats have revealed that pre-treatment with omega-3 fatty acids 
prevented the initiation and reduced the severity of arrhythmias in response to 
various stimuli (138). In cultured rat cardiac myocytes, omega-3 fatty acids 
inhibited induced tachyarrhythmias (139).  These properties may be as a 
result of incorporation of omega-3 fatty acids into myocardial membrane 
phospholipids affecting electrophysiological properties. In patients with 
implantable cardiac defibrillators, the effect of omega-3 fatty acids on 
arrhythmic events is uncertain but there is no reduction in mortality (140-142).  53 
 
1.8.6 Omega-3 Fatty Acids and Inflammation 
Once again, it was first suggested that omega-3 fatty acids had anti-
inflammatory properties from the epidemiological observations of the low 
incidence of autoimmune and inflammatory disorders in the Greenland 
Eskimos (143). As discussed previously, inflammation plays a key role in the 
development of atherosclerosis and so the anti-inflammatory properties of 
omega-3 fatty acids are thought to contribute further to their cardioprotective 
effects. 
Consumption of omega-3 fatty acids increases EPA in the cell membrane, 
which competes with arachidonic acid as a substrate for cycloxygenase and 
lipoxygenase enzymes. Those derived from arachidonic acid are pro-
inflammatory whereas those derived from omega-3 fatty acids are anti-
inflammatory(144). Furthermore, they suppress the production of pro-
inflammatory cytokines and reduce expression of cell adhesion molecules 
such as I-CAM, V-CAM and e-selectin (145). 
The beneficial anti-inflammatory effects of omega-3 fatty acids have been 
seen in a number of conditions other than CHD. Studies have suggested 
benefits in patients with inflammatory bowel disease (146), rheumatoid 
arthritis (147) and asthma (148). 
 
1.8.7 Omega-3 Fatty Acids and Endothelial Function 
Evidence from in vitro and in vivo studies have shown that omega-3 fatty 
acids are thought to have a beneficial effect on vascular endothelium. Chin et 
al showed an improvement in endothelial function with omega-3 fatty acids 
using forearm venous occlusion plethysmography (149;150). Goodfellow 54 
 
examined endothelial function using non-invasive ultrasonic vessel wall 
tracking of brachial artery flow mediated dilatation (151) and found an 
improvement in the group treated with fish oil. In vitro, Goode et al 
demonstrated an improvement in endothelial function with an in vitro study of 
small arteries from subcutaneous gluteal fat biopsies in hypercholesterolaemic 
patients treated with omega-3 fatty acids(152). 
The mechanism behind these improvements is unclear. It has been suggested 
that omega-3 fatty acids cause changes in the composition of the membrane 
bilipid layer. The in vitro study by Goode et al found that the greatest 
improvement in endothelial function occurred in patients with greater EPA and 
DHA levels in their red cell membrane. Therefore, changes in the membrane 
fluidity may promote increased release of endothelium derived NO in 
response to ACh(152). 
 
1.8.8 Omega-3 Fatty Acids and Hypertension 
As a result of clinical and animal studies, it has been postulated that omega-3 
fatty acids have hypotensive properties. They are thought to stimulate 
prostaglandins that control sodium and water excretion, inhibit thromboxane, 
which is a vasoconstrictor, and regulate renin release(153). A meta-analysis 
of 31 studies showed a significant reduction of 3.4 mmHg  systolic and 2.0 
mmHg diastolic pressure with a 5.6g consumption of omega-3 fatty 
acids(154). Similarly, a further meta-analysis of 17 trials found a 5.5 mmHg 
systolic and 3.5mmHg reduction in diastolic blood pressure with daily doses of 
greater than 3g(155).  
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1.8.9 Omega-3 Fatty Acids in the Treatment of IgA Nephropathy 
Trials of omega-3 fatty acids in the treatment of IgA nephropathy have shown 
conflicting results.  A trial from the Mayo clinic treated patients with 12g daily 
of omega-3 fatty acids. They found at 4 years that patients receiving the fish 
oil had a significantly lower incidence of doubling of serum creatinine and a 
lower incidence of death or end stage renal failure(156). Other studies have 
failed to confirm these results and a meta-analysis of five randomised 
controlled trials concluded that the variation in results were due to differences 
in the duration of follow-up and once this was adjusted for statistically, there 
was no benefit from fish oil treatment (157). A more recent trial by the 
Southwest Paediatric Nephrology Study elucidated no significant difference in 
renal progression observed at 3 years in the patients treated with 4g daily of 
fish oil(158). In summary, there is currently no clear evidence supporting the 
use of omega-3 fatty acids in IgA nephropathy. 
 
1.8.10 Tolerability of Omega-3 Fatty Acids 
The Food and Drug Administration has ruled that intakes of up to 3g daily of 
marine omega-3 fatty acids are generally recognized as safe for inclusion into 
the diet. This includes particular consideration of bleeding tendencies and 
their effect on LDL-C.  
Omega-3 fatty acids are generally well tolerated, with a fishy aftertaste as the 
most commonly reported side effect in most studies. In the GISSI Prevention 
study, when 0.85g of omega-3 fatty acids were given daily to subjects for 3.5 
years, gastrointestinal upset and nausea were the most commonly reported 
side effect (4.9% and 1.4% respectively)(113). In a study examining 275 56 
 
patients given 6.9g daily of omega-3 fatty acids for 6 months, gastrointestinal 
upset was reported in 8% of patients (159).  
 
In summary, both observational and randomised controlled trials have 
suggested that omega-3 fatty acids have cardioprotective properties. In 
addition to their effect on lipids and lipoproteins, they have been shown to 
have anti-inflammatory, anti-thrombotic, anti-hypertensive, anti-arrhythmic 
properties and improve endothelial function as well as being well tolerated. 
However, it is difficult to compare the results of these studies due to differing 
doses and treatment duration. 
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Figure 1.6 Structures of Omega-3 Fatty Acids 
Reproduced with permission (160) 
Structures of the two classes of polyunsaturated fatty acids. The omega 3 
fatty acids have their first double bond at the third carbon molecule from the 
methyl (CH3) end of the fatty acid, whereas the omega 6 fatty acids have their 
first double bond at the sixth carbon molecule. The chemical names for each 
fatty acid are also given: the number of carbon atoms is given first, followed 
by the number of double bonds and the position of the first double bond. 
Omega-6 linoleic acid can be desaturated in certain plants to form omega-3 
linolenic acid. Whereas linoleic acid is mainly converted into arachidonic acid, 
linolenic is elongated and desaturated into eicosapentenoic acid and then 
docosahexenoic acid 
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1.9 Proteinuric Renal Disease 
1.9.1 Dyslipidaemia of Proteinuric Renal Disease 
The  prevalence  and  extent  of  dyslipidaemia  in  proteinuric  renal  disease is 
variable depending on the aetiology of the renal dysfunction,    the  degree  of 
the  renal  impairment  and  level  of  proteinuria.  The  association  between 
nephrotic  syndrome  and  hyperlipidaemia  was  first  reported  in  1917(161).  
However, despite extensive clinical and animal work, the mechanism behind 
this has not yet been fully established. 
The development of nephrotic range proteinuria is associated with abnormal 
lipoprotein metabolism and both qualitative and quantitative changes in lipids 
and lipoproteins. Total cholesterol and LDL are invariably raised  (162;163). 
Triglyceride levels may also be elevated (164) and VLDL is raised (162;163). 
Furthermore, it has been shown that patients with nephrotic range proteinuria 
have excess LDL III (165). 
This  pattern  of  abnormalities  is  probably  a  result  of  a  number  of  different 
mechanisms.  Firstly,  the  increase  in  plasma  LDL  is  thought  to  be  due  to 
increased  LDL  synthesis  (166)  and  reduced  catabolism  of  LDL.  Indeed  a 
previous study in our laboratory by Warwick et al showed that there was a 
significant  reduction  in  the  rate  of  catabolism  of  Apo  B,  which is  the  main 
constituent of LDL (167;168). Furthermore, Vaziri et al have suggested that 
not  only  does  proteinuria  lead  to  the  up-regulation  of  3-hydroxy-3-
methylglutaryl  (HMG)  CoA  reductase  (the  rate-limiting  enzyme  required  for 
cholesterol biosynthesis) but also leads to a deficiency in receptor mediated 
LDL clearance. This results in a limitation of hepatic cholesterol uptake and 
leads to an increase in cholesterol and LDL levels (169). Furthermore, it has 59 
 
been  shown  that,  in  patients  with  nephrotic  range  proteinuria,  there  is  an 
increase in HDL3 with a reduction in protective cholesterol rich HDL2 (170). 
Proteinuria  is  thought  to  lead  to  urinary  losses  of  lecithin:  cholesterol 
acyltransferase (LCAT) which has a similar molecular weight to albumin(171). 
This  limits  HDL  mediated  uptake  of  surplus  cholesterol  from  extra  hepatic 
tissues  leading  to  HDL  abnormalities  and  subsequent  effect  on  VLDL  and 
chylomicrons  (172).  The  increase  in  triglyceride  rich  lipoproteins  has  been 
shown  to  be  due  to  impaired  chylomicron  (173;174)  and  VLDL  clearance 
(173).  Deighan  et  al  reported  a  deficiency  of  VLDL  apolipoproteins  in 
proteinuria  and  hypothesised  that  this  deficiency  resulted  in  its  defective 
clearance  (175).  Impaired  lipoprotein  lipase  activity  has  been  observed  in 
patients with proteinuria. LPL is the rate-limiting enzyme involved in lipolysis 
of chylomicrons and VLDL. LPL binds to heparan sulphate proteoglycans on 
the cell surface of the endothelium. Many studies have shown a reduction in 
LPL activity in both nephrotic humans and animals (169).  
 
Data  from  the  Framingham  heart  study  has  shown  that  patients  with 
proteinuria have RLP-C and RLP-TG concentrations 2-3 fold higher than the 
reference range for males(176). In patients with nephrotic range proteinuria, it 
has been demonstrated that there is an excess of remnant lipoproteins as well 
as  LDL  III  thereby  significantly  increasing  cardiovascular  risk(177).  In  this 
study, plasma triglyceride level was the most important factor determining LDL 
III and remnant lipoprotein levels.  
The  formation  of  LDL  III  requires  excess  triglycerides  and  hepatic  lipase. 
Triglyceride  transfers  via  CETP  from  VLDL1  to  LDL  in  exchange  for 60 
 
cholesteryl ester. This produces a triglyceride enriched LDL particle, which is 
hydrolysed by hepatic lipase resulting in the formation of small dense LDLIII. 
This  is  also  the  suggested  mechanism  for  small  dense  LDL  formation  in 
proteinurics  due  to  higher  levels  of  triglyceride  and  the  strong  correlation 
between triglyceride concentration and LDL III concentrations.  
 
1.9.2 Endothelial Function in Proteinuric Renal Disease 
It has been suggested that proteinuria itself, or pathophysiological changes 
associated with it, may cause endothelial dysfunction. There are a number of 
theories  to  explain  the  possible  link  between  proteinuria  and  endothelial 
dysfunction.  These  include  elevated  blood  pressure,  dyslipidaemia, 
hypoalbuminaemia,  disordered  coagulation  pathways,  inflammation  and 
oxidative stress that all may occur in proteinuric patients, particularly those 
with  the  nephrotic  syndrome.  Endothelial  function  has  been  shown  to  be 
abnormal by both venous occlusion plethysmography(178) and brachial artery 
ultrasound(179), in patients with proteinuria.  
 
3.5  Hypotheses and Aims 
1.10.1 Hypotheses 
The purpose of this project is to examine the ability of omega-3 fatty acids 
derived from fish oils to correct the dyslipidaemia observed in patients with 
nephrotic range proteinuria, thus reducing the risk of coronary heart disease 
(CHD), and to clarify the mechanism underlying this dyslipidaemia.   
It is important to establish a lipid lowering therapy that is effective, tailored to 
the specific problem in proteinuric patients but is also safe and well tolerated.  61 
 
Fish  oil  derived  fatty  acids  lower  plasma  triglyceride  by  reducing  VLDL 
production  and  at  the  start  of  the  study,  Omacor,  a  therapeutic  agent 
containing omega-3 fatty acids in a concentrated form had recently become 
available and seemed an ideal therapy for this population. 
Our main hypotheses are (i) Omacor will be well tolerated in subjects with 
nephrotic range proteinuria and will give adequate triglyceride lowering with 
consequent benefits on levels of small dense LDL and HDL.  (ii) VLDL and not 
chylomicrons (intestinally derived lipoproteins) possess structural 
abnormalities that delay clearance and result in hypertriglyceridaemia.  Fish 
oils will correct this.  (iii) Omacor will improve endothelial function in 
proteinuric patients. 
 
1.10.2 Aims 
The following questions summarise the rationale behind this research: 
In patients with nephrotic range proteinuria: 
1.  Does treatment with omega-3 fatty acids give adequate triglyceride control 
with  consequent  benefits  for  levels  of  small  dense  LDL  and  remnant 
lipoproteins? 
2.  Is postprandial lipaemia improved with omega-3 fatty acids? 
3.  Do omega-3 fatty acids have an effect on chylomicron and VLDL1 structure 
and composition? 
4.  Are HDL subfractions affected by treatment? 
5.  What is the effect of treatment on endothelial function and inflammation? 
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2.1 Study Population 
19 Subjects with primary glomerular disease, nephrotic range proteinuria 
(defined as either >3g of proteinuria or >2g of albuminuria per 24 hours) and 
serum creatinine <250µmol/l were recruited. Patients with diabetes mellitus or 
who were on steroids, other immunosuppressive agents or warfarin treatment 
were excluded.  Comparisons were made with age and sex matched controls. 
If used, lipid-lowering treatment was stopped 4 weeks prior to the study and 
restarted following the study. All patients and controls gave written consent 
prior to participating and Glasgow Royal Infirmary Research Ethics Committee 
approved the study. Patients and controls attended after an overnight fast. 
The laser Doppler scan was carried out as outlined in chapter 8. An 
intravenous cannula was inserted and fasting samples were taken. A fat load 
amounting to 90g of fat in the form of “Calogen” drink was given to the 
subject. Subsequent samples were taken at 2, 4, 6 and 8 hours following the 
fat load. This procedure was repeated after 8 weeks treatment with Omega-3 
fatty acids (Omacor) 2g twice daily.  
 
2.2 Statistical Power 
Sample size calculations are to give 80% power at α = 0.05. Omacor reduces 
triglyceride levels by 37% in subjects with hypertriglyceridaemia and 27% in 
familial  combined  hyperlipidaemia(180).  To  detect  a  30%  change  in 
triglyceride concentration, 17 subjects will be required. 
Based  on  results  from  a  previous  study  comparing  VLDL  apolipoprotein 
content  in  subjects  with  proteinuria  and  controls,  each  VLDL  particle  in 
controls contained 10 moles of apoCII, 30 moles of apoCIII and 0.5 moles of 64 
 
apoE(175).    A  meaningful  difference  in  apoCII  between  proteinurics  and 
controls would be 4 moles per lipoprotein particle. Using a standard deviation 
(SD) of 2.5 for this measurement, 8 subjects will be required in each group. 
For apoCIII, 17 subjects  would be required for a  meaningful change of 15 
moles/particle(SD  15).  For  apoE,  17  subjects  would  be  required  for  a 
difference between proteinurics and controls of 0.3 moles/particle (SD of 0.3).  
The  apolipoprotein  content  of  patients  and  controls  post  treatment  with 
Omacor will be compared by ANOVA. For apoCII to detect a difference of 4 
moles/particle (SD 2.5), 8 patients will be required.  For apoCIII, (difference of 
15  moles/particle,  SD  15),  sample  size  =17.  For  apoE  (difference  of  0.3 
moles/particle (SD 0.3), sample size =17.  
The  sample  size  being  studied  is  small  and  so  if  the  standard  deviation 
exceeded  those  predicted  or  if  there  is  marked  heterogeneity  within  the 
population, there will be a significant chance of a Type II error. Given that a 
number of variables studied are inter-related, formal statistical advice was that 
correction  for  multiple  comparisons  was  not  necessary.  However,  we 
acknowledge  that  multiple  analyses  could  result  in  statistically  significant 
results  by  chance  and  so  therefore  we  have  endeavoured  to  avoid  over 
interpreting the data. 
 
2.3   Quantification of Lipoproteins 
VLDL cholesterol, LDL cholesterol and HDL cholesterol were measured 
according to the Lipid Research Clinics Program Manual of Laboratory 
Operations (1975)(12). VLDL (d 1.006g/ml) was isolated by ultracentrifugation 
at 35 000 rpm at 4 C for 18 hours in a Beckman Ti 50.2 rotor. LDL was 65 
 
precipitated by adding an equal volume of 92mmol/l sodium heparin (5x10
5) / 
Mn Cl2(181). This was followed by centrifugation at 10,000 rpm at 4 C for 30 
minutes. HDL remained in solution. Cholesterol measurements were carried 
out on total plasma, VLDL and HDL. The HDL level was subtracted from the 
cholesterol content of the supernatant giving LDL cholesterol. All coefficients 
of variations (CV) were less than 2%. 
 
2.4 Preparation of Chylomicrons 
Chylomicrons were isolated by a short ultracentrifugation at a density of 
1.006g/ml. 2ml of plasma was overlayered with 4ml d=1.006g/ml solution and 
centrifuged in a Beckman Ti 40.3 rotor at 4 C for 30 minutes at 10,000rpm. 
The chylomicrons were removed carefully using a finely drawn glass Pasteur 
pipette in 2ml. The 2 ml removed were then overlayered with 4ml d=1.006g/ml 
solution and centrifuged in a Beckman Ti 40.3 rotor for 16 hours at 15 C at 
35,000rpm for 16 hours. The purified chylomicrons were removed using a 
finely drawn Pasteur glass pipette. 
 
2.5 Isolation of VLDL1 (Sf 60-400), VLDL2 (Sf 20-60), IDL (Sf 12-20) and LDL   
(Sf 0-12) 
VLDL1 (Sf  60-400), VLDL2 (Sf 20-60), IDL (Sf 12-20), LDL (Sf 0-12) were 
isolated from fresh plasma by modification of the cumulative gradient 
ultracentrifugation method (15). Stock solutions of density 1.006g/ml and 
1.182g/ml were prepared using NaCl, NaBr and Na2EDTA. These were used 
to make 6 density solutions, which ranged from 1.0588 to 1.0988g/ml. The 
density of 2mls of plasma (after removal of chylomicrons described above) 66 
 
was adjusted to 1.118g/ml using 0.341g NaCl. The adjusted plasma was 
carefully overlayered by the density solutions as described in Table 2.1. 
Ultracentrifugation of the sample was performed as outlined in Table 2.2. 
Samples were carefully removed after each run using a finely drawn Pasteur 
pipette. 
VLDL1 was removed in 1ml, VLDL2 and IDL in 0.5ml, and LDL in 1ml. After 
removal of VLDL1, The sample was overlayered with 1ml of 1.0988g/ml 
density solution. 
 
 
 
Table 2.1 Density Gradients for Separation of VLDL1, VLDL2, IDL and 
LDL 
Solution      Density (mg/l)    Volume (mls)  Position 
6      1.0588        2    Top 
5      1.0641        2       
4      1.0722        2 
3      1.0790        2 
2      1.0860        1 
1      1.0988        1 
Plasma    1.118 (adjusted)      2 
      1.182          0.5    Bottom 
 
(Adapted with permission(15)) 
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Table 2.2 Conditions for Preparation of VLDL1, VLDL2, IDL and LDL   
    Sf      Speed (rpm)     Time (h/min) 
______________________________________________________________ 
VLDL1   60-400    39,000        1.38 
VLDL2   20-60     18,500        15.41 
IDL    12-20     39,000        2.35 
LDL    0-12      30,000        21.10 
______________________________________________________________ 
(Adapted with permission(15)) 
 
2.6 LDL Subfraction Analysis 
Three LDL subfractions were separated directly from fresh plasma by 
nonequilibrium density gradient ultracentrifugation(59). Again, stock solutions 
of density 1.006g/ml and 1.182g/ml were prepared using NaCl, NaBr and 
Na2EDTA. These were used to make 6 density solutions, which ranged from 
1.060g/ml to 1.019g/ml. The density of plasma was adjusted to 1.09g/ml by 
using KBr. The adjusted plasma was carefully overlayered as described in 
Table 2.3 in an ultraclear Beckman SW 40 tube, which had been coated with 
polyvinyl alcohol. This was centrifuged for 24h at 40,000rpm at 23°C in a 
swinging bucket rotor with slow acceleration and no deceleration. The 
gradient containing separated LDL subfractions was displaced upwards by a 68 
 
dense hydrophobic material (Maxidens 1.9g/ml), which was introduced using 
a constant infusion pump at a flow rate of 0.5ml/min. The presence of 3 
fractions (LDL I d 1.025-1.034 g/ml, LDL II d 1.034-1.044 g/ml and LDL III d 
1.044-1.063 g/ml) was detected by continuous monitoring at 280nm. The 
individual subfraction areas were quantified, corrected for previously 
calculated extinction coefficients and expressed as a percentage of total LDL. 
The lipoprotein mass of LDL (d 1.019 –1.063 g/ml) was determined and used 
to generate individual subfraction concentrations in mg lipoprotein per 100ml 
plasma. 
 
Table 2.3 Density Gradient for LDL Subfractions 
Solution          Density (mg/l)    Volume (ml)           Position 
______________________________________________________________ 
6        1.019            1      Top 
5        1.024            2     
4        1.034            2   
3        1.045            1 
2        1.056            1 
1        1.060            1 
Plasma      1.09 (adjusted)        3 
        1.182            0.5         Bottom 
______________________________________________________________ 
(Adapted with permission (15)).   
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2.7 Sequential preparation of HDL2 and HDL3 
HDL2 (d 1.063 – 1.125 g/ml) and HDL3 (d 1.125 – 1.215 g/ml) were separated  
using sequential density ultracentrifugation. The remaining 4ml of infranatant 
following LDL separation with a density of 1.019- 1.063 g/ml was adjusted 
to d 1.125 g/ml by the addition of NaBr solution at density 1.3104 g/ml. After 
  a 24 hour spin at 15°C at 35, 0000 rpm in a Beckman 50.4 fixed angle rotor in 
a Beckman L8-60M ultracentrifuge, during which the lighter particles floated to 
the top and heavier particles sank, the top 2 ml containing HDL2 at d 1.063-
1.125g/ml were removed carefully from the top. The infranatant was adjusted 
to d 1.215 g/ml by addition of NaBr solution at d 1.3104 g/ml. After a further 
24-hour spin again at 15°C and 35,000 rpm, the top 2 ml containing HDL3 at   
d 1.125- 1.215 g/ml were aspirated. 
    
2.8 Compositional Analysis: Cholesterol, Free Cholesterol, Triglyceride, 
Phospholipid and Protein 
Total lipoprotein composition of VLDL1, VLDL2, IDL, LDL d 1.019 – 1.063, 
HDL2 and HDL3 were quantified as follows. Total cholesterol was measured by 
enzymatic hydrolysis of cholesteryl esters to form free cholesterol followed by 
oxidation to give hydrogen peroxide. This is quantified by formation of a 
coloured product at 505nm (Roche Diagnostics, UK, Kit 11491458216). Free 
cholesterol was assayed by the same method omitting the enzyme cholesteryl 
esterase. (Wako Chemicals: Alpha Laboratories, UK Kit 279-47106). 
Cholesteryl ester was calculated as the total cholesterol minus the free 
cholesterol times 1.68 to correct for mass of esters.  Triglyceride was assayed 
by enzymatic hydrolysis followed by enzymatic determination of liberated 70 
 
glycerol by colorimetry at 505nm (Roche Diagnostics, UK, Kit 12016648122). 
Phospholipid was determined by an enzymatic colorimetric assay method 
using absorbance at 500nm (Wako Chemicals through Alpha Laboratories, 
UK). Lipid analyses were performed on IL 600 clinical chemistry analyser 
(Instrument Laboratories, Cheshire, UK). Protein was analysed by 
modification of the method by Lowry et al(182). The free cholesterol, 
cholesteryl ester, triglyceride, phospholipid and protein content of the VLDL1, 
VLDL2, IDL and LDL collected were assayed and their lipoprotein 
concentration were calculated as the sum of these products. CVs for assays 
were: cholesterol 2.86%, triglyceride 3.83%, free cholesterol 2.15%, 
phospholipid 3.82% and protein 5.06%. 
 
2.9 Remnant Lipoprotein 
RLP-C was separated from plasma by an immunoaffinity mixed gel containing 
monoclonal antibodies to human apo B-100 and human apo A-1. (Japan 
Immunoresearch lab, Takasaki, Japan). The unbound fraction was measured 
after 2 hours incubation on automatic shaker cholesterol by an ultrasensitive 
enzymatic spectrophotometric assay using an I lab 600 clinical chemistry 
analyser. Interassay CV was 5.8%. 
 
2.10 Highly Sensitive CRP 
C reactive protein (CRP) was measured by an in house double antibody 
sandwich enzyme linked immunosorbent assay with rabbit anti-human CRP 
and peroxide conjugated rabbit anti-human CRP(183). Interassay CV was 
2.72%. 71 
 
 
2.11 I-CAM and V-CAM 
ICAM was measured using a quantative sandwich enzyme immunoassay from 
R&D Systems (Abingdon, Oxfordshire) Quantikline Human Soluble ICAM-1 
Immunoassay Kit BBE 1B. VCAM was analysed using a quantative sandwich 
enzyme immunoassay commercially available kit from R&D Systems 
(Abington, Oxfordshire, UK). Interassay CV was less than 5%. 
 
2.12 Insulin and Glucose 
Insulin was measured using a solid phase two-site immunoassay purchased 
from Mercodia (Uppsala, Sweden). Glucose was analysed using a 
commercially available kit from Randox Laboratories, Crumlin, UK.  The 
principle of this assay is glucose-6-phosphate is oxidised in the presence of 
NADP and glucose-6-phosphate dehydrogenase.  The rate of NADPH 
formation during the reaction is directly proportional to the glucose 
concentration. Insulin CV was 4% and glucose 2%. 
 
2.13 Oxidised LDL 
Oxidised LDL was measured using a solid phase two-site antibody 
immunoassay in which two monoclonal antibodies are directed against 
separate antigenic determinants on the same oxidised LDL apoB molecule.  
This is commercially available from Mercodia (Uppsala, Sweden).Interassay 
CV 16.4%. 
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2.14 Apolipoprotein Measurements 
Apolipoprotein were analysed A1, B, CII, CIII and E were analysed on an 
IL600 clinical chemistry analyser (Instrument Laboratories, Warrington, 
Cheshire, UK) using Immunoturbidimetric commercially available kits from 
WAKO Chemicals through Alpha Laboratories, UK. CVs were as follows: AI 
5.23%, B 1.54%, CII 2.46%, CIII 7.31% and E 5.78%. 
 
2.15 HDL Gel Electrophoresis 
HDL sizes were determined using non-denaturing polyacrylamide gel 
electrophoresis using 2-30% linear gradient pre-poured slab gels from Alamo 
Gels, San Antonio, Texas. The gels were scanned by laser densitometry and 
particle size was determined using high molecular weight standards(184) 
[HDL2b 9.7- 12 nm; HDL2a 8.8- 9.7 nm; HDL3a 8.2- 8.8 nm, HDL3b 7.8- 8.2 nm; 
HDL3c 7.2- 7.8 nm]. HDL CVs less than 2%. 
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Chapter 3: Baseline Patient & 
Control Characteristics 
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3.1 Baseline Characteristics 
19 patients who fulfilled the inclusion criteria outlined in the methods section 
(Chapter 2) were recruited from the renal out-patient clinic of Glasgow Royal 
Infirmary. One patient withdrew prior to the first visit and one patient withdrew 
during  the  treatment  period  as  he  became  intolerant  of  Omacor  due  to 
gastrointestinal upset (diarrhoea). Therefore data for 18 patients at baseline 
and 17 patients post treatment were analysed. In the patient group, median 
serum creatinine was 143μmol/l (IQR 118-163). This represented a median 
estimated glomerular filtration rate (eGFR) of 46ml/min (IQR 38-58) using 4 
variable  MDRD  formula(185).  Mean  24  hour  urinary  protein  excretion  was 
4.3g (IQR 3.4-6.0) and mean serum albumin was 36g/dl (IQR 31- 40). Primary 
renal  diagnoses  were  as  follows:  8  idiopathic  membranous  nephropathy,  3 
focal segmental glomerulosclerosis, 2 mesangiocapillary glomerulonephritis, 2 
IgA nephropathy with a further 3 patients with chronic glomerulonephritis that 
was unable to be classified further on renal biopsy.   16 out of the 18 patients 
(84%) were on statin therapy prior to the study and all of the patients were on 
either  an  ACE  inhibitor  or  Angiotensin  receptor  antagonist  with  2  on  dual 
therapy. 
Baseline data was compared with that obtained from 17 control patients who 
were age and sex matched (table 3.1). We attempted to match patients and 
controls  for  triglyceride.  However,  in  view  of  the  significant 
hypertriglyceridaemia observed in the patient population, it proved difficult to 
screen and recruit controls with higher triglyceride levels. This explains why 
the triglyceride levels in the control population were higher than expected in a 
normal population but still lower than the patient group. 75 
 
3.2 Lipids and Lipoproteins 
The results for baseline lipids, lipoproteins, insulin and glucose are outlined in 
table 3.1. Plasma cholesterol was higher in the patient population (p=0.003). 
Plasma  triglyceride  was  also  increased  in  the  patient  population  (p=0.01). 
However,  with  the  initial  attempts  to  match  for  triglyceride,  the  mean 
triglyceride  observed  for  the  control  patients  was  higher  than  would  be 
expected  in  a normal  population.  Total  VLDL-C was  higher  in  the  patients 
(p=0.004) however, LDL-C and HDL-C did not differ significantly despite the 
mean  LDL-C  in  the  patient  group  being  0.5mmol/l  higher  than  controls. 
Notably, fasting insulin and glucose levels were similar despite the observed 
difference  in  plasma  triglyceride  and  there  was  no  relationship  between 
baseline triglyceride concentration and either insulin or fasting glucose in both 
patients and controls.  
 
3.3 Plasma Lipoprotein Concentrations  
Total VLDL concentration in the patients was increased due to an increase in 
both larger, lighter VLDL1 and smaller, denser VLDL2 subfractions although 
only  the  increase  VLDL2  reached  statistical  significance  (p=0.02).  Despite 
similar  LDL-C  levels,  total  LDL  lipoprotein  concentration  was  higher  in  the 
patient  group  (p=0.03),  however  no  difference  in  IDL  concentration  was 
observed (table 3.2).  
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3.4 LDL Subfractions and Remnant Lipoproteins  
The  plasma  concentration  of  small  dense  LDL  (LDLIII)  was  increased 
threefold (p=0.03) in the patient population. LDL II was the major subfraction 
in controls whereas LDL III was the major subfraction in the patient population 
with its mean percentage being twice that in controls. The concentrations of, 
and relative percentages of LDL I and II did not differ significantly between the 
groups. 
 
Remnant-like  lipoproteins  were  increased  in  patients  with  nephrotic  range 
proteinuria. There was an almost three fold increase in the concentration of 
RLP-Cholesterol  (RLP-C)  in  the  patient  group  (p=0.03)  and  although  the 
median RLP-Triglyceride (RLP-TG) concentration was doubled, this did not 
reach statistical significance (table 3.2). 
 
3.5 Factors associated with Baseline LDL III and Remnant Lipoproteins 
in Patients and Controls 
Tables 3.3 and 3.4 outline these relationships. In the patient group, LDL III 
concentration  and  LDLIII  percentage  correlated  with  plasma  triglyceride 
concentrations, VLDL1, VLDL2 and remnant lipoproteins. There is a greater 
correlation between % LDL III and RLP than LDL III concentration as shown in 
table 3.3. No relationship was observed between LDL III and RLP baseline 
renal function, proteinuria, HDL-C, insulin or fasting glucose. 
When  examining  factors  associated  with  LDL  III  and  RLP  across  the  two 
groups  studied,  similarities  and  differences  were  identified.  In  the  control 
group, LDL III concentration and %LDLIII also correlated closely with plasma 77 
 
triglyceride concentrations, VLDL1, VLDL2 and remnant lipoproteins. Also in 
the  control  group,  there  was  a  much  closer  correlation  between  LDL  III 
concentration  and  remnant  lipoproteins.  In  the  control  group,  an  inverse 
relationship between both LDL III concentration and RLP-TG with HDL was 
observed. This was not observed in the patient group however in multivariate 
analysis,  subject  group  was  not  an  independent  predictor  for  LDL  III 
concentration, %LDL III or RLP. 
 
3.6 Discussion 
Analysis of   quantification of lipids at baseline demonstrated that patients 
had  higher  levels  of  total  cholesterol,  triglyceride  and  VLDL-C  and  no 
difference in LDL-C or HDL-C. Detailed lipoprotein analysis demonstrated an 
increase in both VLDL subfractions with a 51% increase in VLDL2 but a non-
significant 39% increase in VLDL1 in patients with nephrotic range proteinuria. 
Higher levels of small, dense atherogenic LDL III were observed in the patient 
group  in  sufficient  quantities  that  is  likely  to  increase  cardiovascular  risk. 
Furthermore,  a  three-fold  increase  in  remnant  lipoprotein  cholesterol  was 
found in the patients with proteinuria.  No direct relationship was observed 
between either RLP or LDL III and urinary protein, plasma albumin or renal 
function.  
 
The results observed in our study are in keeping with previously published 
studies  examining  patients  with  nephrotic  range  proteinuria  both  in  our 
laboratory and by other authors. The most commonly observed abnormality 
observed  in  patients  with  nephrotic  range  proteinuria  is  a  raised  plasma 78 
 
cholesterol (162). Triglyceride levels are often raised but their range is more 
variable(164).  These  changes  have  been  found  to  correlate  inversely  with 
serum albumin(186). Furthermore, previous studies have shown that LDL-C 
levels  are  invariably  raised  in  these  patients(163)  and  VLDL  levels  are 
frequently increased. A previous study from our laboratory has demonstrated 
that  patients  with  nephrotic  range  proteinuria  possessed  excess  remnant 
lipoproteins as well as raised LDL III in quantities significantly increasing CV 
risk. Plasma triglyceride levels have been shown to be the  most important 
factor determining both LDLIII and remnant lipoprotein levels(187) . Data from 
the  Framingham  heart  study  has  shown  that  patients  with  urinary  dipstick 
analysis positive for protein have RLP-C and RLP-TG concentrations 2-3 fold 
higher than the reference range for males(176). In contrast to previous work 
from our laboratory, the 63% rise in median VLDL1 concentration we observed 
in patients compared with controls was not significant. It is recognized that the 
VLDL1  subfraction  predominates  in  patients  with  hypertriglyceridaemia.  In 
keeping  with  this,  plasma  triglycerides  were  elevated  in  the  patient  group. 
However marked heterogeneity was seen in the control group. We suspect 
that  this  results  from  the  higher  than  normal  triglyceride  concentration 
obtained  in  our  control  population  and  accounts  for  the  lack  of  difference 
observed in the VLDL1 results. We did not observe any difference in HDL-C 
concentration.  This  is  a  frequent  finding  with  a  number  of  authors  not 
identifying  any  difference  in  HDL  levels  in  patients  with  nephrotic  range 
proteinuria without renal failure(170;186;188). Thus, our baseline results are 
in  keeping  with  previously  published  work  in  patients  with  nephrotic  range 
proteinuria.  79 
 
 
We did not find subject group to be an independent factor predicting LDL III 
concentration,  %  LDL  III  or  remnant  lipoproteins  suggesting  that  the 
differences  observed  between  the  two  populations  are  due  to  differing 
baseline parameters, and almost certainly, the increased plasma triglyceride 
levels  seen  in  the  patients.  Correlations  between  LDL  III  concentration, 
remnant lipoproteins and plasma triglyceride concentration were tighter in the 
control population. Plasma triglyceride is the most important determinant of 
LDL  III  formation  followed  by  hepatic  lipase  activity.  Increased  triglyceride 
levels lead to triglyceride enrichment of LDL II. Hepatic lipase hydrolyses the 
triglyceride  thereby  shrinking  it  to  LDL  III(65).  This  may  explain  why  we 
observed a weaker correlation between LDL III and triglyceride in the patient 
group as it is likely that due to the hypertriglyceridaemia, hepatic lipase was 
not rate-limiting.  
Increasing number of studies has shown that higher LDL III concentrations are 
associated  with  increased  cardiovascular  risk.  LDL  III  concentration 
>100mg/dl confers a seven-fold increase in risk of myocardial infarction (61). 
Moreover,  there  is  evidence  to  suggest  that  remnant  lipoproteins  are 
atherogenic and an independent risk factor for coronary heart disease (34;35). 
In  summary,  this  combination  of  increases  in  total  cholesterol,  triglyceride, 
VLDL,  LDL  III  and  remnant  lipoproteins  are  all  likely  to  contribute  to  the 
significantly increased risk of cardiovascular disease observed in patients with 
proteinuria. 
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______________________________________________________________ 
          Patients          Controls 
          n= 18             n=17 
                                                         (All median & IQR) 
______________________________________________________________ 
Age (years)        63.0 (55.8- 71.0)    61 (47.0-70.5) 
Sex (M:F)        15:3        14: 3 
Cholesterol (mmol/l)      6.2 (5.5- 7.5)     5.5 (4.7 – 5.9)* 
Triglyceride (mmol/l)    2.1 (1.8- 2.6)     1.4(1.1 – 2.0) ** 
VLDL-C (mmol/l)      0.7 (0.6 -1.2)     0.5(0.3- 0.7) † 
LDL-C  (mmol/l)      4.2 (3.3- 5.4)     3.7 (3.0- 4.3) 
HDL-C (mmol/l)      1.0 (0.90 -1.1)    1.1 (0.9- 1.4) 
Insulin (mmo/l)      10.4 (7.9 -16.8)    8.4 (3.8- 15.8) 
Glucose (mmol/l)      5.3 (4.8 -6.2)     5.3 (4.4- 5.9) 
 
 
Table 3.1 Baseline Patient and Control Characteristics 
Baseline patient characteristics compared with controls. Prior to statistical 
analysis, any parameter which was not normally distributed was normalised 
by log transformation. All data were compared using unpaired t-tests. 
Statistical differences are indicated (* p=0.003, **p=0.01, †p=0.004). 
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______________________________________________________________ 
 
      Patient      Control      p 
           
(n=18 )       (n=17) 
             
   (All median & IQR) 
______________________________________________________________ 
 
Total VLDL    182 (122- 240)    107 (78- 175)             ns 
 
 
VLDL1 (mg/dl)  106 (62-138)     65(35- 115)                       ns 
 
   
VLDL2 (mg/dl)  88 (44-106)      43 (35- 61)                  0.02 
 
 
IDL (mg/dl)    59 (44- 82)      53 (43- 64)               ns 
 
 
LDL I conc(mg/dl)  43 (21- 62)      29 (15-57)              ns 
 
 
LDL II conc(mg/dl)  198 (112- 246)    167 (73-261)              ns 
 
 
LDL III conc(mg/dl)  195 (64-237)     53 (30-182)                     0.03       
 
 
T-LDL conc(mg/dl)  411 (278-492)    315 (254-374)                    0.03 
 
 
% LDL I    8.9(5.5-15.8)     8.1 (3.8-16.1)             ns 
 
 
%LDL II    41.1 (34.3-61.6)                 65.2 (27.3-68.3)            ns
                     
       
%LDL III    48.4 (17.8-60.3)    24.7 (12.0-63.9)             0.07 
 
 
RLP- C (mg/dl)  14.8 (6.0- 20.5)    5.6 (4.1- 12.7)             0.03 
 
 
RLP-TG (mg/dl)  46.5 (22.2- 51.3)    23.8 (20.8 – 49.2)             ns 
 
 
Table 3.2 Patient and Control Lipoproteins at Baseline 
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      LDL III conc         LDL III%             RLP-C    RLP-TG 
 
      (r
2%)           (r
2%)               (r
2%)      (r
2%) 
 
 
 
Triglyceride    32.7
 c           53.5
 a    64.1
 a     71.5
 a   
 
 
VLDL1 conc    30.5
 c           50.4
 a              72.4
 a    79.7
 a 
 
 
VLDL2 conc    52.7
 a          56.0
 a    36.8
 b    30.7
 c 
 
 
RLP-C    19.8
 d          40.5
 d     _    _ 
 
 
RLP-TG    20.4
 d          45.7
 b    _    _ 
 
 
HDL-C    0.0          0.0    0.0    0.0 
 
 
 
 
Table 3.3 Factors associated with LDL III and Remnant Lipoprotein 
Concentration in Patients at Baseline 
 
Linear regression analysis of baseline LDL III and remnant lipoproteins with 
baseline triglyceride, VLDL1, VLDL2, remnant lipoproteins and HDL in patient 
group. r
2% = coefficient of determination and level of statistical significance is 
indicated: 
a p<0.001, 
b p<0.005, 
c p<0.01, 
d p<0.05. 
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       LDL III conc    LDL III%           RLP-C             RLP-TG 
 
            (r
2%)       (r
2%)           (r
2%)     (r
2%) 
 
 
 
Triglyceride    70.0
 a       49.4
 a    80.1
 a    77.6
 a   
 
 
VLDL1 conc    64.5
 a       37.8
 b    68.5
 a    60.7
 a 
 
 
VLDL2 conc    59.4
 a      32.4
 d    44.3
 b    19.4
 d 
 
 
RLP-C    67.2
 a       59.0
 a     _     _ 
  
 
RLP-TG    49.1
a       39.5
 b     _     _ 
 
 
HDL-C    30.8
 d       6.5      16.8    27.7
 d 
 
 
 
 
 
Table 3.4 Factors associated with LDL III and Remnant Lipoprotein 
Concentration in Controls at Baseline 
     
Linear regression analysis of baseline LDL III and remnant lipoproteins with 
baseline triglyceride, VLDL1, VLDL2, remnant lipoproteins and HDL in controls 
group. r
2% = coefficient of determination and level of statistical significance is 
indicated: 
a p<0.001, 
b p<0.005, 
c p<0.01, 
d p<0.05. 
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Chapter 4: The Effect of 
Omega-3 Fatty Acids on 
Atherogenic Lipoproteins in 
Proteinuric Patients 
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4.1 Introduction 
It  is  known  that  patients  with  nephrotic  range  proteinuria  posses  the 
atherogenic  lipoprotein  phenotype  characterised  by  hypertriglyceridaemia, 
small  dense  LDL  and  low  HDL-C(187).  These  abnormalities  are 
proatherogenic conferring an increase in cardiovascular risk with an LDL III 
concentration of > 100 mg/dl which has been associated with a seven-fold 
increase in the risk of myocardial infarction (61). Remnant lipoproteins and 
remnant  lipoprotein  cholesterol  (RLP-C)  are  also  known  to  be 
proatherogenic(189)  and  an  independent  risk  factor  for  coronary  artery 
disease (190). Their presence is characteristically observed in patients with 
hypertriglyceridaemia. Deighan et al have previously shown that excess levels 
of  both  LDLIII  and  RLP-C  were  present  in  patients  with  nephrotic  range 
proteinuria  and  these  levels  were  closely  correlated  with  triglyceride 
concentration (187). 
Omega-3  fatty  acids  have  cardioprotective  effects  through  a  number  of 
mechanisms. These have been discussed in chapter 1 and include triglyceride 
reduction. Theoretically therefore, they would appear to be an ideal treatment 
to reduce the hypertriglyceridaemia present in patients with proteinuria and as 
a  result,  have  beneficial  effects  on  both  small  dense  LDL  and  remnant 
lipoproteins.  
Our  aim,  therefore,  was  to  examine  the  effect  of  high  dose  omega-3  fatty 
acids on atherogenic triglyceride rich lipoproteins in patients with nephrotic 
range proteinuria and also in age and sex matched controls. In particular we 
aimed to assess changes in small dense LDL and remnant lipoproteins. 
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4.2 Subjects and Methods 
18 patients with nephrotic range proteinuria and 17 controls were recruited as 
described in chapter 3. One patient did not tolerate omega-3 fatty acids and 
so 17 patients and 17 controls were analysed. Samples following a ten hour 
fast were taken at baseline and after an eight-week treatment period with 4g 
of  omega-3  fatty  acids  daily  (Omacor  –Solvay).  Patients  receiving  lipid-
lowering therapy had their treatment stopped for a period of four weeks prior 
to inclusion into the study. 
 
4.3 Statistics 
Statistical  analyses  were  carried  out  using  MINITAB  13.1  for  Windows 
(Minitab inc). Results are shown as median and interquartile ranges (IQR). 
Prior to statistical analysis, any factor that was not normally distributed was 
normalised by log transformation. Patient and control results were compared 
using unpaired t-tests. Results pre and post treatment were compared using 
paired t-tests. Linear regression analysis was performed to identify significant 
correlations.  Multivariate analysis was performed using stepwise regression 
and a general linear model. 
 
4.4 Results 
4.4.1 Lipids and Lipoproteins 
Changes in lipids and lipoproteins in patients following treatment with omega-
3 fatty acids are outlined in table 4.1. In proteinuric patients we found that 4g 
daily of omega-3 fatty acids reduced plasma triglyceride (TG) concentration by 87 
 
a mean of 0.45mmol/l (95%CI:  0.16 to 0.74, p=0.005). Plasma VLDL-C also 
fell following treatment (mean decrease 0.38mmol/l 95% CI:  0.01 to 0.75, 
p=0.04). This was mainly due to a decrease in larger TG rich VLDL1 rather 
than VLDL2 with a mean reduction of VLDL1 33.2mg/dl (95% CI 4.2 to 62.2, 
p=0.03). It is noteworthy that total plasma cholesterol increased by a mean of 
0.25mmol/l  (95%  CI:  0.0  to  0.5,  p=0.05)  with  an  increase  in  LDL-C  in 
proteinuric patients following treatment with omega-3 fatty acids with a mean 
increase of 0.6 mmol/l (95% CI 0.2 to 1.1, p=0.06). Plasma concentration of 
HDL-C  did  not  differ  following  treatment  in  the  proteinuric  patients.  In  the 
control  group,  no  significant  change  in  plasma  concentration  of  total 
cholesterol, triglyceride, VLDL-C, LDL-C, or HDL-C was observed following 
treatment with omega-3 fatty acids (table 4.2).  
 
4.4.2 LDL Subfractions 
In the patient population, there was a significant reduction in the proportion 
(percent LDL III) and concentration of LDL III. The overall percentage of LDL 
that was in the form of LDLIII (LDLIII %) fell by a mean of 8.6 (95% CI: 0.8 to 
16.4 p=0.01) and LDL III concentration fell by a mean of 26.4 mg/dl (95% CI –
14.5 to 67.4, p=0.05). In the patient group, the percentage and concentration 
of  large,  light,  cholesterol-rich  LDLI  increased  following  treatment,  with  a 
mean  increase  in  LDLI%  of  2.6  (95%CI  0.8  to  4.3  p=0.03  and  a  mean 
increase in LDL I concentration of 13.4mg/dl (95%CI 5.2 to 21.6), p=0.001. No 
change  in  LDL  II  concentration  or  percentage  was  observed.  Total  LDL 
lipoprotein  concentration  only  rose  marginally  not  reaching  statistical 88 
 
significance despite an increase in LDL-C following treatment with omega-3 
fatty acids. 
Changes in the LDL subfraction profile of the controls were less marked, with 
no  observed  difference  in  LDL  III  concentration  or  LDL  III  %.  There  was, 
however, an increase in larger, lighter, less atherogenic LDL with an increase 
in LDL II concentration of 33.6mg/dl (95% CI 2.1 to 65.0, p=0.02). A significant 
increase in total LDL concentration was also observed in the controls (31.9 
mg/dl: 95% CI 0.6 to 63.2, p=0.04)  
Of  the  patients  who  completed  the  study,  13  out  of  17  patients  (72%) 
possessed LDL III concentrations above 100mg/dl at baseline falling to 7 out 
of  17 (41%)  after  treatment  with  omega-3  fatty  acids. 8  out  of  17  controls 
(47%) had LDL III concentration above 100mg/dl prior to treatment falling to 6 
(35%) following treatment. 
The  effect  of  omega-3  fatty  acids  on  LDL  subfractions  was  very 
heterogeneous in  both  the  patient  and  control  populations,  ranging  from  a 
reduction of 164 mg/dl to an increase of 150 mg/dl in LDL III concentration in 
the patients group and from a reduction of 78mg/dl to an increase of 92mg/dl 
in the control group. Figure 4.1 illustrates the effect on LDL subfraction profile 
before and after treatment with omega-3 fatty acids in one individual patient 
with a marked reduction in the % LDL III. 
 
4.4.3 Remnant Lipoproteins 
Following  treatment  with  omega-3  fatty  acids,  RLP-C  concentration  fell  in 
patients by a mean of 3.5mg/dl (95% CI 0.1 to 6.9), p=0.05. Similarly RLP-TG 
concentration fell by a mean of 12.4mg/dl (95% CI 2.6 to 22.2), p=0.03. In the 89 
 
control group, RLP-C and RLP-TG were unchanged following treatment with 
omega-3 fatty acids.  
 
 
 
 
Fig 4.1 Effect on LDL profile in one Patient 
Shift in LDL Subfraction profile in an individual patient before and following 
treatment with Omega-3 fatty acids. Profile changes form predominantly LDL 
III to LDL II. 
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4.4.4 Factors determining change in LDLIII and Remnant Lipoproteins 
In the patient group, there was no association between either the change in 
LDL III concentration or the proportion of LDL III (expressed as a percentage) 
with  change in  triglyceride,  VLDL1,  VLDL2,  RLP-C or  RLP-TG (table 4.5  & 
figure 4.2). In contrast, a correlation was demonstrated in the control group 
between  the  change  in  both  LDL  III  concentration  and  LDLIII%  and  the 
change  in  plasma  triglyceride,  VLDL2  and  RLP-TG.  As  a  result  of  these 
contrasting  results,  we  proceeded  to  further  statistical  analysis  using  the 
subject group as an independent variable. This did not show patient group to 
be an independent predictor of the change in LDLIII concentration or LDLIII% 
following treatment.  
The relationship between remnant lipoprotein reduction and reduction in TG 
and  TG  rich  lipoproteins  were  similar  in  the  two  groups  studied.  In  the 
patients,  the  reduction  in  RLP-C  was  associated  with  the  reduction  in 
triglyceride  and  VLDL1  (r
2  47.5,  p=0.001  and  r
2=40.2,  p=0.004). Whilst  the 
change in RLP-TG correlated with change in VLDL1 (r
2=27.6, p=0.02) but not 
triglyceride concentration. In the controls, the change in RLP-C and RLP-TG 
strongly correlated with change in triglyceride, VLDL1 and VLDL2 (table 4.6 & 
figure  4.3).  Again,  when  subject  group  was  included  as  an  independent 
variable  in  multivariate  analysis,  it  was  not  found  to  be  an  independent 
predictor of change in remnant lipoproteins. 
 
4.5 Discussion 
In this study, we have demonstrated that treatment with omega-3 fatty acids in 
patients with nephrotic range proteinuria has a beneficial effect on atherogenic 91 
 
lipoproteins. Treatment significantly reduced LDL III concentration and caused 
a  reduction  in  remnant  lipoproteins.  Furthermore,  they  decreased  plasma 
triglyceride  and  VLDL  levels  particularly  VLDL1.  We  also  observed  an 
increase in plasma LDL- C with omega-3 fatty acid treatment although this 
was potentially offset by a redistribution to larger, lighter, less atherogenic LDL 
These effects were not observed in the control group as omega-3 fatty acids 
neither significantly affected the proportion of, or concentration of LDL III nor 
did treatment influence plasma triglyceride or VLDL concentration.  
The cardioprotective effects of omega-3 fatty acids were first noted following 
the observation that the Greenland Inuit had a low mortality from CHD despite 
a high incidence of smoking and obesity. A number of epidemiological and 
population  studies  have  since  demonstrated  the  cardioprotective  effects  of 
omega-3 fatty acids. The Nurses‟ Health Study found that CHD deaths were 
50% lower in those women who consumed fish five times a week. A subgroup 
of  these  women  with  diabetes  showed  a  stronger  relationship  with  a  60% 
reduction in CHD death (106).  The diet and reinfarction trial (DART) (111) 
found that patients who received dietary advice on increasing fish intake had a 
relative  reduction  in  mortality  of  29%  during  the  2  year  follow-up  mainly 
because  of  reductions  in  deaths  from  CHD.  The  Physician‟s  Health  Study 
(112) found a reduced risk of sudden cardiac death in subjects with increased 
levels of omega- 3 fatty acids. Furthermore, the Italian GISSI-Prevenzione trial 
found that patients randomised to a daily capsule of omega 3 fatty acid (1g) 
had  a  reduction in  relative risk  of  15%  in  the  composite  end-point  of  total 
mortality, non-fatal myocardial infarction and stroke (113). As a result of these 
studies,  the  American  Heart  Association  now  recommends  that  high  risk 92 
 
patients or patients with cardiovascular disease eat fish (particularly fatty fish) 
at least twice a week. 
 
The  cardioprotective  effects  of  omega-3  fatty  acids  may  be  as  a  result  of 
various  different  mechanisms.  These  include  their  effects  on  atherogenic 
lipoproteins.  In  normal  controls,  omega-3  fatty  acids  are  known  to  exert  a 
number  of  effects  on  plasma  lipoproteins.  They  reduce  plasma  triglyceride 
concentration  in  a  dose  dependant  manner  with  doses  of  4g  causing  a 
reduction  of  25-30%  (191).    This  is  thought  to  be  through  suppression  of 
hepatic  VLDL  and  triglyceride  production.  It  has  also  been  suggested  that 
there is increased catabolism of VLDL to LDL through enhanced binding of 
omega-3  fatty  acid  enriched  VLDL  to  lipoprotein  lipase  (192).  A  review  by 
Harris of human trials concluded that omega-3 fatty acids had no clinically 
significant  effect  on  total  cholesterol  with  an  increase in  LDL-C which  was 
more  marked  in  hypertriglyceridaemic  patients  and  a  minimal,  inconsistent 
effect on HDL levels(191). At higher doses (3-5g) the LDL-C raising effect of 
omega-3  fatty  acids  are  well  recognized  with  a  redistribution  of  LDL 
phenotype  to  one  that  is  larger,  lighter  and  potentially  less  atherogenic 
particles(126).  
 
We observed a fall in LDL III proportion and concentration following treatment 
with omega-3 fatty acids in the patients with nephrotic range proteinuria. This 
was not observed in the normal controls. In that context, the mean reduction 
of triglyceride concentration was 17.5% in the patient group and 5.9% in the 
control group. However, there was a strong relationship between change in 93 
 
plasma triglyceride and change in LDL III reduction in the control group, which 
was not observed in the nephrotic group. We did not find subject group to be 
an independent factor responsible for these observed differences and so it is 
likely that these differences are due to a difference in baseline parameters, 
particularly  the  baseline  levels  of  plasma  triglyceride.  It  has  been 
hypothesised that in males, in order to produce atherogenic levels of LDL III, 
adequate hepatic lipase activity and a plasma triglyceride level of >1.5 mmol/l 
is required. In this study, the majority of the patient group were male (82%) 
and  in  15  out  of  the  17  patients  who  completed  the  study,  triglyceride 
concentration was >1.5 mmol/l at baseline. This fell to 10 out of 17 at the end 
of treatment. We propose that this explains the lack of relationship between 
triglyceride  reduction  and  LDL  III  reduction  in  the  patients  group,  as  the 
triglyceride  reduction  was  not  enough  to  make  plasma  triglyceride  a  rate-
limiting factor in the production of small dense LDL with the mean triglyceride 
in  the  patients  following  treatment  remaining  elevated  at  1.8mmol/l.  In 
contrast, 8 out of 17 controls had a baseline triglyceride concentration of >1.5 
mmol/l  falling  to  6  at  the  end  of  treatment  with  a  mean  triglyceride  of 
1.5mmol/l. Thus, we suggest the difference in effect of omega-3 fatty acids on 
LDL III concentration in the 2 populations is due to the difference in baseline 
triglyceride levels rather than the 2 groups responding differently to treatment. 
 
Remnant lipoproteins were significantly reduced by omega-3 fatty acids in the 
patient group but not in the control group. Once again, we did not find this to 
be  a  group  effect  and  this  might  be  due  to  the  higher  baseline  levels  of 
triglyceride and VLDL1 in the patient group. We know that triglyceride is a 94 
 
major  determinant  of  remnant  lipoprotein  production  and  we  have  already 
shown that they are strongly related to plasma triglyceride and VLDL1 levels. 
Therefore, both groups display a similar response to the omega-3 fatty acids 
but as there are higher baseline levels of triglyceride, remnant lipoproteins 
and a significant triglyceride reduction in the patient group, this results in a 
marked fall in remnant lipoproteins. 
 
A concerning effect of omega-3 fatty acids was the observed increase in LDL-
C in the patient group. This LDL raising effect is a well recognized effect of 
omega-3 fatty acids (123;191) but is poorly understood. Possible mechanisms 
include  down  regulation  of  the  LDL  apolipoprotein  B/E  receptor  or  a 
preferential  conversion  of  synthesized  VLDL  to  LDL.  This  effect  on  LDL 
represents one of the controversial aspects of omega-3 fatty acids. Several 
epidemiological  and  clinical  trials  (193-195)  have  established  that  the 
relationship between LDL-C and relative risk for CHD is log-linear. Thus, at 
any level of LDL-C, for any given mg/dl change in LDL-C level, the change in 
relative risk is the same (196). This reduction of LDL-C levels, irrespective of 
how,  has  been  shown  to  reduce  the  risk  of  CHD  (197).  As  discussed  in 
chapter  1,  patients  with  nephrotic  range  proteinuria  have  an  increased 
cardiovascular risk, and so increasing levels of LDL-C in these patients could 
potentially increase this risk. However, it is not known whether the increase in 
LDL-C caused by omega-3 fatty acids coupled with the redistribution to larger, 
lighter  and  therefore  potentially  less  atherogenic  LDL  would  result  in  an 
increased cardiovascular risk or whether the other beneficial effects of omega-
3 fatty acids (discussed in chapter 1) outweigh this. It has been shown that 95 
 
cerivastatin reduces LDL III concentrations by 27% in patients with nephrotic 
range proteinuria(198),  therefore it  may  be useful  to  combine  a  statin  with 
omega-3 fatty acids to offset the LDL raising effect. 
 
Omega-3 fatty acids in the form of Omacor were generally well tolerated by 
both  patients  and  controls.  One  patient  withdrew  during  the  study  as  he 
suffered gastrointestinal upset in the form of abdominal pain and diarrhoea. 
Other  reported  minor  effects  were  a  fishy  after  taste.  Anecdotally,  several 
patients  reported  that  their  arthritis  had  improved  on  treatment  with  one 
patient requesting to continue on treatment after completion of the study. 
 
In conclusion, in patients with nephrotic range proteinuria omega-3 fatty acids 
reduce LDL III remnant lipoproteins and triglyceride rich lipoproteins thereby 
reducing cardiovascular risk. However these beneficial effects are offset by an 
increase  in  LDL-C.  It  is  not  clear  whether  this  increase  in  LDL-C  with 
redistribution  in  LDL  size  confers  an  increase  in  cardiovascular  risk.  One 
potential role for omega-3 fatty acids could be in conjunction with a statin in 
order to combine LDL-C lowering with a reduction in atherogenic triglyceride 
rich lipoproteins. Further work is required in this area to clarify this. 
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Patients 
(n=17) 
Baseline  Post Treatment  p 
Cholesterol (mmol/l)  6.2 (5.5- 7.3)  6.4 (5.5- 7.5)  0.05 
Triglyceride (mmo/l)  2.2 (1.7- 2.6)  1.8 (1.2- 2.2)  0.005 
VLDL-C (mmol/l)  0.7 (0.6- 1.3)  0.6 (0.4- 0.9)  0.04 
LDL-C (mmol/l)  4.1 (3.2- 5.4)  4.6 (4.0- 5.8)  0.06 
HDL-C (mmol/l)  1.10 (0.9- 1.2)  1.2 (0.9- 2.4)  ns 
IDL-C (mg/dl)  58.2 (43.0- 79.2)  62.3 (48.0- 130.3)  ns 
VLDL1 concentration (mg/dl)  106.1 (60.8- 141.1)  70.9 (35.8- 108.0)  0.03 
VLDL2 concentration (mg/dl)  87.1 (43.4- 107.9)  73.2 (47.7- 95.2)  ns 
RLP-C (mg/dl)  14.6 (5.9- 22.0)  8.8 (6.1- 16.9)  0.05 
RLP-TG (mg/dl)  46.0 (21.8- 52.2)  26.4 (19.6- 46.9)  0.03 
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Controls 
(n=17) 
Baseline  Post Treatment  p 
Cholesterol (mmol/l)  5.6 (4.7- 5.9)  5.4 (5.0- 6.2)  ns 
Triglyceride (mmol/l)  1.5 (1.1- 2.0)  1.3 (1.0- 1.8)  ns 
VLDL-C (mmol/l)  0.6 (0.3- 0.7)  0.4 (0.3- 0.7)  ns 
LDL- C (mmol/l)  3.8 (3.0- 4.3)  3.9 (3.4- 4.4)  0.07 
HDL- C (mmol/l)  1.1(0.9- 1.4)  1.2 (1.0- 1.5)  ns 
IDL (mg/dl)  52.7 (43.4- 63.6)  53.8 (43.8- 62.7)  ns 
VLDL1 concentration (mg/dl)  64.6 (35.2- 114.8)  59.6 (25.4- 96.1)  ns 
VLDL2 concentration (mg/dl)  43.4 (34.8- 60.6)  43.2 (31.7- 100.0)  ns 
RLP-C (mg/dl)  5.6 (4.1- 12.7)  5.2 (3.7- 12.4)  ns 
RLP-TG (mg/dl)  23.8 (20.8- 49.2)  22.0 (19.4- 40.6)  ns 
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Patients  Baseline  Post Treatment  p 
LDL I %  8.4 (5.4- 17.2)  11.5 (6.5- 19.3)  0.03 
LDL II%  40.4 (33.6- 62.4)  55.2 (34.2- 64.8)  ns 
LDL III %  49.9 (17.4- 61.2)  29.8 (14.9- 58.5)  0.01 
LDL I conc (mg/dl)  41.3 (20.6- 59.4)  54.9 (24.9-  81.2)  0.001 
LDL II conc (mg/dl)  184.8 (104.9- 248.4)  215.9 (138.2- 309.2)  ns 
LDL III conc (mg/dl)  178.8 (61.6- 231.0)  96.1 (49.3- 204.5)  0.05 
Total LDL conc (mg/dl)  370.5 (270.8- 480.7)  397.8 (313.8- 527.3)  ns 
 
Table 4.3 The Effect of Omega-3 Fatty Acids on LDL Subfractions in Patients 
 
 
 
Controls  Baseline  Post Treatment  p 
LDL I %  8.1 (3.8- 16.1)  13.2 (7.5- 54.6)  0.07 
LDL II%  65.2 (27.3- 68.3)  66.1 (39.4- 72.0)  ns 
LDL III %  24.7 (12.0- 68.4)  16.9 (11.6- 38.8)  ns 
LDL I conc (mg/dl)  28.9 (14.8- 57.3)  41.0 (25.2- 62.2)  ns 
LDL II conc (mg/dl)  167.0 (72.8- 260.6)  213.7(132.5- 258.3)  0.02 
LDL III conc (mg/dl)  53.3 (29.8- 182.0)  50.3 (36.9- 142.6)  ns 
Total LDL conc (mg/dl)  317.5 (253.9- 374.2)  338.0 (299.1- 400.8)  0.04 
 
Table 4.4 The Effect of Omega-3 Fatty Acids on Lipoproteins in Controls 
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    ∆LDL III conc      ∆LDL III%    ∆RLP-C  ∆RLP-TG 
 
            (r
2%) 
 
 
∆Triglyceride       0.7    11.9      47.5
a        0 
   
 
∆VLDL1 conc      0      2.3      40.2
b       27.6
c
   
 
∆VLDL2 conc      5.1     12.4      0       8.9 
 
 
 
∆RLP-C               0      13      -      -      
         
 
∆RLP-TG       0      3.5      0      - 
         
 
 
 
 
 
 
 
Table 4.5 Factors Associated with Change in LDL III and Remnant 
Lipoprotein Concentration in Patients  
 
Linear regression analysis of change in LDL III and remnant lipoproteins with 
change in triglyceride, VLDL1, VLDL2 and remnant lipoproteins in the patient 
group. r
2% = coefficient of determination. Level of statistical significance is 
indicated: 
a p=0.001, 
bp=0.004, 
cp=0.02. 
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     ∆LDL III conc      ∆LDL III%        ∆RLP-C   ∆RLP-TG 
 
            (r
2%) 
 
 
∆Triglyceride   50.2
b         38.5
c              74.9
a                  80.7
a 
 
 
∆VLDL1 conc   4.6         9.4     69.7
a                  56.0
a
   
 
∆VLDL2 conc   41.1
b        41.5
b    35.3
c         51.3
a
   
 
 
∆RLP-C    17.1        16.3     -           - 
               
 
∆RLP-TG    30.7
d        41.4
b    83.5
a           - 
   
 
     
 
 
 
Table 4.6 Factors associated with Change in LDL III and Remnant 
Lipoprotein Concentration in Controls  
 
Linear regression analysis of change in LDL III and remnant lipoproteins with 
change in triglyceride, VLDL1, VLDL2 and remnant lipoproteins in the control 
group. r
2% = coefficient of determination. Level of statistical significance is 
indicated: 
a p<0.001, 
b p<0.005, 
c p<0.01, 
d p<0.05. 
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Figure 4.2 Change in LDL III concentration vs Change in Triglyceride 
 
Linear Regression analysis of change in LDL III concentration with change in 
triglyceride concentration in patients and controls as indicated.  
(Patients r
2=0.7%, p=ns & Controls r
2=50.2%, p<0.005) 
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 Figure 4.3 Change in RLP-C vs Change in Triglyceride Concentration 
 
Linear Regression analysis of change in RLP-C with change in triglyceride 
concentration in patients and controls as indicated.  
(Patients r
2= 47.5%, p=0.001 & Controls r
2= 74.9, p<0.001) 
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Chapter 5: Omega-3 Fatty 
Acids and Postprandial 
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5.1 Introduction 
The  importance  of  postprandial  lipid  metabolism  in  the  development  of 
coronary artery disease is well established. 
Chylomicrons are the largest and lightest triglyceride-rich lipoproteins. They 
are  plentiful  postprandially  but  almost  absent  when  fasted.  They  are 
synthesised  in  response  to  dietary  lipid  intake  and  are  responsible  for 
transporting dietary triglyceride and cholesterol. They are composed mainly of 
triglyceride with apo B48 as the structural protein. VLDL are also triglyceride- 
rich but have apo B100 as the structural protein. They are responsible for the 
transport  of  endogenously  synthesised  triglyceride.  VLDL  particles  can  be 
subdivided into two subfractions according to their flotation coefficients using 
cumulative gradient centrifugation (described in chapter 2). VLDL1 (Sf 60-400) 
is larger, lighter and more triglyceride-rich. VLDL2 (Sf 20-60) is smaller, denser 
and more enriched in cholesteryl ester. These two subfractions appear to be 
independently regulated. VLDL1 is associated with raised plasma triglyceride 
and  overproduced  in  patients  with  insulin  resistance  (199).  VLDL2  is 
overproduced  in  patients  with  raised  LDL  cholesterol.  VLDL1  is  inefficiently 
converted to LDL in contrast to VLDL2 which is rapidly metabolised to LDL. 
Patients  with  nephrotic  range  proteinuria  have  been  found  to  have  an 
increase in plasma concentrations of both these VLDL subfractions (162;163). 
The effects of omega-3 fatty acids on postprandial lipaemia is not completely 
understood  but  they  are  known  to  decrease  hepatic  VLDL  production, 
increase VLDL to LDL conversion, reduce the magnitude of the postprandial 
triglyceride response (119;200;201) and increase chylomicron clearance.  We 105 
 
aimed  to  examine:  (1)  chylomicron  and  VLDL1  metabolism  in  patients  with 
nephrotic range proteinuria compared with controls (2) The effect of omega-3 
fatty acids on chylomicron and VLDL1 metabolism in patients compared with 
controls. 
 
5.2 Methods 
The same study population described in the methods section were used for 
this study. Patients and controls were treated with 4 g daily of omega-3 fatty 
acids (Omacor) for a period of eight weeks and attended on 2 occasions: once 
prior to treatment and also at the end of the treatment period. They ingested a 
90g fat load in the form of a calogen drink. Chylomicrons and VLDL1 were 
isolated  by  density  ultracentrifugation  from  EDTA  plasma  (as  described  in 
chapter 2) in fasting and at 2 hour, 4 hour, 6 hour and 8 hour samples after 
the  fat  load.  Separation  of  lipoproteins  was  performed  immediately  after 
sampling to prevent degradation of the chylomicrons. Chylomicron and VLDL1 
concentrations were measured also as described in chapter 2. Incremental 
area under the curve (AUC) was calculated by standard methods to quantify 
postprandial lipoprotein concentrations. 
 
5.3 Statistics 
Statistical analyses  were  performed  using MINITAB  14X  for Windows.  Any 
factors that were not normally distributed were subject to log transformation. 
These included chylomicron incremental area under the curve. Results are 
shown as median and interquartile range (IQR). Paired data were compared 
using  a paired  t-tests  and  comparison  between  patients  and  controls  were 106 
 
carried  out  using  2  sample  t-tests.  Simple  regression  analyses  were 
performed  to  elucidate  associations.  A  General  Linear  Model  was  used  to 
perform multivariate analysis if a categorical variable was included. 
 
5.4 Results 
5.4.1 Postprandial Chylomicron Concentration 
 
AUC (mmol/l.h)  Baseline  Post Treatment  p 
Patients  18.5 (8.9- 32.6)*  13.5 (7.4-22.9)  0.05 
        Controls  9.2 (4.8- 14.4)  7.2 (4.6- 14.5)  ns 
 
Table  5.1  Chylomicron  AUC  in  Patients  and  Controls  at  baseline  and   
following treatment 
*p=0.05 when compared with controls 
 
 
At baseline, postprandial chylomicron AUC was greater in patients compared 
with controls (Median 18.5mmol/l.h: IQR 8.9-32.6 vs 9.2 mmol/l.h:4.8-14.4) 
p=0.05. Following treatment we observed a fall in patient chylomicron AUC 
with a mean reduction of 6.8mmol/l.h (95% CI 0.1-13.6, p=0.05). However, in 
the control population, the reduction in chylomicron AUC was not significant 
with a mean decrease of 3.9mmol/l.h (95% CI –3.6 to 11.5, p=ns). As a result 
of the decrease in patient chylomicron AUC, at the end of 8 weeks treatment, 
patient and control chylomicron AUC concentrations were no longer 
significantly different (Table 5.1). Figure 5.1 shows chylomicron triglyceride 107 
 
concentration in patients and controls before and after treatment with omega-
3 fatty acids. 
In patients, peak postprandial chylomicron triglyceride concentration fell 
following treatment with omega-3 fatty acids from 5.5mmol/l (95% CI 2.5- 7.4) 
to 3.8mmol/l (95% CI 1.7- 5.3, p=0.04). This reduction was not observed in 
the control group 3.7mmol/l (95% CI 1.0- 4.1) at baseline to 2.7 (95% CI 1.2-
4.1), p=ns. 
 
 
 
Figure 5.1 Postprandial Chylomicron Triglyceride Concentration 
Mean chylomicron triglyceride concentration over 8 hours following a fat load 
in patients and controls at baseline and following treatment 
(Pv1: patients at baseline, Pv2: patients post treatment, Cv1: controls at 
baseline Cv2: controls post treatment) 
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5.4.2 Relationship Between Chylomicron AUC and Baseline Parameters 
The relationship between baseline chylomicron AUC and baseline parameters 
are shown in table 5.2. There was no relationship between baseline 
chylomicron AUC and baseline urinary proteinuria or renal function in patients. 
In the patient group, chylomicron AUC correlated with baseline triglyceride, 
VLDL1, VLDL2, remnant lipoproteins and LDL III concentrations. Similar 
associations were observed in the control group with tighter correlations. 
 
5.4.3 Relationship Between Change in Chylomicron AUC 
No association was identified between any of the baseline parameters and the 
change in chylomicron AUC in the patient group. In the control population only 
the baseline levels of remnant lipoproteins correlated with change in 
chylomicron AUC (RLP-C  r
2 27.2, p=0.02 and RLP-TG r
2 20.6, p=0.04) 
(figures 5.3 and 5.4).   
 
Associations between change in chylomicron AUC and change in other lipid 
and lipoprotein parameters following treatment with omega-3 fatty acids are 
outlined in table 5.3. The only factors, which were associated with the change 
in chylomicron AUC in the patient group, were the change in LDL III 
concentration and the change in LDL III %. However, in the control group, 
extensive associations were seen with change in chylomicron AUC related to 
change in triglyceride, VLDL1, VLDL2, LDL III%, LDL III concentration, RLP-C 
and RLP-TG (figures 5.5 and 5.6). 
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In view of the apparent differences between the two groups, we proceeded to 
multivariate analysis using patient group as an independent categorical 
variable. This demonstrated that the difference between the 2 groups was not 
related to differences in either baseline chylomicron AUC or baseline 
triglyceride, but that the categorical variable of patient group appeared to be 
an independent predictor of the change in chylomicron AUC following 
treatment with omega-3 fatty acids (p=0.03).110 
 
Baseline Parameters    All                    Patients                            Controls 
        r
2         p         r
2    p            r
2        p 
________________________________________________________________________________________________________ 
Triglyceride      35.7    <0.001      20.8    0.04                                     74.4    <0.001 
                                             
VLDL1       37.0    <0.001      40.6    0.004         76.2    <0.001 
 
VLDL2       9.9    0.04        25.3    0.02         77.6    <0.001 
 
RLP-C      39.2    <0.001      31.2    0.01         61.3    <0.001 
 
RLP-TG      37.9    <0.001      27.8    0.02                  37.3           0.005 
               
LDLIII conc      31.0    <0.001       19.9    0.04          65.6    <0.00 
 
Table 5.2: Association Between Baseline Chylomicron AUC and Baseline Parameters 
Linear regression analysis of baseline chylomicron AUC with baseline parameters in all subjects as a whole, patients and controls. 
(r
2= coefficient of determination).111 
 
Parameters        All                 Patients              Controls 
        r
2    p      r
2    p          r
2    p 
________________________________________________________________________________________________________ 
∆ Triglyceride    2.7    ns      0    0          49.7    0.001 
 
∆ VLDL1      1.3    ns      0    0          30.3    0.01 
 
∆ VLDL2      0    ns      0    0          41.6    0.003 
 
∆ LDL III conc    0.3    ns      28.1    0.02          28.4    0.02 
 
∆ LDL III %      0    ns      21.9    0.03          41.7    0.03 
 
∆ RLP-C      0.7    ns      0    0          43.3    0.002   
 
∆ RLP-TG      0    ns      0    0          59.7    <0.001 
 
Table 5.3: Association Between Change in Chylomicron AUC and Change in Parameters 
Linear regression analysis of change in chylomicron AUC with change in parameters in all subjects as a whole, patients and 
controls. (r
2= coefficient of determination).112 
 
5.4.4  Postprandial VLDL Concentration 
 
AUC (mmol/l.h)  Baseline  Post Treatment  p 
       Patients  7.4 (4.2- 11.8)  5.6 (4.2- 10.1)  ns 
      Controls  4.6 (1.1- 9.8)  3.2 (1.5- 5.9)  ns 
 
Table 5.4 VLDL1 AUC in Patients and Controls at Baseline and Following 
Treatment 
 
At  baseline,  postprandial  VLDL1  AUC  did  not  differ  between  patients  and 
controls [Median 7.4mmol/l.h (IQR 4.2- 11.8) vs 4.6mmol/l.h (1.1- 9.8), p=ns]. 
Following treatment with omega-3 fatty acids, there was a mean reduction of 
1.7mmol/l.h (95% CI -1.0 to 3.4) in patients and 1.5mmol/l.h (95% CI -1.9 to 
3.2) in control, both p=ns.  
At  the  end  of  treatment,  patients  and  control  postprandial  VLDL1  AUC 
remained  similar  (Median  5.6mmol/l.h  (4.2- 10.1)  vs  3.2mmol/l.h  (1.5-  5.9), 
p=ns).  Figure  5.2  shows  VLDL1  triglyceride  concentration  in  patients  and 
controls  before  and  after  treatment  with  omega-3  fatty  acids.  Patient  peak 
postprandial  VLDL1  triglyceride  concentration  fell  from  3.3mmol/l  (IQR  2.0- 
4.2)  to  2.4mmol/l  (1.5-  3.4),  p=0.04.  Similarly,  in  the  control  group,  peak 
postprandial  VLDL1  triglyceride  concentration  fell  from  2.7mmol/l  (IQR  1.1- 
3.5) to 1.7mmol/l (0.8- 2.7), p=0.03.  
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5.4.5 Relationship Between VLDL1 AUC and Baseline Parameters 
The association between baseline VLDL1 AUC and baseline parameters in 
patients and controls are shown in table 5.5. Baseline VLDL1 AUC did not 
correlate with baseline serum creatinine, eGFR or urinary proteinuria in the 
patient group. In the patient group, the lack of relationship between baseline 
VLDL1  AUC  and  baseline  triglyceride  is  noteworthy.  A  clear  outlier  who  is 
behaving differently from the other patients can explain this. Once this outlier 
is removed, a strong correlation is present (r
2=31%, p=0.015). On multivariate 
analysis, subject group was not an independent predictor of baseline VLDL1 
AUC.  
Change in VLDL1 AUC did not correlate with any baseline parameter or 
change in triglyceride, VLDL1, VLDL2, LDL III%, LDL III concentration, RLP-C 
and RLP-TG in either patients or controls. 
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Figure 5.2 Postprandial VLDL1 Triglyceride Concentration 
Mean VLDL1 triglyceride concentration over 8 hours following a fat load in 
patients and controls at baseline and following treatment 
(Pv1: patients at baseline, Pv2: patients post treatment, Cv1: controls at 
baseline Cv2: controls post treatment). 
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Baseline Parameters                Patients                 Controls 
                r
2    p          r
2    p 
_______________________________________________________________________________________________________ 
Triglyceride              14.6    0.07          82.9    <0.001 
                                                         
VLDL1               36.7    0.006          91.6    <0.001 
               
VLDL2               30.3    0.01          74.0    <0.001 
             
RLP-C              15.0    0.07          65.0     <0.001 
               
RLP-TG              16.8    0.06          49.4     0.001 
                            
LDLIII %              10.9    0.1          39.1     0.004  
         
LDLIII mass              23.7    0.03          67.0     <0.001 
 
 
Table 5.5: Association Between VLDL1 AUC and Baseline Parameters 
Linear regression analysis of VLDL1 AUC with baseline parameters in patients and controls, r
2= coefficient of determination. 
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5.5 Discussion 
The aim of this study was to investigate chylomicron and VLDL1 metabolism in 
patients with nephrotic range proteinuria, compare them to normal controls 
and  to  examine  the  effect  of  treatment  with  omega-3  fatty  acids  on  their 
metabolism.  By  separating  chylomicrons  and  VLDL1  from  plasma  through 
density  gradient  ultracentrifugation,  we  have  shown  that  postprandial 
chylomicron  concentration  is  significantly  greater  in  patients  with  nephrotic 
range  proteinuria  compared  to  normal  controls.  We  demonstrated  that 
baseline  triglyceride  and  triglyceride  rich  lipoproteins  were  associated  with 
baseline  chylomicron  concentration  and  that  treatment  with  omega-3  fatty 
acids led to a significant reduction in chylomicron AUC in the patient group but 
not  the  controls.  In  patients,  change  in  chylomicron  concentration  was 
associated with change in LDL III proportion and concentration. There was no 
association  between  change  in  chylomicron  concentration  and  change  in 
triglyceride,  VLDL1,  VLDL2  and  remnant  lipoproteins  in  the  patient  group. 
However, in the control group there was a strong association with all these 
parameters.  
VLDL1  AUC  did  not  differ  at  baseline  between  patients  and  controls. 
Furthermore,  there  was  no  significant  effect  on  VLDL1  AUC  following 
treatment  in  patients  or  controls.  However,  peak  postprandial  VLDL1 
triglyceride concentration was significantly lowered by treatment with omega-3 
fatty  acids  in  all  subjects.  Baseline  VLDL1  AUC  correlated  with  baseline 
VLDL1, VLDL2 and LDL III mass in patients. In controls, there was a strong 
correlation between VLDL1 AUC and triglyceride-rich lipoproteins. 
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There  is  little  information  in  the  literature  on  chylomicron  metabolism  in 
humans  with  nephrotic  syndrome.  Animal  studies  have  shown  changes  in 
chylomicron  synthesis  and  catabolism  as  well  as  qualitative  compositional 
changes  (202;203).  Warwick  et  al  examined  chylomicron  metabolism  in  9 
patients with nephrotic range proteinuria by measuring changes in triglyceride 
and  retinyl  palmitate  concentration  in  the  d<1.006g/ml  fraction  of  plasma 
following  Vitamin  A  loaded  standard  fat  meal.  They  found  no  significant 
difference in the time course of the lipaemic response, which was confirmed 
by  comparing  AUC  curves  for  controls  and  patients.  They  concluded  that 
chylomicron metabolism did not differ between patients and controls  (204). 
This was a small study, which has not been confirmed.  
As discussed earlier, the effects of omega-3 fatty acids on lipid metabolism is 
not completely understood. There is evidence to suggest that omega-3 fatty 
acids reduce triglyceride levels after a postprandial challenge(130) and they 
have  also  been  shown  to  lower  postprandial  chylomicron  and  chylomicron 
remnants (122). This is thought to be through acceleration of chylomicron lipid 
clearance  by  facilitation  of  lipoprotein  lipase-mediated  lipolysis  (120).  We 
observed a  reduction in  chylomicron  AUC  in  the  patient  group but  not  the 
controls and found this reduction was independent of change in triglyceride 
(figures  5.5  &  5.6)  and  baseline  chylomicron  AUC.  Multivariate  analysis 
showed  that  subject  group  was  an  independent  predictor  of  change  in 
chylomicron AUC following treatment with omega-3 fatty acids. The reasons 
behind  this  are  unclear  but  may  be  related  to  structural  or  compositional 
change  in  the  chylomicrons  of  patients  with  nephrotic  range  proteinuria. 
Westphal et al examined the effect of 4g of omega-3 fatty acids (Omacor) on  
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hypertriglyceridaemic  men  following  a  fat  load.  They  found  chylomicron 
concentration  to  fall  by  49-64%  over  4-8  hours(205).  Thus,  the  effect  of 
omega-3  fatty  acids  on  chylomicrons  is  more  marked  at  higher  baseline 
triglyceride levels.  
Treatment  with  omega-3  fatty  acids  has  been  shown  to  reduce  VLDL  by 
reducing their synthesis and secretion. They inhibit 1,2-diacylglycerol-sterol O-
acyltransferase(206) or phosphatidate phosphatase (207) thereby resulting in 
a substantial reduction in synthesis of VLDL. This reduced synthesis would be 
in  keeping  with  our  finding  that  peak  postprandial  VLDL1  was  reduced  but 
VLDL1 AUC was unchanged by treatment with omega-3 fatty acids.  
 
Zilversmit described atherosclerosis as a „postprandial phenomenon‟ over 20 
years  ago  (42).  Since  then,  a  number  of  studies  have  linked  disturbed 
metabolism of postprandial lipoproteins with increased cardiovascular risk. A 
meta-analysis of 17 prospective studies found that a 1 mmol/l rise in fasting 
plasma triglyceride was associated with a 30% risk of total CVD in man and 
75%  increase  in  women  (208).  Postprandial  lipaemia  is  defined  as  the 
physiological transitory alteration in lipoprotein metabolism lasting from 6 to 12 
hours after ingesting a fatty meal.  Fasting plasma triglycerides are known to 
predict  the  duration  and  magnitude  of  postprandial  lipaemia  (119).  The 
hypertriglyceridaemia,  which  occurs  following  a  meal,  reflects  the 
accumulation of triglyceride rich lipoproteins such as chylomicrons and their 
remnants (early response) plus VLDL and its remnants (late response). These 
triglyceride  rich  lipoproteins  are  important  in  the  pathogenesis  of 
atherosclerosis as they allow the accumulation of lipids within the arterial wall  
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through  the  generation  of  small  dense  LDL  and  reduction  in  HDL(209). 
Patients  with  nephrotic  range  proteinuria  are  known  have  an  increased 
cardiovascular  risk.  They  are  known  to  have  higher  levels  of  fasting 
triglycerides at baseline than normal controls(164) therefore it would follow 
that they would have higher levels of postprandial  triglyceride rich lipoproteins 
contributing  to  their  higher  cardiovascular  risk.  The  recognition  of  these 
abnormalities is important as it allows us to target treatment thereby reducing 
this excess cardiovascular risk in this population. 
 
The effect of omega-3 fatty acids on postprandial lipaemia in patients with 
nephrotic range proteinuria has not, to our knowledge, been studied before. 
Statins  are  currently  the  mainstay  of  treatment  for  these  patients  as  they 
reduce cholesterol and LDL-C concentration. Fibrates are effective in reducing 
triglyceride levels particularly in hypertriglyceridaemic patients but are poorly 
tolerated in patients with renal disease. Monotherapy with statins alone may 
not be sufficient in this group of patients to have an adequate effect on both 
cholesterol  and  postprandial  lipaemia.  We  have  shown  that  omega-3  fatty 
acids are effective in reducing postprandial lipaemia in patients with nephrotic 
syndrome. This effect is not related to the change in triglyceride level but is 
related to higher baseline triglyceride levels in these patients.  
 
In  summary,  we  have  shown  that  there  is  increased  postprandial  lipaemic 
response in patients with nephrotic range proteinuria and that this is reduced 
by  treatment  with  omega-3  fatty  acids.  These  differences  may  be  due  to 
structural and compositional differences in chylomicrons and VLDL in patients  
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with nephrotic range proteinuria compared with the controls. Further analysis 
of the composition and structure of these particles may provide us with more 
information on how to interpret these results. 
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Figure 5.3:  Patient Change in Chylomicron AUC vs Baseline Triglyceride 
Concentration 
 
Linear regression analysis of change in chylomicron concentration with 
baseline triglyceride concentration in patients. 
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Figure 5.4: Control Change in Chylomicron AUC vs Baseline Triglyceride 
Concentration 
Linear regression analysis of change in chylomicron concentration with 
baseline triglyceride concentration in controls. 
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Figure 5.5: Patient Change in Chylomicron AUC vs Patient Change in 
Triglyceride Concentration 
Linear regression analysis of change in chylomicron concentration with 
change in triglyceride concentration in patients.  
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Figure 5.6: Control Change in Chylomicron AUC vs Control Change in 
Triglyceride Concentration 
 
Linear regression analysis of change in chylomicron concentration with 
change in triglyceride concentration in controls, r
2= 49.7%, p=0.001. 
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Chapter 6: The Effect of 
Omega-3 Fatty Acids on 
Structure and Composition of     
Chylomicron and VLDL1 
Particles 
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6.1 Introduction 
Patients with nephrotic range proteinuria have an excess of triglyceride rich 
lipoproteins such as chylomicrons and VLDL. In the previous chapter, we 
have demonstrated that there is delayed postprandial chylomicron clearance 
in patients with proteinuria. Several studies have shown that the increase in 
the VLDL1 subgroup of VLDL in patients with nephrotic range proteinuria is as 
a result of delayed lipoprotein clearance and increased hepatic production 
although our data from chapter 5 did not confirm the presence of impaired 
clearance(162;165;168;210).  
Our laboratory has previously shown abnormalities in the structure of VLDL1 
in patients with nephrotic range proteinuria (175) with a smaller more 
crystalline structure and we postulated that this abnormal structure contributed 
to the impaired clearance of VLDL particles. The evidence regarding the 
structure of chylomicrons in humans is sparse. 
Therefore, the aim of our study was firstly to examine the apolipoprotein and 
lipid components of chylomicrons and VLDL1 in patients with nephrotic range 
proteinuria thereby establishing the structure of these particles in both patient 
and control populations. Thereafter, we examined the effect of omega-3 fatty 
acids on the structure of these lipoproteins in patients and controls. 
 
 
 
 
 
  
125 
 
6.2 Subjects and Methods 
 
The patients and controls described in the method section were studied in this 
chapter. Chylomicrons and VLDL1 fractions were separated as described 
previously. Apolipoproteins B, AI, CII, CIII and E were measured on fasting 
EDTA plasma samples from patients before and following treatment with 
omega-3 fatty acids. Apolipoproteins B, CII, CIII and E were measured on 
fasting VLDL and peak chylomicrons in both patient and control groups pre 
and post treatment.  
 
 
6.3 Results 
 
6.3.1 Baseline Plasma Apolipoproteins 
 
The plasma content of apolipoproteins is shown in table 6.1. There was 
significantly less apolipoprotein CIII in the controls with a trend towards less 
apolipoprotein B and CII.  
Each VLDL, IDL and LDL particle carries one moiety of apo B therefore, using 
this as a reference, a crude estimate of the amount of apo CII, CIII and E 
moieties per lipoprotein particle in the plasma was obtained. As a result, we 
found no difference between the amount of CII, CIII and E per lipoprotein 
particle (table 6.1). 
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Apolipoprotein    Patients      Controls        p 
______________________________________________________________ 
 
B (mg/dl)    122.5 (100.9- 139.2)  112.1 (96-0- 119.4)           ns 
 
AI (mg/dl)    125.6 (115.0- 138.9)  137.4 (116.0- 167.9)          ns 
 
CII (mg/dl)    5.6 (4.4- 7.1)     4.29 (3.3- 5.5)                 ns
               
CIII (mg/dl)    15.1 (13.1- 18.2)    12.6 (10.1- 14.3)           0.02 
 
E (mg/dl)    4.7 (4.1- 5.6)     4.0 (3.5- 5.0)              ns 
 
Apo CII/B*    4.4 (3.5- 5.9)     4.2 (2.9- 4.8)              ns
     
Apo CIII/B*             12.2 (10.6- 15.5)    11.7 (9.6- 12.8)             ns 
 
Apo E/B*    3.8 (3.0- 5.1)     3.8 (3.3- 4.4)              ns 
 
* (mg/mg x 10
-2) 
 
Table 6.1: Plasma Apolipoproteins (n=17) 
Plasma apolipoproteins in patients compared with controls. Prior to statistical 
analysis, any parameter which was not normally distributed was normalised 
by log transformation. All data were compared using unpaired t-tests. 
 
 
 
6.3.2 The Effect of Treatment on Plasma Apolipoproteins 
Tables 6.2 and 6.3 represent the effect of treatment with omega-3 fatty acids 
on plasma apolipoprotein concentration in patients and controls. The plasma 
apolipoproteins of patient and controls were not affected by treatment with 
omega-3 fatty acids. There was, however, a significant reduction of CII per 
lipoprotein particle in the patient group. This was not seen in the control 
population 
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Apolipoprotein    Baseline       Post Treatment    p 
_____________________________________________________________ 
 
B (mg/dl)    122.5 (100.9- 139.2)  123.7 (114.8- 154.8)           ns
         
AI (mg/dl)    125.6 (115.0- 138.9)  124.2 (113.5- 138.9)           ns 
 
CII (mg/dl)    5.6 (4.4- 7.1)     5.0 (4.1- 6.9)              ns
     
CIIII (mg/dl)    15.1 (13.1-18.2)    14.4 (13.2- 18.8)             ns 
 
E (mg/dl)    4.7 (4.1- 5.6)     5.0 (4.3- 5.6)              ns 
 
Apo CII/B*    4.4 (3.5- 5.9)     4.1 (3.1- 5.3)                     0.01 
 
Apo CIII/B*    12.2 (10.6- 15.5)    11.6 (10.0- 12.6)             ns 
   
Apo E/B*    3.8 (3.0- 5.1)         3.7 (3.3- 4.5)              ns 
 
 
All values median & IQR 
* (mg/mg x 10
-2) 
 
 
Table 6.2: Effect of Treatment on Patient Plasma Apolipoproteins (n=17) 
 
The effect of treatment on plasma apolipoproteins in patients. Prior to 
statistical analysis, any parameter which was not normally distributed was 
normalised by log transformation. All data were compared using paired t-tests. 
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Apolipoprotein    Baseline       Post Treatment     p 
______________________________________________________________ 
 
B (mg/dl)    112.1 (96.0- 119.4)    110.0 (96.2- 122.1)             ns 
         
AI (mg/dl)    137.4 (116.0- 167.9)  138.8 (114.6- 172.0)           ns 
 
CII (mg/dl)    4.3 (3.3- 5.5)     4.3 (3.1- 5.6)               ns 
     
CIIII (mg/dl)    12.6 (10.1- 14.3)    12.7 (9.1- 13.9)              ns 
 
E (mg/dl)    4.0 (3.5- 5.0)     4.3 (3.6- 5.4)               ns 
 
Apo CII/B*    4.2 (2.9- 4.8)     4.1 (2.9- 4.7)               ns 
 
Apo CIII/B*    11.7 (9.6- 12.8)    11.2 (9.0- 13.3)         ns 
 
Apo E/B*    3.8 (3.3- 4.4)     3.8 (3.4- 4.5)             ns
       
 
 
Table 6.3: Effect of treatment on Control Plasma Apolipoproteins (n=17) 
The effect of treatment on plasma apolipoproteins in controls.  All values 
expressed as median & IQR. * (mg/mg x 10
-2) 
 
  
 
6.3.3 Chylomicron Apolipoproteins & Compositions: Patients vs 
Controls 
The concentration of chylomicron apolipoproteins in both patient and control 
groups are shown in table 6.4. The analysis of the chylomicron 
apolipoproteins was performed in 10 patients and 6 controls as the 
concentration of chylomicrons were too low in some patients and controls to 
allow accurate measurement of either apo CII, CIII or E. If one of the 
chylomicron apolipoproteins was undetectable, then all of the apolipoprotein 
and composition results for that subject were disregarded to avoid biasing the 
result.  There was twice as much apo B present in the control chylomicrons 
(p=0.03) compared with patients, but the quantities of other chylomicron  
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apolipoproteins did not differ significantly. The molar ratio of apolipoprotein 
CII, CIII and E to apolipoprotein B was calculated in order to assess the 
quantity of apolipoprotein CII, CIII and E on each chylomicron particle (table 
6.5). This showed that the patient group had significantly higher levels of apo 
CII, III and E per lipoprotein particle. In addition, the patients‟ chylomicron 
particles contained greater quantities of triglyceride, total cholesterol, free 
cholesterol and phospholipids compared to the controls. Given that the 
triglyceride is the greatest constituent of chylomicron particles, the 3 fold 
increase in chylomicron triglyceride strongly suggests that larger chylomicron 
particles are present in the patients with proteinuria. However, surface 
structure of chylomicrons did not differ between the patient and control group 
as outlined in table 6.6. In the control group, we observed a strong 
relationship between chylomicron size and baseline fasting plasma triglyceride 
(r
2 85.9%, p=0.005). This was not observed in the patient group (r
2 0, p=0.6). 
On multivariate analysis, subject group was not an independent predictor of 
particle size. 
Apolipoprotein    Patients        Controls    p 
        (n=10)             (n=6) 
______________________________________________________________ 
 
 
B (mg/dl)    0.25 (0.20- 0.39)    0.51 (0.45- 0.83)          0.04 
     
CII (mg/dl)    0.34 (0.26- 0.62)    0.19 (0.13- 0.74)            ns 
     
CIIII (mg/dl)    0.90 (0.52- 1.82)    0.32 (0.18- 1.83)            ns 
     
E (mg/dl)    0.13 (0.09- 0.28)    0.09 (0.05- 0.34)            ns 
 
 
Table 6.4: Plasma Concentration of Chylomicron Apolipoproteins: 
Patients vs Controls 
 
(All values median & IQR)  
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Moles per Particle   Patients         Controls        p 
        (n=10)             (n=6) 
______________________________________________________________ 
 
 
Apo CII              68.3 (56.9- 95.2)  24.6 (13.8- 60.4)    0.03 
   
Apo CIII              179 (145- 248)  58.3 (16.4- 134.8)           0.03     
           
Apo E                7.3 (5.7- 9.8)       2.8 (1.7- 6.6)                  0.02        
              
Triglyceride
*    491000 (406000-740000)   156000 (89000-312000)            0.008 
 
Total Cholesterol*  58000 (42000- 85000)  19000 (9500- 40000)         0.01 
   
Free Cholesterol*  29000 (21000- 44000)  10000 (4000- 25000)       0.03 
 
Phospholipid*  46000 (36000- 79000)      19000 (9000- 39000)      0.02 
      
 
 
Table 6.5: Apolipoproteins and Lipid Content per Chylomicron Particle: 
Patients vs controls 
 
Prior to statistical analysis, any parameter which was not normally distributed 
was normalised by log transformation. All data were compared using unpaired 
t-tests. 
* Expressed to the nearest 1000. 
(All median & IQR) 
 
 
 
Patients        Controls      p 
mg/mg    (n=10)             (n=6) 
______________________________________________________________ 
 
 
FC:PL     0.58 ± 0.13          0.50 ± 0.15     ns 
 
CII:PL             1.5 x 10
-3 ± 0.6 x 10
-3   1.4 x 10
-3 ± 0.3 x 10
-3               ns
 
   
CIII:PL           3.6 x 10
-3 ± 1.5 x 10
-3   2.7 x 10
-3 ± 1.1 x 10
-3               ns 
 
E:PL            0.15 x 10
-3 ± 0.07 x 10
-3     0.18 x 10
-3 ± 0.08 x 10
-3       ns 
           
 
Table 6.6 Surface Structure of Chylomicrons 
(All mean & SD)  
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6.3.4 Chylomicron Apolipoproteins & Compositions: Treatment Effect in 
Patients & Controls 
 
 
The effect of treatment with 4 g daily of omega-3 fatty acids on chylomicron 
apolipoproteins and compositions in both patients and controls is shown in 
tables 6.7 and 6.8. No significant change in chylomicron apolipoprotein 
content or chylomicron lipid composition was observed in either population 
following treatment. 
 
 
Moles per particle    Baseline    Post Treatment    p 
                         
______________________________________________________________ 
 
 
Apo CII    68.3 (56.9- 95.2)    87.5 (41.7- 158.3)        ns 
                
Apo CIII    179 (145- 248)    184 (122- 326)                 ns
                          
Apo E     7.3 (5.7- 9.8)      8.7 (6.2- 16.2)        ns
                            
Triglyceride
*    491000 (406000-740000)   455000(196000-701000)   ns 
   
Total Cholesterol
*  58000 (42000- 85000)  53000 (24000- 89000)        ns 
   
Free Cholesterol
*  29000 (21000- 44000)   22000 (15000- 39000)        ns 
   
Phospholipid 
*  46000 (36000- 79000)  44000( 20000- 98000)        ns 
 
 
 
Table 6.7: Apolipoproteins and Lipid content per chylomicron particle: 
Treatment Effect in Patients (n=10) 
 
Prior to statistical analysis, any parameter which was not normally distributed 
was normalised by log transformation. All data were compared using unpaired 
t-tests. 
* Expressed to the nearest 1000. 
(All median & IQR) 
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Moles per particle    Baseline      Post Treatment    p 
                         
______________________________________________________________ 
 
Apo CII      24.6 (13.8-60.4)  40.0(6.6-146.7)            ns 
                  
Apo CIII      58.3(16.4-134.8)  222(18-848)       ns 
                              
Apo E       2.8 (1.7-6.6)    5.3 (2.7-13.5)     ns 
                                
Triglyceride
*    156000 (89000-312000)  157000(43000-684000)   ns 
         
Total Cholesterol
*  19000 (9500-40000)  9000(4000-98000)             ns
     
Free Cholesterol
*  10000(4000-25000)   15000(1000-41000)             ns
   
Phospholipid 
*     19000 (9000-39000)  18000 (7000-83000)   ns
   
 
Table 6.8: Apolipoproteins and Lipid Content per Chylomicron Particle: 
Treatment Effect in Controls (n=6) 
 
* Expressed to the nearest 1000. (All values median & IQR)  
 
 
 
6.3.5 VLDL1 Apolipoproteins & Compositions: Patients vs Controls 
The concentration of VLDL1 apolipoproteins are shown in table 6.9. Once 
again as with the chylomicrons, complete data was only available for 15 
patients and 13 controls therefore only these subjects were included in the 
analysis. No difference in apolipoprotein concentration of VLDL1 between 
patients and controls was seen. 
Furthermore, after calculating the molar ratio of apolipoprotein CII, CIII and E 
to apo B, there was no difference identified between patients and controls 
(table 6.10). The triglyceride, cholesterol and phospholipids content of the  
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VLDL1 particles were also similar. In addition, surface structure did not differ 
between patients and controls (table 6.11). 
 
Apolipoprotein    Patients       Controls      p 
        (n=15)           (n=13) 
______________________________________________________________ 
 
 
B (mg/dl)      3.33(1.79-5.12)  2.82 (1.15-3.71)                  ns
             
CII (mg/dl)      1.14 (0.50-1.77)  0.78 (0.34-2.0)                    ns 
         
CIIII (mg/dl)      3.10 (1.68-4.50)  1.65 (1.04-3.54)                  ns 
       
E (mg/dl)      0.12 (0.09-0.34)  0.17 (0.11-0.29)                  ns
   
 
Table 6.9: Plasma Concentration of VLDL1 Apolipoproteins: Patients vs 
Controls 
(All values median & IQR) 
 
 
 
 
 
Moles per particle    Patients       Controls              p 
        (n=15)                   (n=13) 
______________________________________________________________ 
 
 
Apo CII    17.8 (12.9-23.6)    24.7 (15.6-36.3)             ns 
                
Apo CIII    46.4 (39.3-67.0)    47.7 (30.7-81.1)             ns
   
Apo E     0.87 (0.54-1.63)    1.00 (0.77-1.63)             ns
       
Triglyceride
*    23000 (20000-2000)  26000 (22000-40000)        ns 
 
Total Cholesterol
*  9000 (8000-10000)    10000 (8000-13000)          ns 
   
Free Cholesterol
*  5000 (4000-6000)    5000 (4000-7000)             ns
             
Phospholipid 
*  7000 (6000-8000)    7000 (6000-11000)             ns         
            
 
Table 6.10: Apolipoproteins and Lipid Content per VLDL1 Particle: 
Patients vs controls 
* Expressed to nearest 1000. (All values median & IQR)  
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mg/mg      Patients        Controls    p 
        (n=15)             (n=13) 
______________________________________________________________ 
 
 
FC:PL       0.7 ± 0.08          0.7 ± 0.07    ns 
 
CII:PL       2.6. x 10
-3 ± 1.1        2.9 x 10
-3 ± 1.2    ns 
   
CIII:PL      7.0 x 10
-3 ± 2.4        6.0. x 10
-3 ± 1.3   ns 
 
E:PL               0.14 x 10
-3 ± 0.08        0.16 x 10
-3 ± 0.02  ns 
           
 
Table 6.11: Surface Structure of VLDL1 
 
(All mean & SD) 
 
 
 
6.3.6 VLDL1 Apolipoproteins & Compositions: Treatment Effect in 
Patients and Controls 
Tables 6.12 and 6.13 display the apolipoprotein and lipid content per VLDL1 
particle following treatment with omega-3 fatty acids in patients and controls. 
Treatment with omega-3 fatty acids did not alter the apolipoprotein or lipid 
content of VLDL1 particles in either patients or controls. 
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Moles per particle    Baseline    Post Treatment    p 
                         
______________________________________________________________ 
 
Apo CII    17.8 (12.9-23.6)    20.4 (13.3-30.7)    ns
     
Apo CIII    46.4 (39.3-67.0)    50.0 (40.3-58.2)    ns 
 
Apo E     0.87 (0.54-1.63)    0.71 (0.44-1.62)    ns
                                  
Triglyceride
*           23000 (20000-27000)     25000 (24000-30000)  ns
       
Total Cholesterol
*  9000 (8000-10000)    10000 (8000-11000)  ns 
   
Free Cholesterol
*  5000 (4000 -6000)    5000 (4000 -6000)    ns 
     
Phospholipid 
*  7000 (6000-8000)    8000(6000-8000)    ns 
 
Table 6.12: Apolipoproteins and Lipid Content per VLDL particle: 
Treatment Effect in Patients (n=15) 
*Expressed to nearest 1000. (All values median& IQR)  
 
 
 
 
Moles per particle        Baseline     Post Treatment    p 
                         
______________________________________________________________ 
 
 
Apo CII    24.7 (15.6-36.3)    18.2 (8.8-31.8)    ns 
     
Apo CIII    47.7 (30.7-81.1)    42.3 (24.5- 62.0)    ns 
     
Apo E     1.00 (0.77-1.63)    1.2 (0.68-2.88)    ns 
 
Triglyceride    26000 (22000-40000)  27000 (19000-341000)  ns
   
Total Cholesterol  10000 (8000-13000)  10000 (8000-11000)  ns
         
Free Cholesterol  5000 (4000-7000)    5000 (4000-6000)    ns
       
Phospholipid   7000 (6000-12000)    7000 (6000-8000)    ns 
 
Table 6.13: Apolipoproteins and Lipid Content per VLDL Particle: 
Treatment Effect in Controls (n=13) 
*Expressed to nearest 1000. (All values median & IQR) 
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6.4 Discussion 
In this study, we have demonstrated that chylomicrons in patients with 
nephrotic range proteinuria differ in structure and composition compared with 
normal controls. Patients had significantly higher levels of apolipoprotein CII, 
CIII and E per chylomicron particle with greater quantities of triglyceride, total 
cholesterol, free cholesterol and phospholipids. The quantity of triglyceride per 
chylomicron particle can be used as a marker of particle size and so this 
strongly suggests that patient chylomicron particles are significantly larger 
than the control population. Treatment with omega-3 fatty acids did not alter 
the structure or composition of chylomicrons in patients or controls. In contrast 
to previous data, however, we found no difference in the structure or 
composition of VLDL1 particles when comparing patients and controls(175). 
Once again, treatment with omega-3 fatty acids did not alter the composition 
or structure of VLDL1 particles in neither patients nor controls. 
There is little in the literature regarding the structure of chylomicrons in human 
nephrotics. Levy et al examined chylomicron structure in nephrotic rats. They 
concluded that chylomicrons of nephrotic rats were larger in size with a higher 
triacyglycerol to protein ratio(202). A further study by this group once again 
showed that chylomicrons of nephrotic rats were larger, deficient in apo E and 
apo AI, rich in triacylglycerol and cholesterol but poor in phospholipid (203).  
To our knowledge, there are no human studies examining chylomicron 
structure in nephrotic humans. 
Our data suggests that patients with nephrotic range proteinuria have larger 
chylomicrons than the control group with decreased apolipoprotein to 
triglyceride ratio. This size discrepancy may be responsible for less efficient  
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lipolysis and therefore clearance of these larger particles. In the previous 
chapter, we demonstrated that treatment with omega-3 fatty acids improved 
chylomicron clearance in patients with nephrotic range proteinuria. However, 
treatment did not alter the structure of chylomicrons in the patient or control 
group. Thus, the better clearance observed is not related to structural 
changes. In the control group, we observed a strong relationship between 
chylomicron size and baseline fasting plasma triglyceride. This was not 
observed in the patient group with no correlation between particle size and 
baseline triglyceride.  Therefore differences in baseline triglyceride levels 
cannot account for the difference in structure of the chylomicron particles. On 
multivariate analysis, subject group was not an independent predictor of 
particle size. However, in view of the small numbers, these results must be 
interpreted with caution. 
We did not show any difference in structure or composition of VLDL1 between 
patients with nephrotic range proteinuria compared with controls. In addition, 
treatment with omega-3 fatty acids did not alter the structure of these particles 
in both groups. There are very few studies examining the structure of VLDL1 in 
nephrotic humans but, in contrast to our findings, data from our laboratory has 
previously shown that VLDL1 from nephrotic patients were deficient in apo CII, 
CIII and E. The particles were smaller, with increased triglyceride content per 
particle with higher free cholesterol to phospholipid ratio(175).  
These differences in results can be explained in a number of ways. Firstly, 
patients with nephrotic range proteinuria are a very heterogeneous group with 
a range of lipoprotein abnormalities and so the numbers may be too small to 
be representative of the group as a whole. The apo B assay used in the  
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laboratory is currently more sensitive at detecting lower levels than the older 
assay used in the previous study. Also, the triglyceride levels in our control 
population are higher than the previous study as we attempted to triglyceride 
match our control group.  
Thus, we have demonstrated that chylomicron particles in patients with 
nephrotic range proteinuria are larger than in normal controls. This structural 
abnormality may be why their clearance is reduced. We did not observe any 
difference in VLDL1 structure. Although treatment with omega-3 fatty acids 
improves chylomicron clearance in patients with nephrotic range proteinuria, 
they do not seem to do this through altering their structure. Therefore, it is 
possible that omega-3 fatty acids reduce synthesis of chylomicrons.  
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7.1 Introduction 
 
Prospective epidemiological studies have demonstrated that reduced levels of 
plasma HDL-C are an independent risk factor for coronary heart disease and 
that increasing HDL-C reduces this risk. This is has been reviewed in detail in 
chapter 1. Plasma high density lipoprotein (HDL) is heterogeneous, 
comprising of a number of particles of differing size and composition. There 
are several ways of separating HDL subfractions. Ultracentrifugation 
separates HDL into 2 subclasses: HDL2 and HDL3. HDL2 is larger and 
cholesterol-rich and HDL3 is smaller and denser. Electrophoretic methods 
separate HDL on the basis of their charge and size. Blanche et al described 5 
subclasses: HDL2a, HDL2b, HDL3a, HDL3b and HDL3c (see chapter 2). It is 
generally thought that larger cholesterol rich HDL2 is cardioprotective while 
smaller dense HDL3 is associated with an increased risk of CHD. However, 
there is conflicting data regarding the atherogenicity of these subfractions. 
In most studies examining patients with nephrotic syndrome or nephrotic 
range proteinuria, HDL-C levels have been reported as normal or 
low(167;170;186;211). Reduced HDL2 levels and normal HDL3 levels are also 
reported(170;212;213). Most of the data regarding the effect of treatment with 
omega-3 fatty acids on HDL metabolism is favourable. 
The aim of this study was two fold. 1. To compare the distribution of HDL 
subfractions in subjects with nephrotic range proteinuria (patients) and in age 
and sex matched controls (controls). 2. To study the effect of omega-3 fatty 
acids on HDL subfraction distribution. 
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7.2 Subjects & Methods 
 
17 patients and 17 controls as described earlier took part in this study. Fasting 
EDTA plasma prior to and following an eight week treatment period with 
omega-3 fatty acids were taken. Analysis was carried out on fresh samples 
within 5 days of drawing the samples. Samples were kept refrigerated at -4°C. 
HDL2 and HDL3 subfractions were isolated by density gradient 
ultracentrifugation as described in the methods section. The sizes of HDL2 and 
HDL3 were quantified using gradient gel electrophoresis as described in 
chapter 2.  
 
7.3 Statistics 
 
 
Statistical analyses were carried out using MINITAB 13.1 for Windows 
(Minitab inc). Results are shown as mean and standard deviation (SD), or 
where data were not normally distributed as median and interquartile ranges 
(IQR). Prior to statistical analysis, any factor that was not normally distributed 
was normalised by log transformation. Patient and control results were 
compared using unpaired t-tests. Results pre and post treatment were 
compared using paired t-tests. Linear regression analysis was performed to 
identify significant correlations with a „p‟ value less than 0.05 considered 
significant. 
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7.3 Results 
 
 
7.3.1 Baseline HDL Concentrations 
 
At baseline, HDL-C, total HDL concentration and HDL2 did not differ 
significantly between patients and controls (table 7.1). HDL3 concentration 
displayed a trend towards being higher in the patient population but this did 
not reach statistical significance (p=0.059). Other baseline parameters in 
patients compared with controls are presented in chapter 3. 
 
 
 
 
Patients      Controls      p 
 
_____________________________________________________________ 
 
HDL-C      1.0 (0.9-1.1)      1.1 (0.9-1.4)      ns 
(mmol/l) 
 
Total HDL      196.3 (172.2-231.6)   177.1 (159.3-216.8)   ns 
(mg/dl) 
 
HDL2          66.5 (52.4 –83.5)        80.9 (38.4 –117.4)    ns 
(mg/dl)   
 
HDL3          132.6 (110.3-143.0)     116.7 (93.3-130.1)          0.059 
(mg/dl) 
 
   
Table 7.1: Baseline HDL Concentrations in Patients vs Controls (n=17) 
 
 
7.3.2 Treatment Effect in Patients and Controls 
The effect of treatment with omega-3 fatty acids on HDL2 concentrations in 
patients and controls is outlined in table 7.2. In the patient group, HDL2 
concentration increased by a mean of 11.3 mg/dl (95% CI 0.6 – 22.0, p=0.05). 
In controls, HDL2 increased by a mean of 17.2 mg/dl (95% CI 1.4- 33.0,  
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p=0.02). Although the medians appear similar, the mean results are shown 
below and statistically differ. 
The effect of treatment on HDL3 and total HDL concentration in patients and 
controls is shown in tables 7.3 and 7.4. Treatment with omega-3 fatty acids 
did not alter HDL3 or total HDL concentration in patients or controls.    
 
 
HDL2 (mg/dl)      Baseline      Post Treatment               p 
 
______________________________________________________________ 
 
 
Patients     66.5 (52.4-83.5)  71.0 (52.6-118.2)    0.05 
 
 
Controls        80.9 (38.4-117.4)*  80.1 (58.6-127.6) **            0.02 
 
 
 
Table 7.2: The Effect of Treatment on Patient and Control HDL2 
Concentrations 
 
(All median & IQR)   
In controls, although the medians quoted above appear similar, the mean 
results statistically differ (*mean 84.5 ± 59.4 vs **mean 101.7± 70.3). 
 
 
 
 
 
HDL3  (mg/dl)    Baseline    Post Treatment     p 
 
______________________________________________________________ 
 
 
Patients     132.63(110.3-143.0)  124.9 (117.1-140.1)   ns 
 
 
Controls     116.7 (93.3-130.1)    109.8 (103.1-118.7)   ns 
 
 
Table 7.3: The Effect of Treatment on Patients and Control HDL3 
Concentrations 
(All median & IQR)  
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Total HDL (mg/dl)    Baseline    Post Treatment    p 
______________________________________________________________ 
 
 
Patients     196.3 (172.2- 231.6)  214.8 (195.3-246.0)   ns 
 
 
Controls     177.1 (159.3- 216.8)  197.8 (168.9- 222.5)           ns
     
 
 
Table 7.4 The Effect of Treatment on Total HDL Lipoprotein 
Concentrations 
(All median & IQR) 
 
 
7.3.3 Association Between Baseline HDL2 and Baseline Parameters 
Table 7.5 displays the relationship between baseline HDL2 concentration and 
baseline parameters for patients and control groups individually and 
collectively.  
For patients and controls collectively, there were strong negative correlations 
between baseline HDL2 and baseline triglyceride, LDL III, VLDL1 and RLP-C 
(table 7.5 and figures 7.1 & 7.2).  In patients, there was no association 
between baseline HDL2 concentration and baseline renal function and 
proteinuria. Baseline triglyceride correlated with baseline HDL2 in patients and 
controls (r
2  -24.4%, p=0.02 and r
2-
 29.5%, p=0.01). Baseline VLDL1 and 
VLDL2 correlated with baseline HDL2 in both patients and control with a tighter 
association in the patient group. When entering the subject group into a 
general linear model as a variable, it was not an independent predictor.  
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7.3.4 Association Between HDL3 and Baseline Parameters 
 
Table 7.6 displays the relationship between baseline HDL3 concentration and 
baseline parameters for patients and control groups individually and 
collectively. For patients and controls as a whole, there were strong 
correlations between baseline HDL3 and baseline triglyceride, LDL III, VLDL1 
and RLP-C (table 7.6 and figures 7.3 & 7.4). In the patient group there was no 
association between baseline HDL3 or baseline parameters including renal 
function and urinary proteinuria. This is likely to be due to a clear outlier. On 
removing this outlier, there is a strong correlation between baseline HDL3 and 
baseline triglyceride (r
2 36.6%, p=0.008) but the other correlations are not 
affected. However, in the control group, several baseline parameters 
correlated with baseline HDL3. These included cholesterol (r
2 22.5%, p=0.03), 
triglyceride (r
2 31.8%, p=0.01), LDLIII% (r
2 32.6%, p=0.01), LDLIII mass (r
2 
34.2%, p=0.008), VLDL1 (r
2 41.3%, p=0.003), VLDL2 (r
2 26.7%, p=0.02) and 
RLP-C (r
2 44.2, p=0.002). Once again, when examining the population as a 
whole, subject group was not an independent predictor. 
 
 
7.3.5 Change in HDL2 and HDL3 Concentrations 
 
There was no association between change in HDL2 concentration and change 
in triglyceride, LDL III, VLDL1, VLDL2, RLP-C and RLP-TG in patients and 
controls.  
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Similarly, with regards to change in HDL3 concentration, there was no 
association with change in triglyceride, LDL III, VLDL1, VLDL2, RLP-C and 
RLP-TG in patients. In controls, only a decrease in VLDL1 concentration 
correlated with an increase in HDL3 (r
2 23.9%, p=0.03).   
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        All                Patients              Controls 
 
      r
2    p        r
2    p        r
2    p 
 
________________________________________________________________________________________________________ 
 
Triglyceride    22.7    0.003        24.4    0.025        29.5    0.014 
 
   
LDL III %    13.0    0.02        20.8    0.038        6.7    ns   
 
 
LDL III conc    24.8    0.002        27.9    0.017        28.7    0.016 
 
 
VLDL1     42.1    0.000        46.8    0.001        41.0    0.003 
 
 
RLP-C    16.7    0.01        14.1    0.076        22.9    0.03 
 
 
 
Table 7.5: Association Between Baseline HDL2 and Baseline Parameters in Patients and Controls 
Linear regression analysis of baseline HDL2 concentration with baseline parameters in all the subjects as a whole, patients and 
controls. (All correlations negative) 
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        All                Patients              Controls 
 
      r
2    p        r
2    p        r
2      p 
 
________________________________________________________________________________________________________ 
 
Triglyceride    17.6    0.008        0    ns        31.8    0.01     
   
 
LDL III %    16.7    0.009        0    ns        32.6    0.01 
 
 
LDL III conc    23.8    0.002        0    ns        34.2    0.008 
 
 
VLDL1     12.5    0.023        0    ns        41.3    0.003 
 
 
RLP-C    18.6    0.006        0    ns        44.2    0.002 
 
 
Table 7.6: Association Between Baseline HDL3 and Baseline Parameters in Patients and Controls 
 
Linear regression analysis of baseline HDL3 concentration with baseline parameters in all the subjects as a whole, patients and 
controls.  
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Figure 7.1 Baseline HDL2 vs Baseline Triglyceride in Patients & Controls 
 
Linear regression analysis of baseline HDL2 with baseline triglyceride in all 
subjects (r
2 = -22.7%, p=0.003). 
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Figure 7.2 Baseline HDL2 vs Baseline VLDL1 in Patients & Controls 
 
Linear regression analysis of baseline HDL2 with baseline VLDL1 in all 
subjects (r
2 = -46.8%, p<0.001). 
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Figure 7.3 Baseline HDL3 vs Baseline Triglyceride in Patients & Controls 
 
Linear regression analysis of baseline HDL3 with baseline triglyceride in all 
subjects (r
2= 17.6%, p=0.008). 
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Figure 7.4 Baseline HDL3 vs Baseline RLP-C in Patients & Controls 
 
Linear regression analysis of baseline HDL3 with baseline RLP-C in all 
subjects (r
2= 18.6%, p= 0.006). 
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HDL Subclass              Patients                  Controls               p 
         (%) 
______________________________________________________________ 
 
2a                              24.4 (23.1- 28.4)           25.5 (21.6- 27.9)             ns 
 
2b                              24.1 (21.8- 26.1)           24.8 (21.3- 29.1)             ns 
 
3a                              25.9 (24.4- 27.2)             26.4 (23.9- 28.4)             ns 
   
3b                              15.8 (13.2- 16.7)           14.3 (11.7- 18.3)             ns 
 
3c                               9.2 (5.7 - 0.7)             7.7 (6.2- 10.2)             ns
   
 
Table 7.7: Baseline Patient and Control HDL Subclasses by Gel 
Electrophoresis 
 
 
 
7.3.6 Baseline Subclasses- Gel Electrophoresis 
 
Patient and control baseline distribution of HDL subclasses are shown in table 
7.7. There was no significant difference in all the subclasses between patients 
and controls. 
 
7.3.7 Treatment Effect on HDL subclasses- Gel electrophoresis 
Table 7.8 outlines the effect of treatment with omega-3 fatty acids on % of 
each HDL subclass as measured by gel electrophoresis in patients and 
controls. 
Omega-3 fatty acids did not affect HDL2a in patients or controls however the 
percentage of HDL2b was increased in patients and controls (mean increase 
patient group 3.98 (95%CI 1.58 to 6.39), controls 3.7 (95%CI 2.0 to 5.3). Both 
percentages of HDL3a and HDL3b subclasses were reduced by treatment 
with omega-3 fatty acids in patients and controls: HDL3a- patients 2.0 (95%CI  
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0.6 to 3.4), controls: 1.8 (95%CI 1.1 to 2.6), HDL3b- patients: 1.5 (95%CI 0.4 
to 2.6), controls: 1.7 (95%CI 0.9 to 2.6). 
The percentage of HDL3c was not significantly affected in patients but in 
controls fell by mean of 0.8 (95%CI 0.1 to 1.7). Mean HDL particle diameter 
increased in both patients and controls following treatment with omega-3 fatty 
acids: patients 9.39nm (IQR 9.34- 9.54) to 9.51nm (9.40- 9.80) p=0.03, 
controls 9.42nm (IQR 9.36- 9.53) to 9.50nm (9.40- 9.82) p=0.001. 
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HDL subclass     Patients                           Controls 
 
      (%)               Baseline         Post Treatment       p        Baseline           Post Treatment            p 
________________________________________________________________________________________________________ 
 
2a                     24.4 (23.1- 28.4)            26.6 (23.2 -27.9)     ns             25.5 (21.6 – 27.9)      25.4 (23.7- 28.4)       ns 
 
2b                     24.1 (21.8- 26.1)             26.7 (23.9- 35.0)   0.003            24.8 (21.3- 29.1)       26.9 (22.9- 36.6)       <0.001 
 
3a                     25.9 (24.4- 27.2)             23.7 (19.5- 27.5)     0.009           26.4 (23.9- 28.4)    24.7 (21.1- 27.4)       <0.001       
 
3b                     15.8 (13.2- 16.7)             13.5 (10.9- 15.6)      0.009            14.3 (11.7- 18.3)    14.1 (8.6- 16.2)    <0.001 
 
3c                      9.2 (5.7- 10.7)              7.3 (5.9- 10.2)            ns              7.7 (6.2- 10.2)     8.2 (4.6- 9.9)      0.03                      
 
 
 
Table 7.8: Effect of Treatment on HDL Subclasses Measured by Gel Electrophoresis 
 
Percentage of each HDL subclass in patients and controls at baseline and following treatment. 
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7.5 Discussion 
 
 
In this study we have identified no difference in the plasma concentration of 
HDL subfractions in patients with nephrotic range proteinuria compared with 
age and sex matched controls analysed either by density ultracentrifugation or 
gradient gel electrophoresis. There was however a trend towards increased 
levels of the smaller denser HDL3 and as mentioned previously, there is a 
clear outlier in the patient group and once this outlier is omitted, HDL3 levels 
are significantly higher in the patient group compared with the controls. 
Omega-3 fatty acids significantly increased HDL2 concentration in patients 
and controls but HDL3 concentration remained unchanged. On gel 
electrophoresis, HDL subclass 2a was unaffected by treatment but %2b 
increased in both patients and controls. Percentage of HDL subclasses 3a 
and 3b were reduced by treatment but only 3c was reduced in controls. 
However, mean particle diameter was increased by omega-3 fatty acids in 
both patients and controls. Baseline lipoprotein concentration of HDL2 was 
inversely associated with atherogenic triglyceride rich lipoproteins in patients 
and controls, whereas lipoprotein concentration of HDL3 correlated with 
atherogenic triglyceride rich lipoprotein, at baseline, in the control group only. 
Subject group was not an independent predictor of baseline HDL2 or HDL3 
concentrations or change in levels following treatment with Omega-3 fatty 
acids.  
As discussed in the introduction, it is widely recognised that high HDL-C levels 
are associated with reduced cardiovascular risk and that raising HDL further 
reduces this risk(29;30;32;33). However, there is conflicting data regarding the  
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atherogenicity of HDL subfractions. Several studies have suggested a strong 
inverse relationship between HDL2 and coronary atherosclerosis. Salonen at 
al examined HDL subfractions in Finnish men. They found HDL-C and HDL2 to 
be inversely related to the risk of myocardial infarction (214). There was also 
an inverse relationship between HDL3 and ischaemic heart disease risk but 
statistical significance was lost when adjusted for HDL2. Furthermore, data 
from the VA-HIT study  showed that levels of small HDL predicted CHD 
events suggesting that the larger HDL (HDL2) particles were more 
protective(215). 
 In contrast, data from the Physicians‟ Health Study (216) and the Caerphilly 
and Speedwell Collaborative Heart Disease Studies found HDL3 to be the 
strongest inverse predictor of IHD(217). While density ultracentrifugation 
separates HDL into 2 subfractions, gradient gel electrophoresis methods have 
reported from 5 to 14 subclasses(184;218). Several studies have suggested 
that reduction in large HDL2b particles are associated with an increased in 
CHD risk(219;220).The variety of results from studies examining HDL 
subclasses reflects the heterogeneity of HDL particles. Quantification of these 
subclasses is useful but the available methods are time consuming and 
difficult as well as lacking in uniformity and validation.  
In patients with nephrotic syndrome, HDL-C levels are usually normal or 
reduced, often with a reduced HDL2 subfraction. The mechanism behind this 
is unclear. It has been shown that levels of cholesteryl ester transfer protein 
(CETP) are increased in this population. This protein mediates transfer of 
esterified cholesterol from HDL2 to VLDL. This increase in CETP activity is 
likely to be driven by increased levels of triglyceride rich lipoproteins prevalent  
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in nephrotic range proteinuria thereby leading to decreased HDL2 and 
increased HDL3. Also, reduced activity of another enzyme, Lecithin cholesterol 
acyltransferase (LCAT) has been documented in human and nephrotic rats. 
LCAT is the enzyme responsible for the esterification of cholesterol within the 
plasma maintaining a concentration gradient for unesterified cholesterol 
between peripheral cells and plasma. The reduced activity of LCAT may be 
due to hypoalbuminaemia as albumin normally binds lysolecithin (a product of 
LCAT reaction) and accumulation of unbound lysolecithin impairs enzyme 
activity (169), or LCAT may be lost in the urine of these patients. The resulting 
reduced levels of LCAT would impair cholesteryl esterification within the HDL 
particle and so inhibit conversion of HDL3 to HDL2.  
 
Omega-3 fatty acids have been shown to have a favourable effect on HDL. 
Doses of 3.5 to 4g have been shown to consistently increase HDL-C primarily 
by increasing HDL2 (221). They are thought to increase larger HDL (HDL2) at 
the expense of HDL3(129) mediated by a reduction in cholesteryl ester 
transfer protein activity thereby favouring large cholesterol-rich HDL formation. 
Using the method of ultracentrifugation to separate HDL, we found that 
treatment with omega-3 fatty acids increased concentration of HDL2 but did 
not affect HDL3. However, using gradient gel electrophoresis, we found that 
%HDL2b increased percentages of HDL3a and 3b fell and mean particle 
diameter of HDL particle increased with treatment in keeping with the above 
mechanism.  
Although we showed that baseline HDL2 concentration was associated with 
baseline triglyceride concentration, we did not find any association between  
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change in HDL 2 concentration and change in triglyceride concentration. This 
may be explained by the fact that treatment did not actually reduce total HDL 
or HDL-C but caused redistribution to larger HDL2. We also did not show a 
group effect, implying that the mechanism in patients and controls is similar 
and the differences are related to differences in baseline characteristics. 
 
Other than omega-3 fatty acids, a number of other agents are known to 
increase HDL-C, primarily statins and fibrates. Treatment with statins has a 
moderate effect on HDL raising it by about 5% (222). The mechanism behind 
the HDL raising effect of statins is not fully understood. They increase HDL 
apo AI production by approximately 15% in the liver (223) thereby increasing 
HDL2 production. In addition, they increase expression of LDL receptors 
causing a reduction in the numbers of potentially atherogenic lipoprotein 
acceptors of cholesteryl ester via the CETP mechanism from HDL.  Fibrates 
have a greater effect on HDL and can raise HDL concentration by up to 25% 
through a number of mechanisms but their use is limited in patients with 
nephrotic range proteinuria as they are poorly tolerated.  
 
In summary, therefore, we have demonstrated that omega-3 fatty acids have 
a favourable effect on HDL subclasses in both patients and controls which 
contributes further to their cardioprotective properties.  
. 
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8.1 Introduction 
As discussed previously, patients with nephrotic range proteinuria have a 
marked increase in cardiovascular risk. However, the lipid and lipoprotein 
abnormalities described earlier cannot alone account for the large burden of 
cardiovascular disease observed in this population.  
The endothelium is thought to play a central role in the early development of 
atherosclerosis(224). The pathological changes associated with proteinuria 
are believed to cause endothelial dysfunction. Both inflammation and 
oxidative stress are important mechanisms in the development of an 
atherosclerotic plaque.  
Omega-3 fatty acids have been shown to have beneficial effects on 
endothelial function and anti-inflammatory properties in the general population 
as discussed in chapter 1.Therefore, the aim of this study was three-fold. 
Firstly to examine endothelial function using the non-invasive technique of 
laser doppler imaging in patients with nephrotic range proteinuria and 
compare with a control population. This technique is based on the 
iontophoretic transdermal delivery of acetylcholine (Ach) and sodium 
nitroprusside (SNP) which are vasodilators(225). Ach induced vasodilatation 
is „endothelium-dependent‟ as it requires an intact endothelium with binding to 
muscarinic receptors and the generation of nitric oxide. SNP induced 
vasodilatation is termed „endothelium- independent‟. Nitric oxide acts on 
vascular smooth muscle leading to vasodilatation therefore, as SNP is a nitric 
oxide donor, it acts as an „endothelium independent‟ control. Laser Doppler 
imaging measures skin perfusion under the influence of these drugs.  
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Secondly, to assess whether omega-3 fatty acids improve endothelial function 
in this population. Finally, we aimed to examine novel markers of endothelial 
function and inflammation in this population both pre and post treatment with 
omega-3 fatty acids. 
 
8.2 Subjects and Methods 
 
 
8.2.1 Subjects 
 
The patients and controls described in the methods section were studied in 
this chapter. Patients and controls attended on 2 occasions as previously 
described: once at the start of the study prior to commencing omega-3 fatty 
acids and once following 8 weeks of treatment with 4g daily of Omacor. 
Endothelial function was measured using the technique of laser doppler 
imaging described below on both occasions prior to venesection. Fasting 
EDTA samples were drawn and plasma isolated as previously described on 
these 2 occasions. Samples were divided into 0.5ml aliquots and frozen at      
-80°C.Highly sensitive CRP (hsCRP), I-CAM, V-CAM, oxidised LDL and PLA2 
assays were performed as described in the methods section on all patients 
and controls completing the study. 
 
 
8.2.2 Iontophoresis Protocol 
 
This LDI protocol is based on one developed in Glasgow(225). We carried out 
the measurements in a temperature-controlled room at 23
oC (±2
oC) after 
allowing the patients and controls to acclimatise for 30 minutes before the 
procedure. A battery-powered constant current iontophoresis controller (MIC-
le; Moor Instruments Ltd. Axminster, UK) allowed drug delivery with Perspex  
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chambers (internal diameter 22 mm, area 3.8 cm
2) and an internal platinum 
wire electrode were used for iontophoresis (ION 6; Moor Instruments Ltd.). 
Doubled-sided adhesive disks were used to attach the two chambers to the 
skin of the volar aspect of the forearm avoiding hair, broken skin, and 
superficial veins, Figure 8.1. The chambers were connected to the anode and 
cathode connections on the iontophoresis controller.  
 
 
 
   
 
 
 
 
Figure 8.1 Drug Delivery Chambers 
Perspex drug delivery chambers with overlying coverslips with a temperature probe 
attached to the skin.  
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Figure 8.2 LDI Experimental Setup 
 
Block Diagram of the experimental setup. The anodal and cathodal chambers 
contained acetylcholine (ACh) and sodium, nitroprusside (SNP) respectively.  
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The laser doppler imager software was programmed in order to control current 
delivery. The current was switched on at the beginning of a scan and 
remained on until the start of the next scan after which the current was then 
either left on for the next scan or was switched off after the total charge had 
been delivered. The duration of the current was the time taken to complete 
each scan (50 s) multiplied by the total number of scans programmed. Low 
currents were used to limit the iontophoresis dose. The procedure involved 
incremental current delivery with four scans at 5 µA, four at 10 µA, four at 15 
µA, and two at 20 µA amounting to a total charge of 8 mC.  2.5 ml of 1% ACh 
(Sigma Chemical Co., St. Louis, MO, U.S.A.) was placed into the anodal 
chamber and 2.5 ml of 1% SNP (Sigma) was placed in the cathodal chamber 
therefore both agents were delivered simultaneously during the delivery of 
current. 0.5% NaCl was used as the vehicle for these agents. Circular 
coverslips (32mm) over the chambers prevented the leakage of fluid.  
 
8.2.3 Perfusion Measurements 
Measurement of skin perfusion was carried out using a laser doppler imager 
(Moor Instruments Ltd.) with a red laser (wavelength, 633 nm; power, 1 mW; 
beam diameter, 1 mm). This non-invasive technique is based on the doppler 
shift  imparted  by  moving  blood  cells  in  the  underlying  tissue  to  the 
backscattered  light.  The  laser is  scanned  over  both  chambers  through  the 
coverslips and so backscattered light is collected by photodetectors which is 
converted  into  a  signal  proportional  to  perfusion.  This  is  expressed  as 
ACh  
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arbitrary perfusion (flux) units (PU). The signal is then displayed as a colour-
coded  image  on  a  monitor.  The  imager  manufacturer's  image  analysis 
software  allowed  perfusion  measurements  by  outlining  a  region  of  interest 
(ROI)  around  the  internal  circumference  of  the  chamber.  The  median  flux 
value across approximately 700 measurement points was calculated through 
statistical analysis of the ROI. Twenty scans were carried out. The first was a 
control prior to current administration followed by 14 scans of the incremental 
current  protocol  outlined  earlier  (14  scans)  and  five  further  scans  without 
current  administration.  (Figure  8.4)  Skin  temperature  close  to  the 
iontophoresis  chambers  was  monitored  continuously  throughout.  No 
significant temperature change occurred between the beginning and the end 
of perfusion measurements, indicating stable conditions. 
8.3 Statistics 
Analysis  was  performed  using  MINITAB  13.1  for  Windows  (Minitab  Inc). 
Differences in measures of endothelial function (VCAM and ICAM) and other 
parameters between patients and controls were tested by the Mann-Whitney 
U test or Students‟ t-test as appropriate. For measurement of skin perfusion 
responses an assessment of the overall response to drugs (or vehicle) was 
obtained  by  taking  the  area  under  the  perfusion-current  curve  (AUC),  with 
comparisons made using the Mann-Whitney U test. All data is expressed as 
mean  ±SD  or  SEM.  A  p  value  of  <0.05  was  considered  as  statistically 
significant throughout. 
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Figure 8.3 LDI Scan Pictures 
 
The photo image is generated by back scattered light and the flux image is the 
doppler shifted component. Flux is colour-coded with lowest perfusion in dark 
blue (0 PU) and highest in dark red (500 PU).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.4 LDI Scan Pictures with Incremental Current Administration 
 
Sodium nitroprusside (SNP) is in the upper chamber and acetylcholine (ACh) 
in the lower chamber. Current was incrementally applied as described in the 
text. The time courses of the drug-induced vasodilator responses differ.  
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8.4 Results 
8.4.1 Laser Doppler Assessment of Microvascular Endothelial Function 
 
At baseline, the vascular response to both SNP and acetylcholine did not 
differ significantly between patients and controls: SNP AUC , 1755 ± 490 vs 
1372 ± 755, Acetylcholine AUC, 1633 ± 411 vs 1654 ± 436 PU, p=ns). This is 
portrayed in figures 8.5 and 8.6. 
Treatment with omega-3 fatty acids did not improve vascular response to 
either SNP or acetylcholine in patients or controls. This is outlined in figures 
8.7, 8.8, 8.9 and 8.10. 
 
 
Figure 8.5 Comparison of ACh Responses Between Patients & Controls 
Comparison of vascular responses to ACh between patients and controls 
represented as arbitrary perfusion units under the perfusion current curve. No 
difference is observed, p=ns. 
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Figure 8.6 Comparison of SNP Response between Patients & Controls 
 
Comparison of vascular responses to SNP between patients and controls 
represented as arbitrary perfusion units under the perfusion current curve. No 
difference is observed, p=ns. 
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Figure 8.7 Acetylcholine Response in Patients Pre and Post Treatment 
 
Vascular response to ACh in patients pre (v1) and post (v2) treatment with 
omega-3 fatty acids. Bars represent standard error of mean, p=ns (two way 
ANOVA). 
 
 
 
 
Figure 8.8 SNP Response in Patients Pre and Post Treatment 
 
Vascular response to SNP in patients pre (v1) and post (v2) treatment with 
omega-3 fatty acids. Bars represent standard error of mean, p=ns (two way 
ANOVA). 
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Figure 8.9 Acetylcholine Response in Controls Pre and Post Treatment 
 
Vascular response to ACh in controls pre (v1) and post (v2) treatment with 
omega-3 fatty acids. Bars represent standard error of mean, p=ns (two way 
ANOVA). 
 
 
Figure 8.10 SNP Response in Controls Pre and Post Treatment 
 
Vascular response to SNP in controls pre (v1) and post (v2) treatment with 
omega-3 fatty acids. Bars represent standard error of mean, p=ns (two way 
ANOVA). 
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8.4.2 Baseline Cardiovascular Risk Markers 
Baseline levels of hsCRP, oxidised LDL, I-CAM, V-CAM and PLA2 in patients 
and controls are portrayed in table 8.1.Plasma V-CAM and PLA2 levels were 
significantly higher in the patient group at baseline (p<0.001 and p=0.04). No 
difference in baseline hsCRP, oxidized LDL and I-CAM was observed.  
 
                                        Patients      Controls     p 
                                         (n=17)                  (n=17) 
______________________________________________________________ 
 
hsCRP (mg/l)                2.2 (0.8-6.2)              1.4 (0.9-8.0)    ns 
 
Ox LDL (mU/l)               83.6 (62.2-100.8)    79.4 (54.9-85.6)  ns 
 
I-CAM (ng/ml)                257 (196 -308)                 262 (218 -294)    ns 
 
V-CAM (ng/ml)               879 (739-1103)             621 (428-701)    <0.001 
 
PLA2 (ng/ml)                  228 (186-241)              185 (170-217)        0.04 
 
Table 8.1 Cardiovascular Risk Markers in Patients and Controls 
(All median & IQR) 
 
8.4.3 The Effect of Treatment on Cardiovascular Risk Markers in Patients 
& Controls 
In the patient group, treatment with omega-3 fatty acids did not significantly 
affect levels of hsCRP, oxidised LDL, I-CAM, V-CAM or PLA2 (table 8.2). 
In the controls, the only observed difference was in V-CAM concentration with 
a mean increase of 80 ng/ml (95% CI: 23 -138) (table 8.3). As in the patient 
group, hsCRP, oxidised LDL, I-CAM and PLA2 were unchanged. 
  
171 
 
 
Patients                               Baseline       Post Treatment    p 
   (n=17)       (n=17) 
______________________________________________________________ 
 
hsCRP (mg/l)  2.2 (0.8- 6.2)    1.6 (0.7-6.2)    ns 
 
Ox LDL (mU/l)  84 (63 -101)    95 (70 -107)    ns 
 
I-CAM (ng/ml)  257 (196-308)    247 (207-340)  ns 
 
V-CAM (ng/ml)  879 (739-1103)    912 (1179-2541)  ns 
 
PLA2 (ng/ml)  228 (186-241)    247 (186-271)  ns 
 
 
Table 8.2 The Effect of Omega-3 Fatty Acids on Cardiovascular Risk 
Markers in Patients 
 
(All median & IQR) 
 
 
 
 
 
 
Controls                              Baseline         Post Treatment   p 
   (n=17)               (n=17) 
______________________________________________________________ 
 
hsCRP (mg/l)  1.4 (0.9- 8.0)    1.6 (0.8-3.4)    ns
   
Ox LDL (mU/l)  79 (55 - 86)     78 (56 -86)    ns 
 
I-CAM(ng/ml)  262 (218- 294)    276 (229-301)  ns 
     
V-CAM (ng/ml)  621 (428- 701)    630 (539- 732)       0.01 
 
PLA2 (ng/ml)  185 (170-217)    175 (168- 217)  ns 
 
 
 
Table 8.3 The Effect of Omega-3 Fatty Acids on Cardiovascular Risk 
Markers in Controls 
 
(All median & IQR) 
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8.5 Discussion 
 
This study has shown no difference between microvascular endothelial 
function assessed by the technique of laser doppler imaging in patients with 
nephrotic range proteinuria compared with controls. Furthermore, we showed 
that omega-3 fatty acids had no demonstrable effect on endothelial function 
measured directly using LDI or through the measurement of soluble markers 
of endothelial activation in either population. We demonstrated that patients 
had higher baseline levels of V-CAM and PLA2 than controls; however the 
only change that was observed following treatment with omega-3 fatty acids 
was an increase in V-CAM levels in the control group. 
There have been two studies examining endothelial function using the 
technique of laser doppler iontophoresis in proteinuric patients. The first failed 
to show any difference in vascular response between patients and controls. 
They examined 21 otherwise healthy patients with asymptomatic proteinuria 
(226). The second examined 39 patients with glomerulonephritis and a mean 
albumin: creatinine ratio (ACR) of 191mg/mmol. Patients with co-existing 
vascular disease were excluded. They stopped ACE inhibitors and 
angiotensin receptor antagonists prior to the study. They demonstrated that 
the patients with proteinuria had significantly abnormal microvascular 
endothelial function compared with the controls. The vascular response to 
both SNP and ACh was impaired in the proteinuric group (227). Other 
techniques of assessing endothelial function have yielded similar results. 
Stroes et al demonstrated endothelial dysfunction in nine patients with 
nephrotic range proteinuria by venous occlusion plethysmography(178) and 
an Australian group found abnormal „endothelium- dependent‟ response but  
173 
 
preserved „endothelium- independent‟ response in patients with nephrotic 
syndrome using brachial artery ultrasound(179). 
 
There are many factors which can affect endothelial function such as age, 
gender and smoking status. Drugs such as ACE inhibitors, angiotensin 
receptor antagonists and statins have all been shown to improve endothelial 
function(228;229). In this study, all statins were stopped for 4 weeks prior to 
enrolment, however we did not feel it was ethical to stop either ACE inhibitors 
or angiotensin receptor blockers in the patients with nephrotic range 
proteinuria and so all the patients were on either agent with two on both. 
Clearly, this may have influenced our results and account for some of the 
differences compared with previously published data. In addition, as we 
attempted to triglyceride match our controls, these subjects may not have 
been representative of a normal control population. Furthermore, the numbers 
in our study were small and the heterogeneous nature of the group may have 
contributed to the lack of observed difference between the patients with 
proteinuria and the control population.  
Studies have shown a beneficial effect of omega-3 fatty acids on endothelial 
function. Supplementation with 4g daily of omega-3 fatty acids improved 
endothelial function measured by brachial artery ultrasound in  a group of 15 
hypercholesterolaemic subjects compared with controls(151). Using laser 
doppler imaging, supplementation with omega-3 fatty acids improved ACh 
mediated vascular response but not SNP response in healthy subjects(230).  
However, their effect on endothelial function in patients with nephrotic range 
proteinuria has not, to our knowledge, been studied.  
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Lipoprotein associated phospholipase A2 (Lp-PLA 2) is a member of the 
phospholipase A2 family of enzymes produced by macrophages, T 
lymphocytes and mast cells. Lp-PLA2 is present in atherosclerotic plaques 
(231). It hydrolyses oxidised phospholipids resulting in pro-inflammatory 
particles(232). This is an emerging marker for vascular events with 
epidemiological studies suggesting an association between increased Lp-
PLA2 levels and CHD (183;233-235). In addition, increased Lp-PLA2  levels 
have been demonstrated in patients with subclinical coronary disease and 
coronary calcifications(236). More recently, Lp-PLA2 has been implicated in 
endothelial dysfunction(232;237) . To our knowledge, no studies have 
examined the effect of omega-3 fatty acids on PLA2 levels in patients with 
nephrotic range proteinuria. There have been a number of studies examining 
markers of endothelial function in patients with chronic renal failure but few 
have looked at the association between endothelial markers and the level of 
proteinuria. Elevated levels of I-CAM and V-CAM have been shown in patients 
with mild renal impairment(238), advanced renal impairment(239) and those 
on dialysis(240). MacKinnon et al demonstrated that patients with urinary 
protein levels greater than 2g in 24 hours had higher levels of I-CAM, V-CAM 
and CRP(241). Our study showed that patients with nephrotic range 
proteinuria had higher levels of V-CAM but I-CAM and CRP did not differ. The 
numbers in our study were small and as described above there were a 
number of confounding factors. 
 
Omega-3 fatty acids are known to have established ant-inflammatory 
properties (242). However, the interventional data is inconsistent (243-246). A  
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recent meta-analysis of four prospective randomised studies showed that 
omega-3 fatty acids did not affect hs-CRP (247). Similarly, studies examining 
the effect of omega-3 fatty acids on markers of endothelial activation have 
displayed varying results. In a study of sixty healthy volunteers, 
supplementation with 6.6g omega-3 fatty acids had no effect on I-CAM or V-
CAM levels(248). However, a study of 563 hyperlipidaemic men showed that 
I-CAM fell but V-CAM was unchanged following treatment (249). This was a 
large, long-term study with a treatment duration of 3 years. The data regarding 
the effect of omega-3 fatty acids on oxidised LDL levels is sparse. There was 
no change in oxidised LDL levels in a study of hypercholesterolaemic  
subjects supplemented with alpha-linolenic acid for 2 years(250).  
It is difficult to draw conclusions from our data in view of the small numbers 
and short treatment duration. 
In summary, we were unable to demonstrate a difference in endothelial 
function between patients with nephrotic range proteinuria compared with 
normal controls. However, to our knowledge, we are the first to observe higher 
levels of Lp-PLA2 in this population. Moreover, treatment with omega-3 fatty 
acids had no beneficial effect in either population. 
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Chapter 9: General Discussion 
and Conclusions 
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9.1 Nephrotic Syndrome and Lipoprotein Abnormalities 
The dyslipidaemia associated with nephrotic syndrome is characterized by 
increased levels of cholesterol, triglyceride, VLDL-C, excess small dense LDL 
and low HDL-C(162-165). This work confirms these abnormalities. 
The mechanism leading to this dyslipidaemia is unclear. Several studies have 
suggested that there is reduced catabolism of Apo B containing lipoproteins 
(TG, VLDL, IDL and LDL) rather than increased hepatic synthesis. Demant et 
al examined metabolism of Apo B containing lipoproteins using radiotracer 
kinetic studies. They found impaired delipidation of VLDL2 and IDL with 
reduced LDL catabolism(251). In addition, a further study of 
hypercholesterolaemic patients with nephrotic syndrome showed that these 
patients had lower catabolic rates of LDL Apo B but no overproduction of LDL 
Apo B (252). Impaired triglyceride metabolism rather than increased synthesis 
is responsible for the increased triglyceride levels observed in these patients. 
Animal work has shown higher triglyceride levels in nephrotic rats than in rats 
with analbuminaemia despite similar rates of triglyceride production(253) .  
Total HDL levels are usually normal even although HDL2 to HDL3 ratio in 
patients with nephrotic syndrome are often low. Levels of LCAT (the enzyme 
responsible for the conversion of HDL3 to HDL2) have been found to be low 
due to urinary losses(254). Hepatic mRNA levels were unaffected suggesting 
increased excretion of LCAT rather than decreased production resulting in 
increased levels of HDL2. 
Increased levels of remnant lipoproteins and small dense LDL have previously 
been described in this population (255). Again, our observations have 
confirmed these abnormalities. Plasma triglycerides were the most important  
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factor influencing LDL phenotype and remnant lipoprotein concentration in our 
study. Once again, confirming previous observations. The increase in 
cholesterol, triglyceride, LDL-C, remnant lipoproteins and small dense LDL all 
contribute to increasing CV risk.   
 
9.2 Postprandial Lipaemia 
There is little published human work examining chylomicron and VLDL 
metabolism in patients with nephrotic range proteinuria. The existing evidence 
in this area is conflicting. Studies in nephrotic rats have found changes in the 
catabolism and composition of chylomicrons(202;203). These studies have 
been difficult to perform due to technical difficulties in separating the 
chylomicrons from VLDL. Warwick et al measured TG and retinyl palmitate in 
the d1.006g/ml fraction of plasma following a vitamin A loaded standard fat 
meal in nephrotic subjects. They found no difference in the time course of the 
postprandial response suggesting that chylomicron metabolism did not differ 
between nephrotic subjects and normal control (204). However, differences 
were observed between individuals in their postprandial response. This 
emphasizes the heterogeneity of the population being studied. The same 
group demonstrated a reduction in clearance of VLDL in nephrotic subjects 
but others have failed to demonstrate this (256). It is likely that the 
discrepancy in results is multifactorial with the heterogeneity of this 
population, the difficulty in separating and measuring chylomicrons and 
differences in fat load administration all contributing. 
There are very few studies examining the structure and composition of 
chylomicrons and VLDL. Chylomicrons from nephrotic rats have been shown  
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to be larger and rich in triacylgycerol(202). To our knowledge, there have 
been no human studies examining this. Our work is in keeping with the animal 
studies. We observed larger chylomicrons in the patients with nephrotic range 
proteinuria. These structural abnormalities may account for their less efficient 
lipolysis that we observed in chapter 5. 
Work from our laboratory previously reported abnormalities in the structure of 
VLDL particles with a smaller more crystalline particle deficient in apo CII, III 
and E(175). We were unable to replicate these findings in our population. 
Again, the heterogeneity of the population being studied along with the small 
numbers involved and advances in the apoB assay may, in part, account for 
this. However, our findings are in keeping with our results from chapter 5 
where we showed delayed postprandial chylomicron clearance but unaltered 
postprandial VLDL metabolism in the patients with nephrotic range 
proteinuria. Further studies are required to clarify this. 
 
9.3 Endothelial Function and Inflammation 
Proteinuria is increasingly being thought of as a marker of vascular disease. 
Microalbuminuria has been linked with endothelial dysfunction (10) .However; 
studies using the technique of laser doppler iontophoresis to assess 
endothelial function in patients with proteinuria are conflicting. A study of 21 
asymptomatic proteinuric patients failed to show any difference in vascular 
response(226). A further study examined 29 patients with a mean ACR of 
191mg/mmol found both impaired SNP (endothelium-independent) and Ach 
(endothelium independent) response in the patients with proteinuria(241). We 
failed to replicate this in our population of 17 patients with nephrotic range  
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proteinuria. Potential confounding factors that may have influenced our results 
included the small number of patients studied and the continued use ACE 
inhibitors and Angiotensin receptor blockers throughout  the study due to 
ethical concerns regarding discontinuing these preparations. 
 
Inflammation is known to play an important role in atherosclerosis. A number 
of biomarkers for endothelial dysfunction and inflammation are emerging 
which have been shown to be useful for the prediction of coronary heart 
disease.  Several studies have indicated that increased levels of hs CRP are 
predictive of cardiovascular events in healthy subjects(88). Increased levels of 
hsCRP have also been observed in patients with proteinuria(241).  Expression 
of adhesion molecules (I-CAM and V-CAM) are increased on endothelial cells 
overlying atheroma and elevated levels of these molecules have been found 
in patients with all levels of renal impairment from mild to end stage renal 
failure and also in patients with proteinuria(238-240). PLA2 is an emerging 
marker for vascular events. It is present in atherosclerotic plaques and 
associated with endothelial dysfunction(232;237). In our study we observed 
increased levels of PLA2 and V-CAM but no difference in I-CAM and CRP. We 
acknowledge that our study was not adequately powered to detect a 
difference in these parameters and there are a number of confounding factors 
as mentioned earlier. However, the increase in PLA2 and V-CAM are 
noteworthy but further more detailed investigation in a large study population 
is required to clarify this. 
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9.4 Omega- 3 Fatty Acids and Nephrotic Syndrome 
Prospective randomised controlled trial evidence has demonstrated the 
benefit of omega-3 fatty acids in different populations. Men without clinical 
heart disease, patients with angiographic evidence of CHD, patients with 
recent myocardial infarctions, adults over  65 years old and 
hypercholesterolaemic subjects are among the groups where the benefit of 
omega-3 fatty acids have been demonstrated(114;125;257-259). However, 
there has been little work examining their effect on dyslipidaemia in patients 
with nephrotic range proteinuria. 
The major effect of omega-3 fatty acids on lipids and lipoproteins is a 
reduction in plasma TG and TRLs. Studies have shown that they inhibit TG 
synthesis and secretion of VLDL from the liver(118;119;191). They are 
thought to reduce production of triglyceride rich lipoproteins rather than 
enhancing their clearance(52;120;121). They are also known to increase LDL-
C. The mechanism behind this is unclear but it has been suggested that they 
down regulate the LDL Apo B/E receptor as well as preferentially converting 
VLDL to LDL(127;128). This increase in LDL-C is potentially offset by a 
redistribution to larger less atherogenic LDL but remains a concern to some 
clinicians. This is thought to be caused by suppression of CETP activity thus 
reducing the transfer of cholesteryl ester from HDL to VLDL and LDL(129) 
resulting in triglyceride enrichment of HDL and LDL. 
We have shown in chapters 3 and 4 that patients with nephrotic range 
proteinuria had increased levels of triglyceride rich lipoproteins and excess 
small dense LDL. We found that treatment with omega-3 fatty acids reduced 
triglyceride rich lipoproteins and levels of small dense LDL concentration in  
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the patients with nephrotic range proteinuria but no reduction was observed in 
the control group. The differing effects are likely to be due to the higher 
baseline TG levels in patients with nephrotic range proteinuria compared with 
the controls. These benefits are similar to those seen in hypertriglyceridaemic 
subject but no underlying renal disease. 
Treatment with omega-3 fatty acids have been shown to reduce postprandial 
lipaemia in the normal population and hypertriglyceridaemic subjects with a 
greater benefit displayed with higher baseline TG levels(120;130;131). It is 
thought that they accelerate chylomicron clearance by facilitation of lipoprotein 
lipase mediated lipolysis(120). However, their effect on postprandial lipaemia 
has not been studied in nephrotic patients. In our study, we observed a 
reduction in chylomicron AUC following treatment with omega-3 fatty acids in 
the patients with nephrotic range proteinuria but not in the control population. 
We postulated that the differences again were related to the higher levels of 
baseline triglyceride in the patient group however on multivariate analysis 
subject group rather than baseline triglyceride concentration was found to be 
an independent predictor of change in chylomicron AUC. This suggests that 
the chylomicrons of patients with nephrotic range proteinuria may differ in 
structure or composition. 
 
Omega-3 fatty acids are thought to reduce VLDL synthesis and secretion 
(118;119;191). We found a reduction in peak postprandial VLDL1 AUC 
following treatment. Once again, this has not been previously studied in this 
population but is in keeping with previous studies suggesting a reduction in 
synthesis. The effect of omega-3 fatty acids on the structure or composition of  
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chylomicrons or VLDL has not been studied in any population. We observed 
no difference in the structure or composition of chylomicron or VLDL particles 
in patients or controls following treatment. This suggests that the effect we 
observed of omega-3 fatty acids on postprandial lipaemia is through either 
increased clearance or reduced the synthesis of chylomicrons and VLDL 
rather than an alteration in their structure. 
 
Omega-3 fatty acids have been shown to have a beneficial effect on HDL. 
They are thought to increase HDL2 at the expense of HDL3 by reducing CETP 
activity(129). In keeping with this suggested mechanism, we found that 
treatment increased levels of HDL2 with an increase in mean particle diameter 
of HDL in both patients and controls but HDL-C was unaltered. We did not 
show a group effect implying a similar mechanism in both groups. Increasing 
levels of HDL-C reduce CV risk(29-33) but the atherogenicity of the HDL 
subfractions is less clear. Quantification and measurement of these 
subclasses is difficult and time-consuming. Thus, the clinical significance of 
the effect of omega-3 fatty acids on HDL in this population is uncertain. 
The evidence regarding the effect of omega-3 fatty acids on endothelial 
function is conflicting. They have been shown to improve endothelial function 
in healthy patients when measured by both brachial artery ultrasound and 
laser doppler imaging(151;230) but their effect on endothelial function in 
patients with nephrotic range proteinuria has not previously been studied. We 
were unable to demonstrate an improvement in endothelial function of 
patients or controls following treatment. It has been suggested that omega-3 
fatty acids exert their effect on the endothelium by causing changes in the  
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composition of the membrane bilipid layer thereby promoting increased 
release of endothelium derived NO in response to Ach(152). As discussed 
earlier, our study was limited by a number of confounding factors such as 
renal dysfunction, co-existing vascular disease, the use of ACE inhibitors and 
Angiotensin receptor blockers and the short duration of treatment.  Further 
work with larger numbers of patients may help clarify the effect of omega-3 
fatty acids but studies may be limited due to the widespread use of ACE 
inhibitors and angiotensin receptor antagonists. They‟re proven efficacy in 
reducing the rate of renal progression makes stopping these preparations 
difficult to justify.  
 
9.5 Clinical Implications 
We observed increased levels of total cholesterol, triglyceride, VLDL-C, sd 
LDL and remnant lipoproteins in the patients with nephrotic range proteinuria 
compared with the controls. These abnormalities are associated with 
increased CV risk and so our data has a number of implications.  
Randomised controlled trials have demonstrated the benefit of omega-3 fatty 
acids. In the Diet and Reinfarction Trial (DART), there was a 29 % reduction in 
mortality in the patients who received dietary advice on fish consumption. 
However, no change in cholesterol levels were observed(111). The GISSI-
Prevenzione trial showed a 10 % reduction in the relative risk for the primary 
end-point of total mortality, non-fatal myocardial infarction and stroke with a 
0.9% reduction in triglyceride in the patients treated with 850mg of omega-3 
fatty acids at 6 months(113). The Study on Prevention of Coronary 
Atherosclerosis by Intervention with Marine Omega-3 fatty acids (SCIMO) also  
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showed a significant reduction in TG (10%) at 6 months with significantly less 
progression of coronary artery disease assessed angiographically(114). 
In our study, we observed a 17.5% fall in triglyceride concentration in the 
patients with nephrotic range proteinuria compared with a 5.9% fall in the 
control group therefore if we extrapolate from these studies, a significant 
reduction in CV risk should be evident. However, even although studies have 
suggested that hypertriglyceridaemia is a risk factor for CHD independent of 
other risk factors(260), the evidence regarding the benefit of triglyceride 
lowering on mortality is less robust. Since we commenced this study, there 
have been further studies examining fibrates, which have also addressed 
previous concerns that fibrates increase serum creatinine levels. The FIELD 
(Fenofibrate Intervention and Event Lowering in Diabetes) trial showed a 29% 
reduction in plasma triglyceride and 12% reduction in LDL-C in patients with 
diabetes but the reduction in the primary end-point of cardiovascular disease 
was not significant. They observed a 15% higher increase in serum creatinine 
in the fibrate group but this was no longer evident following discontinuation 
suggesting that this was due to a functional rather than a structural 
change(261). The JELIS (Japan EPA Lipid Intervention Study) randomised 18 
645 patients with total cholesterol of 6.5mmol/l or greater to 1800mg of EPA 
and statin or statin alone with a 5 year follow-up. They showed a 19% relative 
reduction in coronary events in the EPA treated group with a 9% reduction in 
triglyceride in this group compared with 4% reduction in the statin alone arm 
(p<0.0001). Both treatments produced only small changes in HDL-C(259). 
A recent study examining the effect of Torcetrapib (a potent CETP inhibitor) 
showed a 72% increase in HDL-C and 25% reduction in LDL-C but treatment  
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was shown to increase mortality and CV events and so was terminated 
prematurely(262). The mechanism behind this is unclear. The role of HDL 
subfractions may play an important role in the protective effect of HDL-C. This 
may, in part, account for the results observed in this study. Further work 
examining the effect of Torcetrapib on HDL subfractions may clarify this. The 
previously mentioned fish oil studies showed a reduction in CV risk with 
smaller reductions in TG levels. This implies that the action of omega-3 fatty 
acids on lipids and lipoproteins is not solely responsible for the effect they 
have on reducing CV risk. As discussed in chapter 2, in contrast to fibrates, 
omega-3 fatty acids act in a number of different ways. It is likely that the 
combination of these different mechanisms act to lower CV risk in this 
population of patients. In addition to triglyceride lowering, we observed 
significant reductions in remnant lipoprotein, small dense LDL and 
postprandial lipaemia. However, the effect we observed on LDL is concerning 
therefore we would suggest that monotherapy with omega-3 fatty acids is 
unadvisable in this population of patients.  
 
Our study was not designed to examine the effect of omega-3 fatty acids on 
renal progression and proteinuria. Studies have suggested that omega-3 fatty 
acids slow renal progression in patients with IgA nephropathy(156;263). 
Investigators from the Mayo clinic showed that treatment with omega-3 fatty 
acids reduced renal progression in patients with idiopathic IgA nephropathy 
and persistent proteinuria over a period of 2 years(156). The same 
investigators examined these patients over a mean follow-up of 6.4 years. 
Once again, they demonstrated reduced rates of renal progression in the fish  
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oil treated patients. However, levels of proteinuria did not differ between the 
two groups(263) and lipid parameters were not measured in these patients. 
Treatment with HMG Co reductase inhibitors has also been shown to reduce 
renal progression. A meta-analysis of 27 randomised controlled trials 
examined the effects of statins on change in eGFR (264). They showed that 
patients treated with statins had 1.2 ml/min per year slower decline in GFR 
than controls and a reduction in proteinuria. Thus, the combination of omega-
3 fatty acids and statins may reduce renal progression further particularly in a 
population with a high risk of progressive renal failure due to the presence of 
significant proteinuria. 
 
In this thesis, we have demonstrated that omega-3 fatty acids were well 
tolerated with beneficial effects on triglyceride-rich lipoproteins, postprandial 
lipaemia and HDL metabolism in patients with nephrotic range proteinuria. 
However, we have also shown that omega-3 fatty acids increase LDL-C in 
these patients which may offset these benefits.  
 
9.6 Further Work 
Further work is required to clarify certain areas which we have studied. We 
plan to carry out electron microscopy of the chylomicrons and VLDL1 in order 
to determine their size and whether they differ between the two populations. 
Kinetic studies examining chylomicron and VLDL1 metabolism in patients with 
nephrotic range proteinuria compared with controls may clarify the differences 
observed between our work and previously published work.  
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In terms of future treatment options, a study examining the effect of 
combination therapy with  HMG Co A reductase inhibitors together with  
omega-3 fatty acids  looking at their effect on lipids and lipoproteins, in 
particular,  postprandial lipaemia and their effect on LDL-C. Furthermore, their 
combined effect on renal progression and proteinuria would also be of interest 
in this population of patients. These further studies would allow us to 
effectively tailor lipid therapy in this high-risk population of patients. However, 
such large scale prospective studies examining CV or renal progression end-
points may prove difficult to undertake due to the low incidence of this 
condition and the large numbers that would be required to be recruited. 
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